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ABSTRACT 
 
Gonorrhea, caused by the human pathogen Neisseria gonorrhoeae, is a severe public health 
problem worldwide with more than 82 million new infections each year. N. gonorrhoeae is 
transmitted by sexual contact and primarily causes urogenital mucosal infections in men and 
women. Left untreated, this infection may cause severe complications, especially in females. Eye 
infections of the newborn can occur. Gonorrhea infections enhance HIV transmission. The 
highly prevalent antibiotic resistance and the emergence of new drug resistances render treatment 
of the infections increasingly difficult. Close monitoring of antimicrobial susceptibility of this 
pathogen is crucial, and enhanced knowledge of molecular mechanisms of gonococcal 
antimicrobial resistance is urgently needed. There are no vaccines available against N. 
gonorrhoeae. Control of gonorrhea relies on comprehensive strategies which can be better 
formulated by understanding, at molecular levels, how N. gonorrhoeae is transmitted in 
communities.  
 
My research aimed to illustrate the severe burden of antimicrobial resistance in N. 
gonorrhoeae temporally and geographically in China and to reveal the molecular mechanisms of 
antibiotic resistance particularly the development of reduced susceptibility to ceftriaxone in N. 
gonorrhoeae isolates. To determine specific strain distributions, N. gonorrhoeae isolates were 
characterized using molecular typing methods such as a modified porB-based typing scheme and 
the N. gonorrhoeae Multi-Antigen Typing (NG-MAST) method, compared to traditional 
epidemiological approaches. The ultimate goal was to provide information for better formulating 
disease control strategies for gonorrhea. 
 
In this research, male patients with gonorrhea and their sex partners were recruited in 
Shanghai (2005 and 2008) and in Urumchi (2007-2008), China. Epidemiological information 
pertaining to sexual contacts was collected. N. gonorrhoeae isolates were investigated for their 
antimicrobial susceptibility. Molecular mechanisms of antimicrobial resistance were explored by 
analysis of potential resistant determinants (gyrA, parC, porB, mtrR, ponA and penA). The 
molecular data were combined with bioinformatic analysis and traditional epidemiological data.  
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High percentages of N. gonorrhoeae isolates (11% - 19% in Shanghai, 4.5% in Urumchi) 
exhibited reduced susceptibility to ceftriaxone (MICs = 0.125-0.25 mg/L), the first line drug 
recommended for the treatment of gonorrhea in China. The majority of isolates (>98%) were 
susceptible to spectinomycin, an alternative regimen for gonorrhea treatment; however, the 
proportion of isolates having intermediate levels of susceptibility increased from 1.9% in 2005 to 
9.9% in 2008. The majority of isolates tested were resistant to penicillin (80% - 93%), 
tetracycline (56% - 65%) and ciprofloxacin (98% - 100%). Plasmid-mediated resistance in N. 
gonorrhoeae isolates were highly prevalent (51% - 79%) in Shanghai and Urumchi.  
 
Analysis of 60 clinical isolates revealed that reduced susceptibility to ceftriaxone is 
mediated by porB1b allele and is associated with specific mutations in penicillin binding protein 
2 and in the DNA binding and dimerization domains of MtrR. Penicillin binding protein 1 is not 
involved in reduced susceptibility to ceftriaxone. Although mutation patterns in quinolone 
resistant determinant regions (QRDRs) varied, the majority of ciprofloxacin
 
resistant isolates had 
double mutations in GyrA (S91F and D95G/A/N) and most isolates also carried a S87R/N 
mutation in ParC. The presence of mutations in the QRDR of ParC is correlated with elevated 
ciprofloxacin MICs.  
 
A modified porB-based molecular typing scheme was developed and involved ~82% of the 
DNA sequence of gonococcal porB. This typing method proved to have high discriminatory 
ability (index of discrimination = 0.93 – 0.96), and was cost effective and easy to perform as 
compared to the NG-MAST analysis. Using the modified porB-based typing method, N. 
gonorrhoeae isolates were reliably differentiated, and transmission clusters were identified. 
Molecular epidemiology using the porB-based method confirmed direct sexual connections and 
identified sexual networks otherwise unrevealed by the patient self-reporting or traditional case-
tracing methods.  
 
 
Key words: Neisseria gonorrhoeae, antimicrobial susceptibility/resistance, molecular 
determinants of antimicrobial resistance, molecular epidemiology, molecular typing, strain 
transmission, sexual networks 
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1.1 Epidemiology and Clinical Features of Gonorrhea 
 
1.1.1 Prevalence of Gonorrhea in China and North America 
 
Gonorrhea, caused by the Gram-negative human pathogen Neisseria gonorrhoeae, is one of 
the most common sexually transmitted infections (STIs) worldwide. In 2001, the World Health 
Organization (WHO) estimated that more than 62 million new gonorrhea cases occur each year 
worldwide (WHO 2001a; Gerbase et al 1998a/b); this number of new cases is now estimated to 
be over 82 million each year (WHO 2011). Although realistic goals for the reduction and 
elimination of N. gonorrhoeae infections have been established by many countries since the 
1990s, following a worldwide reduction in prevalence, the incidence of gonorrhea is now rising 
again (Hughes et al 2000; Nicoll & Hamers 2002).  
 
Gonorrhea is the second most commonly reported notifiable disease in the United States 
(Jajosky 2006). In 2004, a total of 330,132 new cases of gonorrhea were reported. Miller (2004) 
estimated the prevalence of gonococcal infection among young adults in the US at 0.25% to 
0.43%. There was an increase in gonorrhea rates for two consecutive years (2005 and 2006) 
(CDC 2008). In 2005, 339,593 gonorrhea cases were reported (a slight increase from 2004), and 
the cumulative incidence rate was 115.6 per 100,000 population (CDC 2007b). In 2006, 358,366 
cases were reported and the cumulative incidence rate was 120.9 per 100,000 population, 
representing an increase of 5.5% from 2005.  
 
In Canada, gonorrhea has resurged since reaching its lowest rate in 1997 (Hansen et al 2003). 
In fact, the reported rate almost doubled between 1997 and 2004, from 14.9 to 28.9 per 100,000 
population; there was a further increase to 33.2 per 100,000 population in 2008 (PHAC 2008a, 
2010). This steady increase in rates since 2000 presents a significant public health concern in 
Canada. 
 
Reportable STIs in China include syphilis, gonorrhea, Chlamydia trachomatis urethritis, 
non-gonococcal urethritis (NGU), condyloma acuminata, genital herpes simplex virus infections, 
lymphogranuloma vernerum, and chancroid (China CDC 2005, 2006, 2007, 2008). 
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Overall reported rates of gonorrhea in China increased between 1995 and 1999, reaching 25 
per 100,000 population in 1999. In contrast to Canada, rates decreased from 2000, and the rate in 
2007 was 14 per 100,000 population (Fig. 1.1A). Gonorrhea rates in Shanghai were around 75-
107 per 100,000 population from 2001 to 2005—significantly higher than that in other parts of 
the country. However, a sharp decline has been observed since 2006 (China CDC 2005, 2006, 
2007, 2008). 
 
Cohen et al (1996) and others (Chen et al 2000; Shao et al 1996) have comprehensively 
reviewed STI history in the 20
th
 century in China. Syphilis, gonorrhea and other STIs were 
common before and during the early period of the founding of the People’s Republic of China in 
1949. The Chinese government launched an STI control program in the early 1950s. Through the 
15 year effort, by 1964 STIs including syphilis and gonorrhea were virtually eliminated from the 
country (Cohen 1996). The situation changed rapidly as China opened its doors to the West in 
the 1980s and STIs become a public health problem once again. Between 1990 and 1998, 
syphilis rates increased 20 times and gonorrhea rates increased 2.6 times. During the period from 
1989 to 1998, gonorrhea was the most commonly reported STI in China. Since the late 1990s, 
chlamydial infections have become prevalent; gonorrhea was the second most common STI in 
1999. The number of gonorrhea cases reported to the Chinese National Center for STD Control 
ranged from ~170,000 to 341,000 annually between 1995-2005 (WHO 2010; Fig. 1.1B).  
 
Because of incomplete reporting systems and a lack of appropriate diagnostic tools in rural 
areas, the number of reported cases of gonorrhea underestimates the true prevalence in China. 
Care for STIs is delivered at many places other than public STI professional clinics in China, and 
the use of private sector or non-STI clinics often leads to underreporting (Cohen et al 2000). 
Indeed, a population-based study showed that the prevalence of gonorrhea was 80 per 100,000 
population for women and 20 per 100,000 population for men aged 20 to 64 years, while 
chlamydial infections were over 50 times higher (Parish et al 2003). The gonorrhea rate in 
pregnant women was 0.8% (Chen et al 2006a). Detels et al (2003) studied STI prevalence in 
1316 market vendors in GuangZhou, a large eastern city in China and found that 1.2% of females 
and 0.8% of males were infected with gonorrhea. Among men who have sex with men (MSM), 
the gonorrhea positivity rate was 2.7% (Jiang et al 2006).  
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Fig. 1.1 Prevalence of Gonorrhea. A. Gonorrhea rates in China and Canada. B. Number of reported gonorrhea cases in China.  
Chinese data were derived from the China CDC (2005, 2006, 2007 and 2008) and the Communicable Disease Global Atlas of the 
World Health Organization (WHO 2010). Canadian data were derived from the Public Health Agency of Canada (PHAC 2010). 
4
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Among long-distance truck drivers in Tongling city, China, the gonorrhea positivity rate was 
8.1% (Chen et al 2006b). Among female sex workers, the rate was over 8% and has been 
reported as high as 37.8% in various cities in China (van den Hoek et al 2001; Chen et al 2000; 
Cohen et al 2000; Parish et al 2003; Chen et al 2005). Underreporting remains a concern for the 
spread of gonorrhea in communities. The economy of China is booming; urbanisation and 
commercialization are increasing; attitudes toward sex are changing, and the sex industry is 
growing. However, knowledge about STI prevention is still lacking in populations with high STI 
risks, as well as in the general population. All of these factors contribute to the high prevalence 
of STIs, including gonorrhea, in China. 
 
The present research focused on the molecular epidemiology and antimicrobial resistance of 
N. gonorrhoeae in Shanghai and Urumchi, China. Shanghai is the trade capital of China, a city 
with a population of more than 17 million. Approximately one quarter of the people in Shanghai 
are migratory, and are more vulnerable to STIs due to disadvantaged social and economic status. 
Urumchi is the capital of the Xinjiang Province of China. It has a population of over 2 million 
with 75.3% Han Chinese, 12.8% Uyghurs, 8.0% Hui and 2.3% Kazakhs and Kyrgyz. The STI 
incidence rates are high, ranging from 70 to 100 per 100,000 population in both Shanghai and 
Urumchi (Fig. 1.2).   
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
 
 
 
 
Fig. 1.2 Distribution of Sexually Transmitted Infections (STIs) in China in 2005. Modified from China CDC (2006). STIs in this 
report include syphilis, gonorrhea, non-gonococcal urithritis (NGU), condyloma acuminata, genital herpes simplex virus infections, 
lymphogranuloma vernerum (LGV) and chancroid.  Locations of the study sites Shanghai and Urumchi are indicated by arrows. 
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1.1.2 Transmission of Gonorrhea 
 
Sexually transmitted infections are transmitted dynamically. STI control programs, like 
control programs for other infectious diseases, are based on the calculation of the basic 
reproductive number (R0) (Brunham 2005; May & Anderson 1987; Ward 2007).  
R0 = βcD 
R0 represents the number of second-generation cases produced from an infected individual 
and is determined by 3 parameters: transmission probability (β), duration of infectiousness (D), 
and the number of individuals that are exposed to the infection (i.e. number of sexual partners) 
(c). If R0 is greater than 1, the infection will spread in the population; if it is less than 1, the 
infection will eventually cease to exist in the population. For gonorrhea, based on empirical 
modeling, it is estimated that the probability of transmission (β) from a single episode of 
intercourse was 0.25 for women-to-men transmission and 0.60 for men-to-women transmission, 
with an average of 0.50 (Jolly & Wylie 2002; Holmes et al 1970; Hooper et al 1978; Nordvik & 
Liljeros 2006). Gonorrhea is a self-limiting infection. The natural duration of infectiousness (D) 
for gonorrhea is estimated to be 55 days (Yorke et al 1978). 
 
Reducing the duration of infectiousness (through early diagnosis and treatment with 
antibiotics), the probability of transmission (through promotion of condom use, and vaccination), 
and the number of sexual partners, effectively reduces R0, which leads to control and elimination 
of the infection (R0 < 1). 
 
Patterns of STI transmission depend upon who has sex with whom, also known as the sexual 
network. Sexual networks portray the sexual inter-relationships within a defined group of people. 
As compared to other infections such as the common cold, influenza, or tuberculosis, STIs are 
the most typical of ―network diseases‖ because the links established through sexual contact are 
relatively low, and each contact is relatively significant (Day et al 1998). Therefore, sexual 
network analysis has been used to study the spread of STIs (both outbreak and epidemic) within 
the context of social interactions.   
  
 Sexual network analysis has been applied in studies of transmission patterns of chlamydia 
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and gonorrhea infections conducted in Manitoba, Canada (Wylie & Jolly 2001; Wylie et al 2005; 
Jolly & Wylie 2002) and in a gonorrhea outbreak in Alberta, Canada (De et al 2004). 
 
For gonorrhea, it has been ascertained that small groups of people joined directly or 
indirectly through sexual intercourse maintain the continued spread of the infection in 
populations (Anderson & May 1992; Potterat et al 1985; Yorke et al 1978). These small groups 
within the population, so called ―core groups,‖ have large numbers of partners, thus are most 
important in the transmission of infection (Yorke et al 1978; Jolly & Wylie 2002). The infection 
also spreads into lower-risk populations (bridging populations) who may represent an important 
sexual link between the core groups and the general population (WHO 2007; Fig. 1.3). Therefore, 
effective identification of core groups in certain populations is critical for the proper and 
effective distribution of resources (WHO 2007). The role of ―core groups‖ in the transmission of 
infectious diseases varies depending on the progression of the spreading phases; they are 
important in the spread of infections during the early epidemic phases, whereas for established 
endemic infections, transmission among the general population could have a major impact on 
disease spread (Ward & Rönn 2010). It has been established that intervention strategies should 
focus on high-risk (core groups) and bridging populations (WHO 2007).    
 
 Traditional methods for the identification of sexual networks in STI studies consist of STI 
surveillance and screening, identification of index cases, partner notification, and contact tracing 
through extended interviews. A combination of epidemiological and molecular biological 
methods can establish a much better view of sexual networks in gonorrhea transmission (Day et 
al 1998). In a population-based study in London, UK, Choudhury and colleagues (2006) 
characterized 2045 isolates of N. gonorrhoeae by DNA sequence analysis of specific genes (i.e. 
porB and tbpB) and matched the sequence types to epidemiological data obtained at the clinics. 
Twenty-one prevalent strains were identified by molecular determination, each infecting between 
20 and 124 individuals. Subsequent analysis on this gonorrhea population (Risley et al 2007) 
revealed that strain types were distinct in male-to-male homosexuals and in heterosexuals. 
Distinct strains, transmitted within localized areas of London, were identified. By combining the 
molecular information of strain types with demographic data, local transmission networks were 
identified (Choudhury et al 2006; Risley et al 2007). 
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Fig. 1.3 Transmission Dynamics of Sexually Transmitted Infections at the Population 
Levels. Adapted from ―Global strategy for the prevention and control of sexually transmitted 
infections 2006–2015- breaking the chain of transmission. World Health Organization 2007.” 
WHO 2007. Permission to use has been obtained (Appendix A2.1).  
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1.1.3 Clinical Manifestations and Complications of Gonorrhea 
 
The primary infection sites of N. gonorrhoeae are the columnar and transitional epithelium 
of the urogenital tract (the urethra in males and the uterine cervix in females), the rectal mucosa, 
the conjunctiva, and pharynx (Sparling 1999; Hook & Handsfield 1999). The incubation period 
of gonococcal infections is about two to five days after exposure to the organism through sexual 
contact. Early symptoms may be mild in both men and women. Over 50% of women and 10% of 
men who have gonorrhea are asymptomatic during the entire infection process. This gives rise to 
misdiagnosis and delay of treatment, facilitating spread of the pathogen.  
 
In men, primary urethral infection results in acute urethritis, manifested by purulent 
discharge from the tip of the penis and symptoms of urethral itch and pain or burning sensation 
when passing urine. In women, primary infections cause cervicitis and urethritis if the urethral 
tract is involved. Symptoms of primary gonorrhea in females are usually non-specific. There 
may be a strong smelling vaginal discharge that may be thin and watery or thick and 
yellow/green. Pain or a burning sensation when passing urine may also be present. Other clinical 
presentations include abnormal vaginal bleeding and low abdominal pain or tenderness. Rectal 
infections may cause irritation or discharge of the anus in both men and women, but are often 
asymptomatic (Sparling 1999; Hook & Handsfield 1999). 
 
Gonococcal ophthalmia neonatorum, an infection in the eyes of the newborn, is acquired 
during passage through the birth canal of an infected mother (Morse & Beck-Sague 1999). 
Typically, gonococcal ophthalmia is bilateral and exhibits purulent discharge. The initial 
conjunctivitis rapidly progresses and, if untreated, results in blindness due to corneal ulceration 
and perforation. Gonococcal ophthalmia in newborns can be prevented by the instillation of 1% 
silver nitrate into the conjunctual sac of the newborn (Goldbloom 1994). Current prophylaxis 
options also include 1% tetracycline drops or 0.5% erythromycin drops applied to newborns eyes 
within the first hours of life (American Society of Pediatrics 2006). Antibiotic regimens are less 
likely to cause chemical conjunctivitis than silver nitrate and may be more acceptable to parents 
(MacDonald et al 2008). 
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Gonorrhea infection can spread to adjacent sites of the urogenital tract or through the 
bloodstream to other parts of the body, causing damage and serious complications (Bolan et al 
1999). In men, ascending infection of N. gonorrhoeae causes epididymitis, a painful condition of 
the testicles that can lead to infertility if left untreated. Additionally, gonorrhea affects the 
prostate gland and may cause scarring in the urine canal. In women, the most common 
consequence of untreated gonorrhea is pelvic inflammatory disease (PID) (Morse & Beck-Sague 
1999). Gonococcal PID often appears immediately after the menstrual period. PID causes scar 
tissue to form in the fallopian tubes, resulting in infertility. If the tube is partially scarred, a 
fertilized egg may not be able to pass into the uterus. If this happens, the embryo may implant in 
the tube causing a tubal (ectopic) pregnancy. This serious complication may result in a 
miscarriage and, possibly, death of the mother. 
 
Rarely, untreated gonorrhea can spread through the bloodstream causing disseminated 
gonorrhea (DG). DG may present as arthralgia or arthritis, endocarditis, or meningitis in both 
men and women (Sparling 1999).  
 
Infection with N. gonorrhoeae has been associated with increased infectiousness of and 
susceptibility to the sexually transmitted human immunodeficiency virus (HIV) (Shannon & 
Cohen 2004). Comprehensive reviews have summarized the findings of clinical trials and 
epidemiological studies on the interrelationships between HIV and STIs including gonorrhea 
(Wasserheit 1992; Fleming & Wasserheit 1999; Shannon & Cohen 2004; Galvin & Cohen 2004). 
It has been shown that both genital ulcerative diseases (syphilis and human simplex virus 
infections) and nonulcerative STIs (gonorrhea, urogenital chlamydial infections and urogenital 
trichomoniasis) increase the risk of HIV transmission approximately 3- to 5- fold (Wasserheit 
1992). Gonorrhea enhances the infectiousness of HIV due to several pathophysiological factors. 
These factors include increased HIV viral load in the urethra, semen, and cervical fluid due to 
high degree of inflammation, as well as increased HIV replication due to the influx of PMNs 
during gonococcal infections (Shannon & Cohen 2004). Gonorrhea makes a person more 
susceptible to HIV infection due to damage of the columnar epithelial barriers and increased 
infiltration of the HIV co-receptor containing cells (Wasserheit 1992; Shannon & Cohen 2004). 
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These interplays are of great concern because the majority of HIV infections are sexually 
transmitted (Cohen 2004).  
 
1.1.4 Relevant Pathophysiology of Neisseria gonorrhoeae 
 
1.1.4.1 Relevant Biological Characteristics of N. gonorrhoeae 
 
Neisseria gonorrhoeae, discovered by Albert Ludwig Sigesmund Neisser (1855 – 1916), is a 
member of the Neisseria genus, which includes at least 21 members (Knapp 1988) (i.e. N. 
gonorrhoeae, N. meningitidis, N. animalis, N. bacilliformis, N. canis, N. cinerea, N. denitrificans, 
N. dentiae, N. elongate, N. flava, N. flavescens, N. iguanae, N. lactamica, N. macacae, N. 
mucosa, N. perflava, N. pharyngis, N. polysaccharea, N. sicca, N. subflava, N. weaver). N. 
gonorrhoeae and N. meningitidis are obligatory human pathogens. Other members of the genus 
are non-pathogenic commensal species, although some of them can cause opportunistic 
infections in human (i.e. N. lactamica). 
 
N. gonorrhoeae, a Gram-negative diplococcus, produces oxidase and utilizes glucose. It 
does not utilize maltose and sucrose. It is a fastidious microorganism and has special nutrient 
requirements for growth in vitro (sulfur in the form of cysteine and iron). Laboratory cultures are 
usually undertaken in nutrient-containing media at 35
o
C under humid conditions and in an 
environment containing 5-7% CO2 (Kellogg et al 1963). Under microscopy, in cultured samples, 
the bacterium appears in pairs. In clinical specimens, gonococci reside inside the 
polymorphonuclear leukocytes (PMNs) and exhibit coffee-bean shapes (Fig. 1.4).  
 
N. gonorrhoeae is highly variable in its genotype and phenotype (Fredlund et al 2004; 
O’Rourke et al 1995). This variability has been used to differentiate gonococcal strains 
circulating in a given community, thereby identifying patterns of specific strain transmission and 
guiding control strategies (Unemo et al 2002, 2004, 2007a/b; Viscidi et al 2000; Martin et al 
2004). In this study, the characteristics of high variability in gonococcal porB and tbpB genes 
were applied to molecular epidemiology. This dual gene analysis has been called Neisseria 
gonorrhoeae Multi-Antigen Sequence Typing (NG-MAST; Martin et al 2004). 
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Fig. 1.4 Gram-strain and Microscopy. Purulent exudates from a male gonorrhea patient (A) 
and smears of cervical swabs from a female gonorrhea patient (B). Arrows indicate 
polymorphonuclear leukocytes containing gonococci. Courtesy from Dr. Wei-Ming Gu, 
Shanghai Skin Disease and STD Hospital, Shanghai, China 
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In response to selective pressure, the porB genes in N. gonorrhoeae undergo positive 
selection for diversity (Smith et al 1995). Alleles of the porB locus are assigned to two isoforms-
- porB1a and porB1b—encoding the major porin protein (PI) of N. gonorrhoeae, PIA or PIB, 
respectively (Smith et al 1995). An individual strain of N. gonorrhoeae expresses either one of 
these two PI isoforms, although hybrid PI forms have occasionally been identified from clinical 
isolates by serological testing (Shinners & Catlin 1988).  
 
Genetically, as compared to porB1b, porB1a lacks sequence fragments in Loop V-coding 
regions (van der Ley et al 1991; Derric et al 1999). The PI protein (PorB) is a transmembrane 
protein comprising eight highly variable loops, separated by nine internal conserved regions (Fig. 
1.5; van der Ley et al 1991; Derric et al 1999). The loops, which are surface-exposed, can elicit 
an immune reaction during infection (van der Ley et al 1991; Ison et al 1988) and were targeted 
for differentiating isolates when serovar determination with monoclonal antibodies was widely 
available (van der Ley 1991; Ison 1988; Dillon et al 1987a/b, 1990; Kanpp et al 1984; Sanstrom 
& Danielsson 1980; Sandstrom et al 1982; Tam et al 1982). 
 
The gonococcal tbp genes encode human transferrin (Tf) binding proteins (TBPs). The two 
components of the TBPs (i.e. TbpA and TbpB) both bind to Tf, allowing N. gonorrhoeae to 
scavenge iron from human Tf. TbpA (encoded by tbpA), an outer membrane transporter, is a 
necessary component of the Tf iron acquisition system and is responsible for transporting iron 
into the bacterial cell. TbpB (encoded by tbpB) is a surface-exposed lipoprotein. TbpB proteins 
are heterogeneous, exhibiting 69 to 84% sequence identity among N. gonorrhoeae strains (Retzer 
et al 1999; Rokbi et al 1995).  
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Fig. 1.5 Schematic Presentation of N. gonorrhoeae PorB. The length of PorB differs between 
PIB (~348 amino acids) and PIA (~328 amino acids), respectively. There are 8 surface exposing 
loops (I – VIII) as shown in black triangles spanned by inter-space regions (van der Lay et al 
1991). DNA sequences used in phylogenetic analysis include coding regions of Loop I to VII as 
shown in hatched box. DNA sequences in N. gonorrhoeae Multi-Antigen Sequence Typing (NG-
MAST) analysis included coding sequences for Loop III to Loop VII. The amino acids G120 and 
A121 locate at Loop III.   
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1.1.4.2 Major Virulence Factors in N. gonorrhoeae 
 
There are four major virulence factors in N. gonorrhoeae: pili (Källström et al 1998), 
opacity-associated proteins (Opa; Dehio et al 1998), porin (Muller et al 1999), and lipo-
oligosaccharide (LOS; Gorter et al 2003). Primary attachment of N. gonorrhoeae to the apical 
surface of mucosal epithelial cells is mediated by the bacterial pilus. This filamentous appendage 
then retracts, pulling the bacterium down onto the host cell membrane (Howie et al 2005). Opa 
proteins mediate tight secondary interactions between bacterial cells and the epithelial cells, 
facilitating invasion. Porins mediate serum resistance in N. gonorrhoeae, and facilitate 
intracellular growth and transcytosis. LOS causes host cell apoptosis and inhibits Opa-mediated 
bacteria-host cell interactions by sialylation and binding to the asialoglycoprotein receptor of the 
host cells. 
 
Tissue damage by N. gonorrhoeae is caused by the host inflammatory response in which 
numerous polymorphonuclear leukocytes (PMNs) are attracted to the site of infection and release 
various chemokines and cytokines (Peeling et al 2006; Simons et al 2005). The inflammatory 
response causes sloughing of epithelial cells from the urogenital mucosa. The majority of the 
bacterial cells are washed away by the passage of urine or mucus drainage. Most attached 
gonococci are discharged along with the sloughed epithelium from the urogenital tract. A small 
portion of the gonococci inside epithelial cells can be transported across the epithelial cytoplasm 
to the basal side of the cell, and is subsequently released into subepithelial spaces (McGee et al 
1983). Gonococci tend to remain within the niches of the subepithelial compartment, in contact 
with cells of the immune system but somehow avoiding triggering a specific immune response 
(Merz & So 2000; Sparling et al 1999). Disseminated gonococcal infections, in rare cases, can 
then occur if the bacterium penetrates across the endothelium and spread through the 
bloodstream. 
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1.2 Antimicrobial Resistance in Neisseria gonorrhoeae and Treatment of Gonorrhea 
 
There are no vaccines available against gonococcal infections. Effective prevention and 
treatment are achieved through a combination of responses (WHO 2007). Control strategies 
include healthy sexual behaviours such as reduction of the number of sexual partners and the 
correct use of condoms, early diagnosis, and effective antibiotic treatment.  
 
Antibiotic treatment is the hallmark in curing gonococcal infections and controlling the 
spread of gonorrhea. According to the accepted definition of gonococcal treatment efficacy, a 
cure rate of over 95% is required for an antibiotic to be recommended for gonorrhea treatment 
(Handsfield et al 1992; WHO 2001b; WHO 1989; CDC 1987). Thus, an antibiotic should not be 
used in situations where resistance is observed in greater than 3% to 5% of gonococcal isolates 
tested (PHAC 2006).  
 
N. gonorrhoeae has developed resistance to most of the commonly used antibiotics. 
Antimicrobial resistance (AMR) in N. gonorrhoeae is increasing in prevalence, and resistance to 
new classes of antibiotics is emerging and spreading globally (Tapsall et al 2009; Barry & 
Klausner2009), giving rise to concerns that gonorrhea may become untreatable.   
 
AMR in N. gonorrhoeae is mediated through chromosomal mutations of various loci, 
plasmid-mediated mechanisms or both (Dillon & Pagotto 1999). Plasmid-mediated resistance 
may confer resistance to penicillin (i.e. penicillinase-producing N. gonorrhoeae, PPNG), or high 
level resistance to tetracycline (i.e. tetracycline-resistant N. gonorrhoeae, TRNG). 
Chromosomally-mediated resistance (CMR) of N. gonorrhoeae is caused by mutations or 
modifications in various genes. The accumulation of chromosomal mutations may confer 
resistance to multiple antibiotics (the multiple drug resistance, MDR), or confer higher levels of 
resistance to single antibiotics (Dillon & Pagotto 1999).  
 
AMR became apparent shortly after the introduction of antimicrobials into clinical practice 
and has continued to appear and expand to each new class of antibiotics. Recommendations for 
the treatment of gonorrhea have evolved in accordance to the emergence of new resistance 
phenotypes and antibiotic availability (Lewis 2010; Workoski et al 2008; Fig. 1.6). 
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Fig. 1.6 Historical Perspective on Antimicrobial Resistance in N. gonorrhoeae in the United States. Reproduced with permission 
from Ann Intern Med (Workoski et al 2008; Appendix A2.2).  
QRNG = quinolone-resistant Neisseria gonorrhoeae; MSM = men who have sex with men 
1
8
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1.2.1 Recommendations for the Treatment of Gonorrhea 
 
Sulfanilamides, introduced in 1936, were the first effective anti-gonococcal antibiotics. The 
use of sulfanilamides was terminated in 1945 because of the spread of resistant N. gonorrhoeae 
isolates (Lees 1946; Kampmeier 1983).  
 
Penicillin became the antibiotic of choice for the next 40 years. The recommended dose of 
penicillin was continually increased because of a progressive decline in susceptibility. The 
emergence of high-level, plasmid-mediated resistance to penicillin in 1976 marked the end of 
penicillin use in the treatment of gonorrhea (Percival et al 1976; CDC 1976). Eventually, 
treatment with penicillin was discontinued in 1985 in most regions (Dillon & Pagotto 1999). 
 
Tetracyclines were used initially to treat gonorrhea in patients allergic to penicillin, and they 
are still in use today for treating suspected or proven chlamydial co-infection (CDC2010). 
However, gonococci became less susceptible to tetracycline shortly after it was introduced (Reyn 
et al 1958) and was no longer recommended for the treatment of gonorrhea together with 
together with penicillin in 1985 as plasmid-mediated tetracycline resistant isolates were 
identified (Roberts et al 1988; CDC 1985; Dillon & Pagotto 1999).   
 
Historically, thiamphenicol has been suggested as a viable alternate therapy regimen to 
penicillin in the treatment of infections with N. gonorrhoeae; however, because cross-resistance 
to thiamphenicol was common in penicillin-resistant isolates and because thiamphenicol can 
produce erythroid suppression, thiamphenicol has not commonly used in the treatment of N. 
gonorrhoeae (Dillon et al 1978a/b). 
 
Erythromycin has not recommended for the treatment of gonorrhea because its limited 
activity against N. gonorrhoeae (Brown et al 1977). Azithromycin are used in some Latin 
American countries although it is not recommended by the WHO as a first-line trearment option 
for gonorrhea (WHO 2003) because of emergence of resistance and side effects. Gonococcal 
resistance to azithromycin was observed in Latin America in 1990s (Dillon et al 2006; Sosa et al 
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2003; Dillon et al 2001). Recently high-level azithromycin-resistant isolates (MIC > 2048 mg/L) 
were reported in Argentina (Galarza et al 2009) and the UK (Chisholm et al 2009).   
 
In 1993, oral fluoroquinolones (ciprofloxacine and ofloxacin) were recommended for 
gonorrhea treatment (CDC 1993). However, the emergence of quinolone-resistance N. 
gonorrhoeae (QRNG) became a concern in 1991 in the US and in the Asia-Western Pacific 
regions (Iverson et al 2004; Tapsall 2002, 2005, 2006; Tapsall et al 1998). Since then, the rates 
of QRNG continuously increased and spread in the US and worldwide. In 2006, the US CDC 
announced that quinolones were no longer recommended for the treatment of gonorrhea (CDC 
2007a). Trends in treatment recommendations for gonorrhea in Canada have been similar to 
those in the US (PHAC 2006, 2007). Due to the rapid increase in rates of QRNG, quinolones 
such as ciprofloxacin and ofloxacin have not been recommended for the treatment of gonococcal 
infections in Canada since 2007 (PHAC 2008a/b). 
 
Because of global spread of QRNG, third-generation cephalosporins are currently the only 
class of antimicrobials available for effective treatment of gonorrhea (Tapsall 2002, 2005, 2006). 
Many countries recommend injectable ceftriaxone or orally administered cefixime as the 
antibiotics of choice (Table 1.1), including Canada (PHAC 2007, 2008a/b), Australia (Sexual 
Health Society of Victoria 2008), the United States (CDC 2006, 2007a, 2010), the United 
Kingdom (HPA 2005), China (Wang & Zhang 2007) and Japan (Jpn Soc STD 2006).  
. 
Spectinomycin has been recommended as an alternative treatment regimen for gonorrhea 
(Table 1.1). However, shortly after its introduction and wide use in the mid-1980s, clinical 
treatment failures caused by spectinomycin-resistant strains began to be appear in US military 
personnel in the Republic of Korea (Boslego et al 1987). Gonococcal resistance to spectinomycin 
has also been reported from the Western Pacific regions (WHO-WPR 2001) and from the Latin 
American countries (Dillon et al 2006). Aminoglycosides kanamycin and gentamicin are rarely 
used for the treatment of gonorrhea because of their low activity against N. gonorrhoeae and 
their toxicity (Dillon 1992; WHO 2003).  
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Table 1.1 Current Recommendations of First Line Antibiotics for the Treatment of 
Uncomplicated Gonorrhea
†
 
 
Countries/ 
Regions 
Recommended 
Antibiotics 
Alternative Treatment 
Regimens 
References 
Australia Ceftriaxone 
 
NA 
 
Sexual Health Society of 
Victoria 2008 
Canada Cefixime 
 
Ceftriaxone, or  
Azithromycin, or  
Spectinomycin,  
 
PHAC  2008b 
China Ceftriaxone 
 
 
Spectinomycin 
 
 
Wang & Zhang 2007; 
Su et al 2007; China 
Ministry of Health 2000 
 
Japan 
 
Ceftriaxone, or 
Spectinomycin 
 
Cefixime 
 
Jap Soc STD 2006; Yokoi 
et al 2007 
United 
Kingdom 
 
Ceftriaxone, or 
Cefixime, or 
Spectinomycin 
 
Cefotaxime, or  
Cefpodoxime, or 
Azithromycin 
 
HPA 2005, 2011  
United States 
Ceftriaxone or 
Cefixime 
 
 
Cefpodoxime or 
Cefuroxime, or  
Azithromycin  
 
 
CDC 2010 
 
 
†: As of February 2011. For more discussion, please refer to Discussion Section of this thesis. 
NA: Not recommended 
 
 
 
 
 
 
22 
 
1.2.2 Prevalence of Antimicrobial Resistance in N. gonorrhoeae in China and Canada 
 
Antimicrobial resistance (AMR) in N. gonorrhoeae poses a significantpublic health burden 
worldwide because of its high prevalence and the emergence and spread of resistance to new 
classes of antimicrobials (Tapsall 2009a/b). In most areas of the world, N. gonorrhoeae has 
developed resistance to sulfanamides, penicillins, tetracyclines, macrolides and fluoroquinolones. 
Decreased susceptibility and sporadic resistance to third-generation cephalosporins, and to 
spectinomycin, has also been observed. Moreover, multiple drug resistant N. gonorrhoeae 
isolates are commonly observed in various areas of the world (Tapsall 2002, 2005, 2006, 2009). 
The global resistance status and trends in N. gonorrhoeae have been extensively reviewed by 
WHO and a variety of researchers (Tapsall 2002, 2005, 2006, 2009; Dillon & Pagotto 1999; 
WHO 2001a/b). In this section, trends of AMR in N. gonorrhoeae since the mid-1990s in China 
are summarized and are compared to those in Canada. Data were derived from the WHO-WPR 
reports (WHO-WPR1997a/b, 1998, 2000a/b, 2001, 2001, 2003, 2005, 2006a/b, 2008, 2010) and 
reports of the Public Health Agency of Canada (PHAC 2008a, 2010). 
 
The burden of gonococcal penicillin resistance (PEN
R
, MIC≥1.0 mg/L) has been high in the 
past 15 years in China; over 50% to nearly 100% isolates were resistant to PEN in China as a 
whole and in Shanghai (Gu et al 2004) (Fig. 1.7). The overall resistance percentages to PEN 
have not been reported by the national surveillance program since 2006. For comparison, PEN
R
 
(MICs≥2.0 mg/L) percentages in Canada are around 10-18% (PHAC 2008a). However, the 
PEN
R 
percentages in Canada are still above the threshold of 3-5% resistance recommended by 
WHO (WHO 1989) for termination of use of that particular antibiotic for the treatment of 
gonorrhea (PHAC 2006).  
 
Tetracyclines (TET) are not commonly used for the treatment of gonorrhea in China; in the 
early 1990s, however, they were used in combination with PEN for treating genital co-infections 
due to Chlamydia trachomatis. Thus, the overall TET resistance (TET
R, MIC≥1.0 mg/L) 
percentages have not been reported. In Shanghai, TET
R
 percentages are reported and the 
percentages increased from ~ 8% in 1995 to ~85% in 1999 and to 99% in 2002. The TET
R
 
percentages have remained high in the past 4 years (74-82%; Gu et al 2004). In Canada, TET
R
 
23 
 
(MIC≥2.0 mg/L) was observed in the early 1970s (Dillon et al 1978b) and was highly prevalent 
in gonococcal isolates tested in the 2000s (Greco et al 2003). TET
R
 percentages remained around 
15-29% from 1999-2006 (Fig. 1.8; PHAC 2008a). 
 
Fluoroquinolones were introduced in the early 1990s, and orally administered ciprofloxacin 
(CIP) had been recommended for the treatment of gonorrhea since 1995 in China. The 
percentages of CIP resistance (CIP
R, MIC≥1.0 mg/L) drastically increased from 15% in 1996 to  
> 50% in 1998, > 85% in 2000, and > 95% in 2006 (Ye et al 2004; WHO-WPR 2010). Thus, the 
use of CIP for the treatment of gonorrhea was terminated in the mid-2000s in China as well as 
many other countries (Wang & Zhang 2007; PHAC 2008b; CDC 2007a). In Shanghai, the 
burden of CIP resistance is even higher than the overall burden in China - almost all isolates 
tested have been resistant to CIP since 1997. For comparison, the CIP
R
 percentages in Canada 
were low before 2003 (< 5%); however, the CIP
R
 percentages increased to 6% in 2004, 14% in 
2005 and 28% in 2006 (Fig. 1.9, PHAC 2010).   
 
The prevalence of plasmid-mediated resistance in N. gonorrhoeae has drastically increased 
since 1998 in China (Fig. 1.10). The percentage of penicillinase-producing N. gonorrhoeae 
(PPNG, β-lactamse positive) was less than 10% before 1999, but rapidly increased to over 50% 
in 2004. PPNG prevalence in China has remained high over the past 5 years (38-48%). Plasmid-
mediated tetracycline resistance N. gonorrhoeae (TRNG, TET MIC ≥ 16.0 mg/L) was first 
reported in 1995, and increased to 34% in 2001 and 40% in 2008. In Shanghai, the trends of 
PPNG are similar to those in China overall, although higher percentages were observed. The 
TRNG percentages in Shanghai were lower than the overall percentages in China before 2006. 
Noticeably, the TRNG percentages in Shanghai significantly increased in the past 4 years, from 
~21% in 2005 (Yang et al 2006) to 56% in 2008. In Canada, the TRNG percentages rose from 
0.02% of reported cases (6 of 35,287) in 1986 and peaked at 18.9% of reported cases (1,164 of 
6,167) in 1994 (Greco et al 2003). 
 
Gonococci resistant to spectinomycin (SPT
R, MIC≥128.0 mg/L) or with reduced 
susceptibility to ceftriaxone (CRO
Red
, MICs=0.06-0.25 mg/L) were sporadically reported in 
various years in China (less than 0.5% of the isolates surveyed) (Ye et al 1994, 2002, 2003, 2004; 
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Su et al 2007; WHO-WPR1997a/b, 1998, 2000a/b, 2001, 2002, 2003, 2005, 2006a/b, 2008, 
2010); however, the data used in these reports were obtained from local STI centers in China and 
lacked confirmation from the National Reference Laboratory of China CDC in Nanjing, China.  
 
Detailed data on the trends of multiple drug resistance (MDR) of N. gonorrhoeae in China 
are not available. However, with consideration of the high percentages of PEN
R
, TET
R
, and CIP
R
, 
it can be expected that the MDR phenotypes of PEN
R
/TET
R
/CIP
R
 are high in China and that the 
phenotypes of PEN, TET, or CIP resistance, combined with SPT
R
 or decreased susceptibility to 
CRO, may also be present. 
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Fig. 1.7 Trends of Penicillin Resistance in N. gonorrhoeae. Chinese data were derived from 
WHO-WPR Reports (WHO-WPR1997a/b, 1998, 2000a/b, 2001, 2001, 2003, 2005, 2006a/b, 
2008, 2010). Shanghai data were derived from Gu et al 2004. Shanghai data for 2005-2007 were 
courtesy of Gu (unpublished data, personal communication). Since 2006, China has not reported 
overall PEN resistance rates. Canadian data were derived from the Public Health Agency of 
Canada (PHAC 2008c). Penicillin resistance breakpoints were MIC = 1.0 mg/L in China and 2.0 
mg/L in Canada, respectively.  
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Fig. 1.8 Trends of Tetracycline Resistance in N. gonorrhoeae. The overall rates of TET 
resistance were not available. Shanghai data were derived from Gu et al 2004. Shanghai data for 
2005-2008 were courtesy of Gu (unpublished data, personal communication). Canadian data 
were derived from the Public Health Agency of Canada (PHAC 2008c). Tetracycline resistance 
breakpoints were MIC = 1.0 mg/L in China and 2.0 mg/L in Canada, respectively. Tetracycline 
resistant data in Shanghai for 2003 and 2004 were not available.  
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Fig. 1.9 Trends of Ciprofloxacin Resistance in N. gonorrhoeae. Chinese data were derived 
from WHO WPR Reports (WHO-WPR1997a/b, 1998, 2000a/b, 2001, 2001, 2003, 2005, 2006a/b, 
2008, 2010). Shanghai data were derived from Gu et al 2004. Shanghai data for 2005-2008 were 
courtesy from Gu (unpublished data, personal communication). Canadian data were derived from 
the Public Health Agency of Canada website (PHAC 2008c). Ciprofloxacin resistance breakpoint 
was P MIC = 1.0 mg/L in both China and Canada.  
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Fig. 1.10 Trends of PPNG and TRNG in China. Chinese data were derived from WHO WPR 
Reports (WHO-WPR1997a/b, 1998, 2000a/b, 2001, 2001, 2003, 2005, 2006a/b, 2008, 2010). 
Shanghai data were derived from Gu et al 2004. Shanghai data for 2005-2008 were courtesy of 
Gu (unpublished data, personal communication).  
PPNG = Penicillinase-producing N. gonorrhoeae; TRNG = Tetracycline resistance N. 
gonorrhoeae (plasmid mediated, TET MIC ≥ 16.0 mg/L).  
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1.3 Modes of Action and Mechanisms of Antimicrobial Resistance in Neisseria gonorrhoeae 
 
Based on the modes of action, commonly used antibiotics are generally categorized into 
three classes (Walsh 2003; Courvalin & Leclercq 2010). Drugs that act on the cell wall include 
the β-lactams (e.g. penicillins, cephalosporins, monobactams and carbapenems) and the 
glycopeptides (e.g. vancomycin, teicoplanin, telavancin, bleomycin and ramoplanin). Drugs that 
act on protein synthesis comprise the macrolides (e.g. erythromycin and azithromycin), 
tetracyclines (e.g. tetracycline and doxycycline), spectinomycin, and aminoglycosides (e.g. 
amikacin, gentamicin, kanamycin, neomycin, streptomycin, tobramycin and oxazolidinones). 
Antimicrobials that act on DNA replication and repair include fluoroquinolones. Other classes 
are antibiotics active against membranes (i.e. polymyxins), inhibits folate synthesis (e.g. 
sulfonamides), or are cationic peptides.  
 
Over their long history of evolution, bacteria have developed various ways to protect 
themselves from antimicrobial attacks. These mechanisms can be generally categorized into four 
groups (Jayaraman 2008, 2009): 1) restriction of intracellular drug concentration by influx and 
efflux, 2) chemical modifications or destruction of drugs, 3) alterations of drug targets in bacteria, 
and 4) bacterial tolerant states which are associated with persistence, biofilm formation, and 
swarming. Some mechanisms mediate cross-resistance to multiple unrelated drugs, whereas 
more than one resistant mechanism can co-exist in a microorganism against a particular 
antibiotic.   
 
Generally, gonoccocal resistance to antimicrobial agents can be classified as plasmid-
mediated or chromosomally mediated resistance or both (Dillon & Pagotto 1999; Tapsall 2002).  
 
Plasmid-mediated resistance may confer resistance to penicillin (i.e. PPNG), or high-level 
resistance to tetracycline (i.e. TRNG). PPNG isolates harbor plasmids containing β-lactamase 
producing determinant (Dillon & Yeung 1986). Penicillinase production in these plasmids is 
mediated by a TEM1-type β-lactamase encoded by the TnA transposon Tn2, which is truncated 
and includes 84% of tnpR, noncoding sequences, the entire bla gene, and the right inverted 
repeat (IR-R) (Chen & Clowes 1987; Fayet et al 1982). TEM-1 was incorporated onto a plasmid 
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originally found in Haemophilus species which was mobilized into N. gonorrhoeae (Dillon & 
Yeung 1989; Brunton et al 1986). TRNG is associated with tetM determinant-containing 
plasmids which were created in nature as the result of the insertion of a tetM-like sequence into 
the endogenous gonococcal conjugative plasmid (Morse et al 1986; Swartley et al 1993; Greco et 
al 2003). The tetM determinant was originally described in Streptococcus species as a mobile, 
transposon-borne element which causes the release of tetracycline from the ribosome. In some 
cases, the tetM determinant is located on the chromosome in both N. gonorrhoeae and other 
species (Morse et al 1986; Swartley et al 1993). 
 
Mutations at various loci, singularly or in combination, are associated with chromosomally 
mediated resistance (CMR; Tapsall 2009a/b). The potential CMR determinants in N. 
gonorrhoeae include the quinolone resistance determining regions (QRDRs) in gyrA and parC, 
porB, penA, mtrR and ponA (Dillon & Pagotto 1999; Tapsall 2009a/b). The accumulation of 
chromosomal mutations may confer resistance to multiple antibiotics (i.e. MDR), or confer 
higher levels of resistance to single antibiotics (Tapsall 2009a/b; WHO 2001; Dillon & Pagotto 
1999). 
 
The following sections summarize the modes of action and mechanisms of gonococcal 
antimicrobial resistance, focusing on antibiotics that have been used for the treatment of 
gonorrhea. 
 
1.3.1 β-lactams: Penicillin and Cephalosporins 
 
The core chemical structure of β-lactams is the four-membered β-lactam-ring consisting of 3 
carbon atoms and one nitrogen atom. β-lactam antibiotics include penicillins, cephalosporins, 
cephamycins, carbapenems, monobactams, and β-lactamase inhibitors (Fig. 1.11). The different 
structure of side chains and other moieties adjacent to the β-lactam-ring give rise to variety of 
antimicrobial spectra and susceptibility to β-lactamase degradation. This class of antibiotics 
inhibits bacterial cell wall synthesis.  
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Fig. 1.11 Structure of β-lactam Antibiotics- Penicillin and Third-generation Cephalosporins. 
The core chemical structure of penicillins and cephalosporins is the four-membered β-lactam-
ring consisting 3 carbon atoms and one nitrogen atom (in red in the core structure). Structures of 
third-generation cephalosporins which have been used for the treatment of gonorrhea are shown 
[i.e. ceftriaxone, cefixime, ceftibuten, cefdinir and cefditoren].  
Adapted from Wikimedia (http://en.wikipedia.org/wiki/Cephalosporin#cite_note-0, accessed 
March 2011). 
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1.3.1.1 Penicillins 
The discovery of penicillin is attributed to Scottish scientist and Nobel laureate Alexander 
Fleming in 1928 (Ho 2000, http://205.188.238.181/time/time100/scientist/profile/fleming.html). 
Chemically, penicillins are derivatives of a 6 amino penicillanic acid nucleus (6 APA) which is 
essential for biological activity. In penicillins, the β-lactam-ring is fused to a five-membered 
sulfur ring system (Fig. 1.11). Penicillins covalently acylate and subsequently inactivate the cell 
wall transpeptidases known as penicillin-binding proteins (PBPs) to inhibit peptidoglycan (PG) 
transpeptidation reactions (Waxman & Strominger 1983; Walsh et al 2003; Zapun et al 2008). 
Penicillin had been used for the treatment of gonorrhea from 1945 to the late 1980s (Workoski et 
al 2008).  
 
Penicillin resistance in N. gonorrhoeae can be mediated by β-lactamase (penicillanse)-
producing plasmids in PPNG, mutations of various chromosomal genes, or both (Dillon & 
Pagotto 1999). Mutations at various loci, singularly or in combination, are associated with 
chromosomally mediated resistance (CMR) to penicillin in N. gonorrhoeae (Tapsall 2009a/b; 
Tanaka et al 2006). The resistance-associated loci include porB (coding for PorB) (van der Ley 
et al 1991; Gill et al 1998), mtrR (coding for MtrR) and the mtrR promoter (Hagman et al 1995), 
penA (coding for PBP2; Dougherty et al 1980) and ponA (coding for PBP1; Ropp & Nicholas 
1997).  
 
PorB, a porin, allows the passage of small molecules, such as β-lactams and tetracyclines, 
through the outer membrane (Danielsson et al 1986; Scudamore et al 1979). Each gonococcal 
isolate, designated as porB1a and porB1b encoding PIA or PIB proteins, respectively (Gotschlich 
et al 1987; Unemo et al 2002), contains only one of the two porB alleles, although hybrid porins 
have been reported (Cooke et al 1998; Gill et al 1994). PorB protein comprises eight surface-
exposed loops and the transmembrane regions interspaced the loops (Fig. 1.5, page 15). The 
surface exposed-loop regions of PorB have a high frequency of amino acid variations (Ison et al 
1988; Smith et al 1995). The PIA phenotype is associated with higher susceptibility to β-lactams 
and tetracyclines (Olesky et al 2006; Liao et al 2008). Amino acid substitutions at Gly-120 and 
Ala-121 of loop 3 of PorB are associated with decreased susceptibility to β-lactams and 
tetracyclines (Olesky et al 2002), and recently, G120K/A121D mutations in PorB were found to 
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be associated with decreased susceptibility of N. gonorrhoeae isolates to penicillins or third-
generation cephalosporins (Zhao et al 2009; Tanaka et al 2006; Tapsall 2009a/b).    
 
MtrR (Fig. 1.12A) is a protein that represses the expression of the N. gonorrhoeae 
MtrC/D/E efflux system, which exports hydrophobic antimicrobials such as tetracycline 
(Hagman et al 1995; Hagman & Shafer 1995). Mutations in MtrR can reduce MtrR repression of 
MtrC/D/E expression and result in enhanced resistance to hydrophobic agents (Hagman et al 
1995). Mutations in MtrR in clinical isolates of N. gonorrhoeae, which cause resistance to 
hydrophobic antimicrobial agents, include the alteration of its DNA binding domain (AA32-53) 
through A39T and G45D (Tanaka et al 2006; Zarantonelli
 
et al 1999) mutations as well as 
H105Y or E202G mutations in the dimerization domain (AA54-210) of MtrR (Shafer et al 1995). 
These mutations may appear singularly or in combination. Also, a single nucleotide deletion (-A) 
within the 13bp inverted repeat of the mtrR promoter reduces MtrR expression (Hagman & 
Shafer 1995), thereby alleviating repression of the efflux pump.  
 
Three major penicillin binding proteins (PBPs) are expressed in N. gonorrhoeae, namely 
PBP1, PBP2 and PBP3 (Dougherty et al 1980; Spratt & Cromie 1988). PBPs possess an amino-
terminal peptidoglycan transglycosylase domain and a carboxy-terminal penicillin-sensitive 
transpeptidase domain (Dougherty et al 1980; Spratt & Cromie 1988). PBPs are the targets of β-
lactam antibiotics (Dougherty et al 1980). Antibiotic binding to the active site of transpeptidase 
domain in PBPs is required for acylation of the PBPs by β-lactam antibiotics.  
 
In N. gonorrhoeae, among the three PBPs, PBP2 (Fig. 1.12B) has the highest affinity for 
penicillin binding (Spratt 1988; Ameyama et al 2002). Research suggests that insertion of Asp-
346 or other mutations in the transpeptidase domain at the C-terminus of PBP2 (AA263-570) are 
associated with altered protein affinity to penicillin (PEN) and PEN resistance of N. gonorrhoeae 
(Spratt 1988; Ameyama et al 2002).  
 
PBP1 proteins (Fig. 1.12C; Ropp & Nicholas 1997) with a L421P mutation exhibit 
decreased rates of acylation by β-lactam antibiotics and reduced affinity to penicillin, resulting in 
high-level penicillin resistance (Ropp et al 2002).  
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Fig. 1.12 Schematic Presentation of Antimicrobial Resistance Determinants in N. 
gonorrhoeae. Amino acid positions were indicated on the top of each sequence. Hatched 
segments were the regions analyzed.  A. MtrR. Promoter region (-1 to -100) was shown with the 
13 bp inverted repeat. Locations of the DNA binding domain (DBD) and the dimerization 
domain were indicated (Hagman & Shafer 1995; Lucas et al 1997). B. PBP2 (Penicillin Binding 
Protein 2). The N-terminal dimerization domain and the C-terminal transpeptidase domain were 
shown (Dougherty et al 1980). C. PBP1 (Penicillin Binding Protein 1). The N-terminal 
transglycosylase and the C-terminal transpeptidase domain were shown (Ropp & Nicholas 1997). 
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1.3.1.2 Cephalosporins 
 
Cephalosporins are the most commonly prescribed class of β-lactam antibiotics for treating 
both Gram-positive and Gram-negative bacterial infections. Cephalosporins are grouped into 
"generations" by their antimicrobial properties. First-generation cephalosporins are mainly active 
against Gram-positive bacteria, whereas, later cephalosporins (i.e. second-, third- and fourth-
generation cephalosporins) have extended-spectrum of antimicrobial activities. Each newer 
generation of cephalosporins has significantly greater antimicrobial properties against Gram-
negative bacteria than the preceding generation, and in most cases with decreased activity against 
Gram-positive organisms. Fourth-generation cephalosporins, however, have broad-spectrum 
activity, and are highly active against both Gram-positive and Gram-negative microorganisms 
(Llarrull et al 2010). 
 
Cephalosporins contain a β-lactam-ring which is fused to an expanded five-membered 
sulfur-containing ring and side chains (Fig. 1.11). Side chain modifications have led to the 
development of four generations of cephalosporins. The modified side chains of the 
cephalosporins allow the drugs to penetrate the cell envelop through the porins of Gram-negative 
outer membranes while retaining high affinities against its targets – penicillin binding proteins 
(PBPs). The side chain modifications also increase resistance of cephalosporins to β-lactamase 
attack, resulting in less susceptible of cephalosporins to penicillinases than penicillins. 
Cephalosporins bind to PBPs and inhibit peptidoglycan crosslinking by the PBP enzymes, 
resulting in inhibition of the final transpeptidation step in the synthesis of the peptidoglycan 
(Zapun et al 2008; Walsh et al 2003).  
 
 Currently third-generation cephalosporins ceftriaxone and cefixime are recommended for the 
treatment of uncomplicated gonorrhea (Workoski et al 2008). There have been few reports of 
clinical treatment failures caused by third-generation cephalosporins (Tapsall 2009a/b; Barry & 
Klausner 2009). However, N. gonorrhoeae isolates exhibiting reduced susceptibility were 
observed in a variety of countries (Tapsall 2009a/b; Barry & Klausner 2009). 
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Reduced susceptibility of N. gonorrhoeae isolates to third-generation cephalosporins is 
mediated via mutations in the products of various chromosomal genes involving chromosomally-
mediated penicillin resistance (Barry & Klausner 2009). Noticeably, a mosaic-like PBP2, first 
identified as PBP2 mutation Pattern X (Ameyama
 
et al 2002), may cause increased MICs to 
cefixime or ceftriaxone (≥ 0.25 mg/L) in N. gonorrheae isolates (Ameyama et al 2002; Ito et al 
2005; Takahata et al 2006). Specific mutations such as A501V and G545S in the transpeptidase 
domain of PBP2 have been identified to be associated with reduced susceptibility to cefixime or 
ceftriaxone in N. gonorrhoeae isolates (Takahata et al 2006; Osaka et al 2008).  
 
PBP1 protein with a L421P mutation which resulted in high-level penicillin resistance 
(Ropp et al 2002), has been noted in clinical N. gonorrhoeae isolates with reduced susceptibility 
to third-generation cephalosporins (Ropp et al 2002; Shigemura
 
et al 2005; Lindberg
 
et al 2007). 
Recently, mutations in the DNA binding domain of MtrR or within the mtrR promoter region 
have been associated with reduced susceptibility of N. gonorrhoeae to third-generation 
cephalosporins (Tanaka et al 2006; Tapsall 2009a/b). G120K/A121D mutations in PorB are also 
associated with decreased susceptibility of N. gonorrhoeae isolates to third-generation 
cephalosporins, in addition its association with penicillin resistance (Tapsall 2009a/b).   
 
The mechanisms behind reduced susceptibility or resistance to third-generation 
cephalosporins in N. gonorrhoeae are not well understood. Plasmid-mediated resistance to third-
generation cephalosporins in N. gonorrhoeae has not been reported (Barry & Klausner 2009). 
Chromosomal alterations in the porB, mtrR, penA and ponA genes may be simultaneously 
involved, and unknown alterations in other genes
 
may also play roles (Barry & Klausner 2009).   
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1.3.2. Quinolones 
Quinolones are synthetic molecules used as antibiotics to combat infections (Blondeau 
2004). Quinolone drugs have evolved through 4 generations based on chemical modifications of 
the 4-quinolone skeleton (Smith et al 2001), from its first developed molecule nalidixic acid (Fig. 
1.13). The second generation quinolones are fluorinated, including norfloxacin, ciprofloxacin 
and Ofloxacin (Ball 2000). Third-generation quinolones include levofloxacin. Further 
modifications of the 3
rd
 generation molecules result in the fourth generation quinolones such as 
gatifloxacin and moxifloxacin (Blondeau 2004; Blondeau & Missaghi 2004). Generation II, III, 
and IV quinolones each contain a fluorine atom attached to the nucleus at position 6, and are all 
known as fluoroquinolones. Ciprofloxacin was commonly used for the treatment of gonorrhea in 
the 1990s (Workoski et al 2008). 
 
Fluoroquinolones display bactericidal activities by inhibiting the prokaryote-specific 
enzymes DNA gyrase and topoisomerase IV (Blondeau 2004). Subsequently, bacterial DNA 
synthesis is blocked and bacterial cell death rapidly occurs (Khodursky et al 1995; Marlans & 
Hiasa 1997). In N. gonorrhoeae, DNA gyrase (GyrA, encoded by gyrA) is the primary target and 
topoisomerase IV (ParC, encoded by parC) the secondary target (Belland et al 1994).  
 
Mutations at key sites in GyrA and ParC - the quinolone resistance-determining region 
(QRDR; Fig. 1.14) can decrease their binding affinity to fluoroquinolones, reducing the drug's 
effectiveness in N. gonorrhoeae (Belland et al 1994; Deguchi et al 1996). QRDR is one of most 
well-characterized CMR mechanisms in N. gonorrhoeae. Key amino acid substitutions occur at 
the codons Ser-91 and Asp-95 in GyrA and Asp-86 or Ser-87 in ParC (Trees et al 1999; Ng et al 
2002a; Su et al 2001; Tanaka et al 2001). Various other mutations have been also reported (Trees 
et al 1999; Giles et al 2004; Tanaka et al 2000b).   
 
 Plasmid-mediated resistant genes produce proteins that can bind to DNA gyrase, protecting it 
from the action of quinolones (Martínez-Martínez et al 2008). These confer the so-called 
transferable fluoroquinolone resistance in Gram-negative and Gram-positive bacteria (Martínez-
Martínez et al 1998, 2008). In N. gonorrhoeae, plasmid-mediated quinolone resistance has not 
been reported. 
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Fig. 1.13 Structure of Quinolone Antibiotics. Quinolones are divided into four generations 
based on their antibacterial spectrum. Nalidixic acid – first generation, ciprofloxacin – second 
generation, levofloxacin – third generation, gatifloxacin and moxifloxacin – fourth generation. F- 
fluorine. Adapted from the Wikimedia website (http://en.wikipedia.org/wiki/Quinolone#First-
generation), accessed in March 2011.  
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Fig. 1.14 Schematic Presentation of Quinolone Resistance Determinant Regions (QRDRs) 
in GyrA (A) and ParC (B) in N. gonorrhoeae. Hatched regions represent QRDR s of GyrA and 
ParC (Belland et al 1994; Trees et al 1998). Amino acid positions are shown above the bars. 
Amino acids frequently mutated in ciprofloxacin resistant isolates are indicated. 
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1.3.3 Macrolides: Erythromycin and Azithromycin 
 
Macrolides are composed of at least two amino or neutral sugars attached to a large lactone 
ring of variable size according to the compound (Fig. 1.15). Erythromycin has a 14-membered 
ring and azithroumycin has a 15-membered ring (Walsh et al 2003). Macrolides are bacteriostatic.  
 
Erythromycin binds to the 50S subunit of the bacterial ribosome, blocking extension of the 
peptide chain by steric hindrance, and stimulates dissociation of peptidyl-tRNA. It also blocks 
assembly of the 50S subunits through its interaction with 23S rRNA. Azithromycin has 
extended-spectrum antimicrobial activities against Gram-positive and Gram-negative 
microorganisms and has a similar mode of action to erythromycin. Erythromycin had been used 
for the treatment of gonorrhea in cases where penicillin or quinolones are contradicted such as 
penicillin-allergy or pregnancy. Azithromycin is still a recommended first-line drug for the 
treatment of gonorrhea in some regions or in cases where cephalosporins are contradicted 
(Workoski et al 2008). Azithromycin has also been used in treating co-infections of N. 
gonorrrhoeae and Chlamydia trachomatis (PHAC 2006). 
 
Gonococcal resostance to macrolides is mediated by mutation of RNA or ribosomal proteins. 
The erm genes encode erythromycin ribosome methylases, which are carried by plasmids or 
transposons (Trees et al 1999). Mutations in the ribosomal genes 16S rRNA or the 23S rRNA rrl 
gene are associated with resistance of N. gonorrhoeae to azithromycin and erythromycin (Ng et 
al 2002b; Roberts et al 1999, 2004;  Chisholm et al 2009, 2010; Galarza et al 2009, 2010). Single 
mutations in 23S rRNA have been associated with high-level resistance to azithromycin 
(Chisholm et al 2009, 2010; Galarza et al 2009, 2010). 
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Fig. 1.15 Structure of Erythromycin and Azithromycin. Adapted from the Wikimedia website 
(http://en.wikipedia.org/wiki/Azithromycin), accessed March 2011.  
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1.3.4 Tetracyclines 
Tetracyclines (tetracycline and doxycycline) contain four hydrocarbon rings (Fig. 1.16) and 
are bacteriostatic. They bind to the 30S ribosomal subunit inhibiting protein biosynthesis 
(elongation). Tetracyclines have been used for treatment of genital chlamydial infections or in 
combination with anti-gonococcal antibiotics for the treatment of co-infections in gonorrhea 
patients (CDC 2010; WHO 2003). 
 
Gonococcal resistance to tetracyclines can be mediated by tetM-containing plasmids, 
causing high levels of resistance to this class of antibiotics, i.e. TRNG (Dillon & Pagotto 1999). 
TRNG is associated with tetM determinant-containing plasmids which were created in nature as 
the result of the insertion of a tetM-like sequence into the endogenous gonococcal conjugative 
plasmid (Morse et al 1986; Swartley et al 1993; Greco et al 2003). The tetM determinant was 
originally described in Streptococcus species as a mobile, transposon-borne element which 
causes the release of tetracycline from the ribosome. In some cases, the tetM determinant is 
located on the chromosome in both N. gonorrhoeae and other species (Morse et al 1986; 
Swartley et al 1993). 
 
Mutations in the rpsJ gene of the gonococcal chromosome and porB types are also 
associated with tetracycline resistance in N. gonorrhoeae (Hu et al 2005; Liao et al 2008). 
 
1.3.5 Spectinomycin 
Spectinomycin (Fig. 1.16) is an aminocyclitol antibiotic, closely related to the 
aminoglycosides and is a bacteriostatic agent. It acts on the 30S ribosomal subunit, inhibiting 
translocation of the peptidyl tRNA. It is recommended for the treatment of gonorrhea in 
individuals that have documented cephalosporin allergy and are pregnant or are strongly 
suspected to have fluoroquinolone resistant gonorrhea (WHO 2003).  
 
Mutations in 16S rRNA N. gonorrhoeae are associated with resistance to spectinomycin 
(Galimand et al 2000). Mutations of ribosomal protein S5 preventing the ribosome from 
spectinomycin binding has also been reported (Kehrenberg & Schwarz 2007). 
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Fig. 1.16 Structure of Tetracyclines, Doxycycline and Spectinomycin.  
Adapted from the Wikimedia websites (http://en.wikipedia.org/wiki/Spectinomycin; 
http://en.wikipedia.org/wiki/Tetracycline; http://en.wikipedia.org/wiki/Doxycycline), accessed 
March 2011.  
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1.4 Molecular Typing and Molecular Epidemiology in Neisseria gonorrhoeae 
 
 1.4.1 Overview of Molecular Typing Methods for N. gonorrhoeae 
 
A number of phenotypic and genotypic typing methods have been developed for use inthe 
epidemiology of infectious diseases to distinguish isolates. These methods have been applied to 
the molecular epidemiology of gonorrhea (Sarafian and Knapp 1989; Unemo & Dillon 2011; 
Table 1.2). 
 
 Index of discrimination (ID) has been used to characterize discriminatory abilities of typing 
methods. ID indicates the probability of a typing method to differentiate two different isolates 
(Hunter & Gaston 1988). An ID of higher than 90% has been considered to be sufficient in 
differentiating N. gonorrhoeae isolates (Dillon et al 1993). 
 
1.4.1.1 Phenotypic Differentiation of N. gonorrhoeae Isolates 
 
The phenotypic characterizations of N. gonorrhoeae (Unemo & Dillon 2011) have included 
auxotyping (A) (Carifo & Catlin 1973; Ng & Dillon 1993), serovar determination (S) (Knapp et 
al 1984; Sandström et al 1982, 1984; Dillon et al 1987a/b), and the combination of A/S (Ng & 
Dillon 1993), as well as antibiogram determination, or a combination of these methods (Ng et al 
1995).  
 
Antibiogram: Antibiogram determinations are used for monitoring antibiotic susceptibility 
and for determining appropriate treatment recommendations (Dillon et al 1978b, 1990; Dillon & 
Pagotto 1999). The discriminatory power of antibiograms is low, and this limits their usefulness 
for isolate differentiation. Antibiograms are inappropriate for epidemiological studies of 
gonorrhea (Ng et al 1995; Dillon et al 1993).  
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Table 1.2 Characteristics of Typing Methods Used in Differentiating N.  gonorrhoeae Isolates
§
 
Method Principles/Targets ID RP EI EU Labor 
intense  
Cost 
Antibiogram Antimicrobial susceptibility 
profiles 
Low High Moderate 
to high 
High High Moderate 
 
Auxotyping 
(A) 
 
Nutritional requirements 
 
Low 
 
High 
 
Moderate  
 
Moderate 
 
High 
 
Moderate 
        
Serovar 
typing (S) 
Detection of outer membrane 
proteins using monoclonal 
antibodies 
Moderate  High Moderate  Low High High 
 
A/S 
 
 
Combination of A & S 
 
High 
 
High 
 
Moderate  
 
Low 
 
High 
 
High 
MLEE Electrophoresis of house-
keeping proteins 
Moderate Moderate Moderate Moderate Moderate Moderate 
to high 
 
Plasmid  
profiles 
 
Drug resistance plasmids based 
on size or PCR amplification 
 
Low 
 
Moderate 
to high 
 
Moderate 
to high 
 
High 
 
Moderate 
 
Low 
 
Ribotyping 
 
Restriction endonuclease (RE) 
digestion and use of  ribosomal 
RNA probes 
 
Low 
 
Low to 
moderate 
 
Moderate 
 
Moderate 
 
Moderate 
 
Moderate 
 
PFGE 
 
Large chromosomal  DNA 
fragments of RE digestion 
separated by pulsed field gel 
electrophoresis 
 
High  
 
Moderate 
 
Moderate 
 
Low 
 
Moderate 
 
Moderate 
 
Opa typing 
 
PCR amplification of opa loci 
and observation of banding 
patterns on agarose gel 
 
High 
 
Moderate 
 
Moderate 
 
Low to 
moderate 
 
Moderate 
 
Moderate 
4
5
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§: Modified from Unemo & Dillon 2011, in press. 
ID: Index of discrimination 
RP: Reproducibility 
EI: Ease of interpretation 
EU: Ease of use 
MLEE: Multiple locus enzyme electrophoresis 
PFGE: Pulsed field gel electrophoresis 
MLST: Multilocus sequence typing 
NG-MAST: Neisseria gonorrhoeae multi-antigen sequence typing 
Lip-typing PCR amplification and DNA 
sequences of repeats in 
lipoprotein coding sequences 
Moderate High Moderate 
to high 
High Low Low 
 
MLST 
 
DNA sequences of internal 
fragments of housekeeping 
genes 
 
Moderate to 
high  
 
High 
 
Moderate 
to high 
 
Moderate 
to high 
 
Low to 
moderate 
 
Moderate 
        
porB-based DNA sequences of porB (full- or 
extended-length) 
High High High High Low Low 
 
NG-MAST 
 
DNA sequences of fragments of 
porB and tbpB 
 
High 
 
High 
 
High 
 
High 
 
Low 
 
Low 
4
6
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 Auxotyping (A): Auxotyping is based on nutritional requirements of N. gonorrhoeae 
isolates. Some nutritional components (e.g. cystine, cysteine) are required for all isolates of N. 
gonorrhoeae, whereas various other components are required by some but not all isolates. 
Auxotyping differentiates N. gonorrhoeae isolates into various nutrient-requiring phenotypes, 
e.g. non-requiring (NR) or prototrophic, proline-requiring (P), arginine-hypoxanthine-uracil-
requiring (AHU), and proline-citrulline-uracil-requiring (PCU) (Ng et al 1995). This method is 
labour-intensive and is insufficient in discriminatory ability (Dillon et al 1987b, 1993).  
 
Serotyping (S) and A/S typing: Serotyping is based on the antigenic diversity of the major 
outer membrane porin proteins, known as the protein I (PI) molecules or PorB (Sandstrom et al 
1982). Building on earlier typing schemes using polyvalent antibodies against whole gonococcal 
proteins or partially purified protein PI (Sandstrom and Danielsson 1980, Buchanan and 
Hildebrandt 1981), typing schemes based on monoclonal antibodies (MAbs) against PI were 
developed (Knapp et al 1984). One of these typing systems is the use of the Genetic system (GS) 
series of MAbs (Knapp et al 1984). Another set of PI-specfic MAbs was designed as the Ph 
panel (Pharmacia; Bygdeman et al 1983; Kohl et al 1990). The utilization of the series of the 
MAbs produces serotyping schemes with high discriminatory ability, especially when it is used 
in combination with auxotyping methods (Dillon et al 1987a/b, 1990, 1993). However, the use of 
this approach is limited by inconsistency in the interpretation of weak reactions, the 
inaccessibility to the MAbs, and the prevalence of non-serotypeable strains (Unemo et al 2003). 
 
Multiple Locus Enzyme Electrophoresis (MLEE): MLEE indexes allelic variations based 
on banding patterns of multiple housekeeping enzymes (Ng & Dillon 1993; De la Fuente & 
Vazquez 1992). MLEE has low discriminatory power if clones are being examined, and can be 
difficult to interpret due to differences in cultural growth conditions and enzyme productivity. 
This method is very laborious. The MLEE method is the ―ancestor‖ of the multilocus DNA 
sequence typing method (MLST) and has largely been replaced by MLST for all bacterial 
species.  
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1.4.1.2 Genotypic Differentiation of Neisseria gonorrhoeae Isolates 
  
 Molecular typing techniques (Table 1.2, page 45) have been developed and used in 
molecular epidemiology to address epidemiologic problems in infectious diseases. The factors 
for evaluating applicability of molecular typing methods to epidemiology include simplicity, 
high throughput, low cost, and appropriateness as compared to conventional methods (Riley 
2004). Selection for molecular typing systems is based on typeability, reproducibility, ease of 
interpretation, ease of use, and high discriminatory power (Maslow et al 1993).  
 
Methods of DNA sequence analysis are reproducible, and all strains are typeable, which 
facilitates inter-laboratory comparisons of results nationally and internationally. These methods 
have gained popularity in molecular epidemiology of gonorrhea. Methods based on DNA 
sequence analysis of single (porB) or combinations of hyper-variable loci (e.g. porB and tbpB) 
have become the most useful tools in short-term molecular epidemiology of N. gonorrhoeae. 
 
Genotypic typing methods are dependent on analysis of chromosomal or plasmid DNA 
molecules (Unemo & Dillon 2011). Analysis of plasmid content includes determination of 
molecular weights of plasmids and banding patterns of products of PCR amplification on 
plasmids (Dillon et al 1987b; Dillon & Carballo 1990; Ison et al 1993; Greco et al 2003). 
Restriction endonuclease (RE) analyses of whole chromosomal genomes include ribotyping, RE 
analysis using pulsed-field gel electrophoresis (PFGE; Li & Dillon 1995; Ng & Dillon 1993; 
Poh et al 1995a/b). Analysis of banding patterns of PCR products of multiple loci of gonococcal 
genome includes Opa-typing (O’Rouke et al 1995) and Lip-typing (Trees et al 2000).  
 
DNA sequence-based typing of single or multiple loci has been widely used such as porB-
based typing (Vicsidi et al 2000; Unemo et al 2002, 2003).Neisseria gonorrhoeae-multiantigen 
sequence typing (NG-MAST; Martin et al 2004), and Multilocus Sequence Typing (MLST; 
Maiden et al 1998; Maiden 2006; Viscidi & Demma 2003).  
 
Plasmid Content Analysis: Most gonococcal strains carry a 4.2-kilobase pair plasmid (2.6 
megadalton, MDa) and a 24.5 MDa transfer plasmid (Sox et al 1978). Plasmid analysis has been 
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used to differentiate plasmid-mediated antimicrobial resistance including penicillinase-producing 
N. gonorrhoeae (PPNG) and plasmid-mediated tetracycline resistant N. gonorrhoeae (TRNG) 
(Dillon & Yeung 1989; Ison et al 1993, Xia et al 1995; Greco et al 2003).  
 
Penicillinase production in the plasmids carried by PPNG isolates is mediated by a TEM1-
type β-lactamase which is encoded by the TnA transposon Tn2 (Chen and Clowes 1987; Fayet et 
al 1982). The family of gonococcal β-lactamase-producing plasmids is genetically related (Dillon 
& Yeung 1989; Roberts 1989). Six plasmid types have been described, i.e. Asia- (generally 
reported as 4.2– 4.4 MDa), Africa- (3.2 MDa), Toronto- (3.05 MDa), Rio- (2.9 MDa), Nıˆmes- 
(3.8 MDa), and New Zealand- types (6.5 MDa) (Brett 1989; Dillon & Yeung 1989; Gouby et al 
1986; Yeung et al 1986). A number of studies, based on restriction endonuclease analysis, 
hybridization analysis, and heteroduplex analysis by electron microscopy have shown that the 
Africa-, Toronto-, Nıˆmes-, Rio-, and New Zealand- type plasmids are deletion or insertion 
derivatives of the prototype Asia-type plasmid (Gouby et al 1986; Yeung et al 1986). Recently, a 
new type of β-lactamase-producing plasmid was identified gonococcal isolates from South 
Africa (Fayemiwo et al 2010). 
 
TRNG is associated with the presence of a 25.2-MDa tetM-containing plasmid (TetM 
plasmid). This plasmid was created in nature as the result of the insertion of a tetM-like sequence 
into the endogenous gonococcal 24.5-MDa conjugative plasmid (Morse et al 1986). Using 
restriction endonuclease analysis, tetM-containing plasmids in N. gonorrhoeae were classified as 
either American type (first originating in the United States) or Dutch type (first originating in the 
Netherlands) (Gascoyne-Binzi et al 1991). The Uruguay TetM type exhibits a unique restriction 
pattern, and its amplimer demonstrates 100% identity with a tetM-containing plasmid from N. 
meningitidis (Marquez et al 2002).  
 
PCR-based plasmid typing methods have been developed for rapidly detecting and 
differentiating β-lactamase producing plasmids of PPNG isolates (Dillon et al 1999) and tetM-
containing plasmids of TRNG isolates (Xia et al 1995). These methods are easy to perform and 
are useful for investigating antimicrobial resistance and outbreak of plasmid-harbouring N. 
gonorrhoeae strains; however, the discriminatory power of plasmid typing is low (Dillon et al 
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1993).  
 
Ribotyping: Ribotyping (Li & Dillon 1995; Ng & Dillon 1993) utilizes techniques of 
restriction endonuclease (RE) analysis and . In RE analysis, chromosomal DNA is cleaved with 
type II restriction endonucleases producing a unique set of DNA fragments for each chromosome. 
The resulting restriction fragment length polymorphisms (RFLP) were analyzed by gel 
eletrophoresis. Ribotyping involves the digestion of the bacterial genome, electrophoresis, and 
visualization of the resulting banding patterns after hybridization with a ribosomal RNA probe 
(rRNA) (Pace et al 1986). Ribotyping has been used in studying strain distribution of N. 
gonorrhoeae (Ng & Dillon 1993). However, ribotyping is laborious and has a low discriminatory 
power (Unemo & Dillon 2011).  
  
Pulsed Field Gel Electrophoresis (PFGE): PFGE improves resolution of DNA fragments by 
repeatedly changing the orientation of the electric field in gel electrophoresis. It can resolve DNA 
fragments ranging in size up to 2000 kb (Li & Dillon 1995; Sor 1988). This method makes use of 
low-frequency cutting REs in comparative analysis of RFLP (Li & Dillon 1995; Ng et al 1995; van 
Looveren et al 1999). PFGE has a high discriminatory power. Major limitations of PFGE, however, 
include laboriousness and difficulties if not impossibility of comparing results between laboratories.  
 
Opa-typing: Opa-typing involves analysis of up to 11 opa genes coding for the neisserial 
colony opacity-associated (Opa) proteins (O’Rourke et al 1995; Palmer et al 2001; Ison 1998; Ward 
et al 2000). In Opa-typing, opa genes are PCR-amplified; PCR products are subjected to RE 
digestion; banding patterns are compared after gel electrophoresis (O’Rourke et al 1995). Opa-
typing has a high discriminatory power and has been used in tracking strain transmission and strain 
clustering in N. gonorrhoeae (O’Rourke et al 1995). Major limitations of Opa-typing, however, are 
laboriousness, and the difficulty in standardizing results and in comparing banding patterns between 
laboratories.  
 
Lip-based DNA Sequence Typing: Lip-typing (Trees et al 2000) characterizes the number 
and sequences of repeats (encoding a five amino acid sequence, AAEAP) in the gene encoding 
an outer membrane lipoprotein (Woods et al 1989). By PCR amplifying the lip gene and 
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subsequently differentiating the sizes of PCR products, the number of the repeat-coding 
sequences can be predicted. DNA sequence analysis of the amplicons further differentiates N. 
gonorrhoeae strains with the same number of repeats, thus identifying Lip subtyping patterns 
(Trees et al 2000). The discriminatory ability of this method remains to be assessed.  
 
Multiple Locus Sequence Typing (MLST): MLST evolved from the MLEE phenotypic 
typing method (De la Fuente & Vazquez 1992). MLST typing scheme for N. gonorrhoeae was 
originally adapted from MLST for N. meningitides (Viscidi & Demma 2003; Maiden et al 1998). 
A slight modification of the ―meningitidis‖ scheme with addition of one gene has been used for 
molecular epidemiology of N. gonorrhoeae (Bennet et al 2007). A similar MLST scheme targeting 
seven loci (fumC, gdh, glnA, gnd, pilA, pyrD and serC) has been used in studying gonococcal 
population dynamics (Viscidi & Demma 2003; Tazi et al 2010). MLST typing is most useful for 
studying bacterial genomic evolution and bacterial populations (Viscidi & Demma 2003) since 
the house-keeping genes are under neutral selection and evolve slowly (Pérez-Losada et al 2005).  
 
Recent work from the Dillon laboratory improved the resolution of gonococcal MLST by 
altering targeted loci, which has been shown to have high discriminatory abilities and abilities to 
identify geographic clusters and outbreaks (Vidovic et al 2010), indicating its usefulness in both 
short- and long-term molecular epidemiology of N. gonorrhoeae (Unemo & Dillon 2011). 
 
porB-based DNA Sequence Typing: porB-based DNA sequence typing is the analysis of 
the entire or a segment of the porB gene (Vicsidi et al 2000; Unemo et al 2002). This method has 
high discriminatory power when extended length or full-length porB sequences are used (Unemo 
& Dillon 2011). The cost for using this method is low as compared to other DNA sequence-
based methods. It has been used to trace the transmission of individual N. gonorrhoeae strains 
within a community, to identify suspected clusters of cases of gonorrhea, and to confirm the 
epidemiological connection of patients (Hobbs et al 1999; Unemo et al 2002; Viscidi & Demma 
2003).  
 
Neisseria gonorrhoeae Multi-Antigen Sequence Typing (NG-MAST): NG-MAST 
involves the analysis of two highly variable loci, porB and tbpB (Martin et al 2004). NG-MAST 
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has been used to confirm sexual contacts and trace strain transmission in geographically 
localized communities (Choudhury et al 2006; Bilek et al 2007). The combination of two 
hypervariable loci establishes that NG-MAST has a very high discriminatory power. A database 
is available for researchers to compare sequence types of N. gonorrhoeae isolates from different 
laboratories and geographical areas (http://www.ng-mast.net, accessed 20 December 2010).  
 
Whole Genome Sequencing of N. gonorrhoeae: Comparative genome analysis for 
differentiating N. gonorrhoeae strains is at its ―infant‖ stage (Unemo & Dillon 2011). Up to date 
(July 30, 2010), the genomes of two N. gonorrhoeae strains have been completely sequenced: N. 
gonorrhoeae FA1090, NCCP11945 and TCDC-NG08107. The genome of N. gonorrhoeae 
FA1090 (GenBank Accession #AE004969) is 2.153922 million nucleotides (Mbp) in length with 
a GC content of 52.0%. There are 2002 protein-coding sequences and 67 structural RNA-coding 
sequences in the N. gonorrhoeae FA1090 genome. Sequencing of the N. gonorrhoeae 
NCCP11945 genome was completed in July 2008 (Chung et al 2008); it contains 2.232023 Mbps 
with a GC content of 52.0% (GenBank Accession # CP001050). There are 2662 protein-coding 
sequences and 67 structural RNA-coding sequences in the N. gonorrhoeae NCCP11945 genome.  
 
Ongoing N. gonorrhoeae genome sequencing projects as of June 2010 utilize 14 N. 
gonorrhoeae strains (Table 1.3). According to the drafted genome data 
(http://www.ncbi.nlm.nih.gov/genomeprj/23), the genome of N. gonorrhoeae F62 (GenBank 
Accession #ADAA00000000), which was used as a reference strain, contains 2.11661 Mbps 
with a GC content of 52.0%. There are 2078 protein-coding sequences and 48 structural RNA-
coding sequences in the N. gonorrhoeae F62 genome. The other 13 N. gonorrhoeae strains used 
in the ongoing genome project included clinical isolates from patients with gonococcal pelvic 
inflammatory diseases (n=4) or from disseminated gonococcal infections (n=4). Two 
antimicrobial resistant isolates used in the genome project had a reduced susceptibility to third-
generation cephalosporins and were resistant to penicillin and tetracycline, respectively (n=2). 
Some other widely used experimental strains were also included (i.e. N. gonorrhoeae 1291, 
FA19 and MS11; n=3). 
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To date, four N. gonorrhoeae plasmids have been completely sequenced, i.e. pJD4 (Pagotto 
et al 2000), pSJ5.2 (Scharbaai-Vázquez et al 2007), pCmGFP (GenBank Accession #FJ172221) 
and pNGK (GenBank Accession #CP001051). These plasmids had lengths of 7.4 (pJD4), 5.16 
(pSJ5.2), 6.1 (pCmGFP), and 4.2 kbp (pNGK), respectively. The GC contents were variable, 
ranging from 38% to 51%.  
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Table 1.3 Current Genome Sequencing Projects in N. gonorrhoeae† 
 
N. gonorrhoeae 
strain/plasmid 
name 
Strain source/characteristics GenBank 
accession number    
Length 
(Mbp) 
GC 
content 
# of 
proteins
* 
 
# of 
RNAs
**
 
Project 
status
§
  
        
N. gonorrhoeae 
FA1090 
 
Serum-resistant, proline-requiring, 
isolated from a patient with 
disseminated gonococcal infection 
(DGI) 
AE004969 2.15392 52.0% 2002 67 Complete 
N. gonorrhoeae 
NCCP11945 
Multiple drug resistant, isolated 
from vaginal smears in Korea 
CP001050 2.23203 52.0% 2662 67 Complete 
N. gonorrhoeae 
F62 
Used for comparative genome 
analysis 
ADAA00000000 2.11661 52.0% 2078 48 Draft 
assembly 
N. gonorrhoeae 
1291 
Extensively used in studies of 
gonococcal pathogenesis 
ABZF00000000 2.03323 51.0% 2110 42 Draft 
assembly 
N. gonorrhoeae 
35/02 
Serovar IB-1, reduced 
susceptibility to cefixime and 
ceftriaxone, isolated in Sweden 
BAZG00000000 2.04374 51.0% 2131 46 Draft 
assembly 
N. gonorrhoeae 
DG118 
DGI isolate ABZH00000000 2.03591 52.0% 2137 49 Draft 
assembly 
N. gonorrhoeae 
DG12 
DGI isolate ACIG00000000 2.09393 51.0% 2352 48 Draft 
assembly 
N. gonorrhoeae 
FA19 
Penicillin susceptible ABZJ00000000 2.09989 51.0% 2183 46 Draft 
assembly 
N. gonorrhoeae 
FA6140 
Resistant to penicillin and 
tetracycline, isolated in North 
Carolina USA 
ABZI00000000 2.03396 52.0% 2144 49 Draft 
assembly 
N. gonorrhoeae 
MS11 
A widely used experimental strain ABZK00000000 2.09815 51.0% 2263 49 Draft 
assembly 
        
        
5
4
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N. gonorrhoeae 
PID1 
A cervical isolate from a case of 
pelvic inflammatory disease (PID) 
ABZM00000000 2.09132 51.0% 2267 49 Draft 
assembly 
N. gonorrhoeae 
PID18 
A cervical isolate from a case of 
PID 
ABZL00000000 2.08326 51.0% 2235 46 Draft 
assembly 
N. gonorrhoeae 
PID24-1 
A cervical isolate from a case of 
PID 
ABZN00000000 2.03375 52.0% 2144 46 Draft 
assembly 
N. gonorrhoeae 
PID332 
A cervical isolate from a case of 
PID 
ABZO00000000 2.10185 51.0% 2265 46 Draft 
assembly 
        
N. gonorrhoeae 
SK-92-679 
An isolate from the blood of a 
patient with DGI 
ABZP00000000 2.06828 51.0% 2218 42 Draft 
assembly 
N. gonorrhoeae 
SK-93-1035 
An isolate from the blood of a 
patient with DGI 
ABZQ00000000 2.04937 51.0% 2200 48 Draft 
assembly 
        
Plasmid pJD4 Submission: Dillon et al 1995 U20374 0.0074 38.0% 1 -- Complete 
Plasmid pSJ5.2 Submission: Scharbaai-Vazquez et 
al 2006 
DQ355980 0.00516 38.0% 3 -- Complete 
Plasmid 
pCmGFP 
Submission: Dowideit et al 2008 
 
FJ172221 0.0061 48.0% 2 -- Complete 
Plasmid pNGK Submission: Yoo et al 2008 CP001051 0.0042 51.0% 12 -- Complete 
 
†: Data was derived from the National Center for Biotechnology Information (NCBI) website 
(http://www.ncbi.nlm.nih.gov/genomeprj/23). 
*: Number of protein-coding genes. 
**: Number of structural RNA-coding genes. 
§: Project status as of July 30, 2010. 
 
 
 
 
 
5
5
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1.4.2 Molecular Epidemiology of Gonorrhea 
 
The term "molecular epidemiology" was first proposed in 1973 by Kilbourne (Kilbourne 
1973). The definition of molecular epidemiology has since evolved. Recently, Riley (2004) 
defined molecular epidemiology of infectious diseases as ―the study of the distribution and 
determinants of infectious diseases that utilize molecular biology methods.‖ Molecular 
epidemiology of infectious disease uses combinatorial approaches of molecular typing methods 
and epidemiology to elucidate observations made in the biological world to formulate new 
concepts and make predictions. Molecular epidemiology determines the dynamics of disease 
transmission and identifies risk factors including genetic determinants.  
 
N. gonorrhoeae is highly variable in its genotype and phenotype (Fredlund et al 2004; 
O’Rourke et al 1995). The characteristics of variability have been exploited to differentiate 
gonococcal strains circulating in a given community, thereby identifying patterns of specific 
strain transmission and guiding control strategies (Unemo et al 2002, 2004; Viscidi et al 2000; 
Martin et al 2004). An objective of this study was to determine strain distributions and 
circulating clusters of N. gonorrhoeae in Shanghai using porB-based DNA sequence analysis 
and NG-MAST analysis as molecular typing tools.  
  
 Molecular typing methods which differentiate N. gonorrhoeae isolates, coupled with 
traditional epidemiological methods, have been used to identify circulating clusters of N. 
gonorrhoeae isolates and transmission networks (Choubury et al 2006; Ward et al 2000). DNA 
sequence analysis of various gene(s) is currently the method of choice for distinguishing N. 
gonorrhoeae isolates as it provides unambiguous and reproducible information, has high 
discriminatory power, and enables data to be stored or shared electronically, permitting reliable 
comparisons to be made between laboratories (Maiden 2006; O’Rouke et al 1995; Viscidi et al 
2000).  
  
 porB-based DNA sequence analysis has been used for studying the molecular epidemiology 
of N. gonorrhoeae since 2000 (Bash et al 2005; Lunback et al 2006; Pérez-Losada  et al 2005; 
Unemo et al 2002, 2003, 2004; Viscidi et al 2000) and involves sequencing either the entire gene 
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or various regions of porB (Unemo et al 2002, 2003, 2004). DNA sequence analysis of 
gonococcal porB genes can provide a high index of discrimination for isolates of N. gonorrhoeae 
(Viscidi et al 2000; Unemo et al 2003) and has been used to identify circulating strains/clusters 
(Unemo et al 2002, 2003; Bash et al 2005; Lynn et al 2005; Hobbs et al 1999), track strain 
transmission in sexual contacts (Cooke et al 1997; Unemo et al 2002; Viscidi et al 2000, 2003), 
and investigate antibiotic resistance  (Lunback et al 2006; Olesky et al 2002, 2006). 
 
The N. gonorrhoeae Multi-Antigen Sequence Typing (NG-MAST) methodology, which has 
been applied since 2004 (Martin et al 2004; Bilek et al 2007; Lunback et al 2006; Unemo et al 
2007a/b), is based on DNA sequence analysis of two highly polymorphic loci, porB and tbpB 
(Martin et al 2004). The NG-MAST database, available online (www.ng-mast.net), allows public 
access for sequence submission and assignment of sequence types for either porB or tbpB 
individually, or for the assignment of strain types (STs) using a combination of the two loci.  
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1.5 Hypothesis and Objectives 
 
China has experienced an increasing burden of gonorrhea and antimicrobial resistance in N. 
gonorrhoeae isolates. The expansion of international trade, and social and travel relationships in 
China facilitates the global diffusion of infectious agents and antimicrobial resistance. This study 
focused on investigating the prevalence of antimicrobial resistance and mechanisms of 
antimicrobial resistance in N. gonorrhoeae in Shanghai, China. This study also explores 
molecular epidemiology of gonorrhea in China. 
 
1.5.1 Hypothesis 
 
 Trends of antimicrobial resistance of N. gonorrhoeae in Shanghai differ temporally and 
geographically from Urumchi, China. Isolates with decreased susceptibility or resistance to third-
generation cephalosporins are emerging; 
 Specific genetic alterations in various loci are associated with gonococcal antimicrobial 
resistance (i.e. gyrA and parC for quinolone resistance; porB, mtrR, penA and ponA for third-
generation cephalosporin resistance). 
 Molecular epidemiology based on porB DNA sequence analysis and NG-MAST typing of N. 
gonorrhoeae isolates will reveal connected clusters of infections not identified by partner tracing 
or traditional epidemiological survey methods and will elucidate temporal and geographic 
differences between N. gonorrhoeae isolates; 
 
1.5.2 Objectives 
 
 To describe patterns and trends of antimicrobial resistance in N. gonorrhoeae in China by 
analyzing antimicrobial susceptibility profiles for isolates collected from: 
 Shanghai in 2005 
 Shanghai in 2008  
 Urumchi in 2007-2008 
 To investigate the underlying molecular mechanisms of gonococcal antimicrobial resistance 
by analysis of: 
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 Quinolone resistance determinant regions (QRDR) of GyrA and ParC 
 Mutations in genes/proteins potentially associated with reduced susceptibility to 
ceftriaxone: 
o PorB (porB) 
o MtrR (mtrR) 
o Penicillin binding protein 2 (PBP2, penA) 
o Penicillin binding protein 1 (PBP1, ponA) 
 To describe the distribution of N. gonorrhoeae strain types in Shanghai by molecular 
epidemiological studies using molecular tools: 
 Refining a typing scheme of porB-based DNA sequence analysis 
 Strain distribution based on porB DNA sequence analysis  
 Strain distribution based on NG-MAST analysis 
 Association of molecular types and epidemiologically revealed sexual contacts 
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CHAPTER TWO 
 
METHODOLOGY 
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An overview of the study design and methodology is provided in Fig. 2.1. In Shanghai, male 
gonorrhea patients were recruited as index patients and interviewed. Sexual partners of the index 
patients were asked to participate and also interviewed. N. gonorrhoeae isolates were collected 
from both male and female gonorrhea positive participants and examined for antimicrobial 
susceptibilities. DNA sequence analysis of targeted loci was conducted and pylogenetic analysis 
based on porB DNA sequences were carried out to determine strain distributions. Finally, 
molecular data were combined with information obtained in traditional epidemiological surveys 
to determine sexual networks and transmission patterns of gonorrhea.  
 
 
Fig. 2.1 Overview of Methods. This is a cross-sectional study. Recruitment of participants, N. 
gonorrhoeae isolation and identification, isolate subculture and storage, antimicrobial 
susceptibility testing and chromosomal DNA isolation were performed at the Shanghai Skin 
Disease and STD Hospital, Shanghai, China. Studies in Shanghai were conducted in 2005 and 
2008, respectively. Studies in Urumchi involved collection of N. gonorrhoeae isolates during 
2007-2008. AMR:  Antimicrobial resistance. PCR: Polymerase chain reaction.  
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2.1 Epidemiological Design 
 
2.1.1 Study Sites 
 
This study used a cross-sectional design and was conducted in the Shanghai Skin Disease 
and STD Hospital (SSDSH) in Shanghai, China, in 2005 and 2008. To investigate the geographic 
distribution of gonococcal strains, N. gonorrhoeae isolates were also collected in 2007-2008 
from Urumchi, Xinjiang Province, China.  
 
Ethics approval was obtained from the Ottawa Hospital Research Ethics Board, Canada, the 
Ethics Committee of the Shanghai Municipal Bureau of Public Health, and the Ethics Office of 
the University of Saskatchewan, Canada. Patients’ identities and isolate identities were re-
assigned to make it impossible to identify individual patients from the data presented herein.  
 
2.1.2 Patient Recruitment and Collection of Epidemiological Information 
 
In Shanghai, participants were recruited and interviewed at the SSDSH. Male patients 
attending the SSDSH STD clinics were examined for gonococcal infections. Gonorrhea 
diagnosis was based on contact history, clinical manifestations, and laboratory examinations as 
described by the STI guidelines (Wang & Zhang 2007). Laboratory diagnosis included screening 
tests by Gram-stain and microscopy of urethral (male) or cervical (female) swabs, and 
confirmatory tests by the culture and identification of N. gonorrhoeae (PHAC 2006; China CDC 
2007b; Wang & Zhang 2007). Male gonorrhea patients were invited to participate in the study as 
index patients. Consenting male index patients were administered a questionnaire by trained 
clinical staff. Questionnaires (Appendix A1) included questions on demographic characteristics 
and sexual behaviour. Demographic questions included information such as age and geographic 
area of residence, while behaviour data collected included use of condoms, type of sexual 
activity (i.e. oral, vaginal, or anal), dates of first and last intercourse with each named partner, 
and numbers of intercourse episodes.  
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Five of the most recent sex partners of each index patient, starting from two weeks before 
the onset of symptoms in the index patient, were identified by name by the index male in the 
questionnaire. The index patients were also asked to provide perceived demographics of their 
partners, such as each partner’s age and mutual sexual interactions, as well as their perceptions 
of each partner’s other sex partners. Index patients were asked to bring in their partners for 
examination and treatment of STIs. Partners were evaluated for symptoms and signs of STI in 
accordance with protocols described by PHAC and the Chinese authorities (PHAC 2006; China 
CDC 2007b; Wang & Zhang 2007).  
 
Each partner attending SSDSH STD clinics was eligible for entry into the study. After 
informed consent was acquired, a questionnaire similar to that given to the index patients was 
administered to each sex partner. Cervical samples were collected and cultured for isolation of N. 
gonorrhoeae.  
 
Because patient/partner recruitment was not successful in Urumchi, 50 N. gonorrhoeae 
isolates collected by the Xinjiang STD Centre (Urumchi) from 2007-2008 were retrieved and 
analyzed for antimicrobial susceptibility testing and analysis of genetic characteristics. 
 
2.2 Collection, Isolation, Identification and Storage of Neisseria gonorrhoeae Isolates 
 
N. gonorrhoeae isolates were consecutively collected from the consenting participants with 
confirmed gonococcal infections at the SSDSH. Gonococcal isolates labeled SH2005 were 
collected over the 6-month period between November 2004 and May 2005 (n=199). The isolates 
labeled SH2008 were collected during the 4 month period between March 2008 and July 2008 
(n=81). The Urumchi N. gonorrhoeae isolates were labeled UQ2008 (n=44). The UQ2008 
isolates were retrieved from frozen stocks stored at the Xinjiang STD Centre (Urumchi) and 
were shipped to the SSDSH for subculture, confirmatory tests, and storage for subsequent 
analysis. 
 
Isolation, identification, and growth of N. gonorrhoeae isolates were conducted in the 
Laboratory Diagnostic Centre of the SSDSH. Standard protocols published by the Public Health 
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Agency of Canada and the Chinese authorities were followed (PHAC 2006; China CDC 2007b; 
Wang & Zhang 2007).  
 
Urogenital specimens were collected using sterile Dacron swabs which were streaked onto 
Thayer-Martin (T-M) medium (Oxoid; distributed by GuangZhou LOSO Science Ltd, Shanghai, 
China) supplemented with 1% IsoVitalex (Oxoid, GuangZhou LOSO Science Ltd). Inoculated 
T-M plates were incubated at 35
0
C in a humid, 5% CO2 environment for 24-48 h. One or two 
colonies were subcultured on GC agar base (Oxoid; GuangZhou LOSO Science Ltd) 
supplemented with 1% IsoVitalex (GCBI) to obtain a pure N. gonorrhoeae culture. N. 
gonorrhoeae was identified using the oxidase test, Gram-stain and glucose utilization tests 
(WHO-WPR 2005; China CDC 2007b). Isolates were stored at the SSDSH at - 80
0
C in brain 
heart infusion medium (Difco; distributed by Shanghai Chemical Reagent Co, China National 
Medicine Group, Shanghai, China) containing 20% glycerol.  
 
 
2.3 Antimicrobial Susceptibility Testing of Neisseria gonorrhoeae Isolates 
 
2.3.1 Determination of Minimal Inhibitory Concentrations 
The antimicrobial susceptibility of N. gonorrhoeae isolates was determined using the agar 
dilution method (CLSI 2006, 2009) at the Laboratory Diagnostic Centre of the SSDSH, Shanghai, 
China. WHO reference strains A, B, C, D and E were utilized in each susceptibility tests (CLSI 
2006, 2009; WHO-WPR 2001).  
 
Five antimicrobial agents were tested against N. gonorrhoeae isolates. The concentration 
ranges of antibiotics included: penicillin (PEN) 0.008-64.0 mg/L, tetracycline (TET) 0.008-64.0 
mg/L, ciprofloxacin (CIP) 0.002-64.0 mg/L, spectinomycin (SPT) 2.0-256.0 mg/L, and 
ceftriaxone (CRO) 0.002–2.0 mg/L (Table 2.1). Antimicrobial agents were purchased from 
Sigma-Aldrich (Distributor: the Shanghai ANPEL Scientific Instrument Co. Ltd., Shanghai, 
China). Each MIC determination was performed in duplicate, and included WHO reference 
strains A, B, C, D and E for each test (Ye et al 1994, 2004; WHO-WPR 2001). The MIC testing 
was performed on GC agar base (Oxoid; GuangZhou LOSO Science Ltd) supplemented with 1% 
IsoVitalex (GCBI).  
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Table 2.1 Determination of Minimal Inhibitory Concentrations and Interpretation Criteria 
for N. gonorrhoeae
§
 
 
§: Clinical Laboratory Standards Institute (CLSI 2006, 2009)  
 
S: Susceptible. 
I: Intermediately susceptible. 
R: Resistant. 
ND: Not defined. 
 
 
 
 
 
 
 
 
 
 
 
 
Antimicrobial agent 
Antibiotic concentration 
Testing range (mg/L) 
Interpretative criteria (mg/L) 
S  I R 
 
Penicillin 
 
 
0.008 – 64.0 
 
≤ 0.06 
 
0.12 – 1.0 
 
≥ 2.0 
 
Tetracycline 0.008 – 64.0 ≤ 0.25 0.5 – 1.0 ≥ 2.0 
 
Ciprofloxacin 0.002 – 64.0 ≤ 0.06 0.12 – 0.5 ≥ 1.0 
 
Ceftriaxone 0.002 – 2.0 ≤ 0.25 ND ND 
 
Spectinomycin 2.0 – 256.0 ≤ 32.0 64.0 ≥ 128.0 
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Gonococcal inocula were prepared by suspending an overnight culture grown on GCBI 
plates in brain heart infusion medium (Difco) to a 0.5 McFarland turbidity standard (Remel, 
Lenexa KS, USA), which equilibrates to10
8
 colony forming units (CFU) per milliliter. This 
suspension was diluted 1:10 with 0.9% saline, resulting in a cell density of ~ 10
7 
CFU/mL. 
Approximately 2 μL of the cell suspension was delivered onto antibiotic-containing and control 
GCBI plates using a multispot inoculator (A400 Denley, England). Thus approximately 2 x 10
4
 
cells were delivered for each inoculation spot. Inoculated plates were incubated for 18-24 hours 
as described in Section 2.2. MICs were done in duplicate and the MIC was determined to be the 
lowest concentration of an antibiotic producing complete inhibition of growth. 
 
2.3.2 Determination of Plasmid-mediated Resistance in N. gonorrhoeae Isolates 
 
β-lactamase production of N. gonorrhoeae (PPNG) isolates was determined using the 
chromogenic cephalosporin test (Oxoid; distributed by GuangZhou LOSO Science Ltd), and all 
isolates with penicillin MICs ≥ 2.0 mg/L were tested for b-lactamase production because some 
strains with penicillin MIC of ≥ 2.0 mg/L can produce β-lactamase. Plasmid-mediated 
tetracycline resistant N. gonorrhoeae (TRNG) was defined as an isolate having a tetracycline 
MIC of  ≥ 16.0 mg/L. 
 
2.3.3 Interpretation Criteria for Resistance Phenotypes 
 
Interpretative criteria for MIC classification were those described by the CLSI (CLSI 2006, 
2009). MICs are classified into susceptible (S), intermediate (I) and resistant (R) for each 
antimicrobial (Table 2.1). 
 
An isolate can exhibit resistance to single or multiple antibiotics, mediated chromosomally 
or by carrying resistance plasmids, or both. The resistance phenotypes classified in this study 
included: PPNG (β-lactamase positive), TRNG (TET MIC ≥16 mg/L and β-lactamase negative), 
PP/TRNG (β-lactamase positive and TET MIC  ≥16 mg/L), PENR (PEN MIC ≥ 2.0 mg/L), TETR 
(TET MIC ≥ 2.0 mg/L), CIPR (CIP MIC ≥ 1.0 mg/L), SPTR (SPT MIC ≥ 128.0 mg/L), CMPR 
(non-PPNG, TET MIC < 2.0 mg/L and PEN MIC ≥2.0 mg/L), CMTR (non-PPNG, non-TRNG, 
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PEN MIC < 2.0 mg/L and TET MIC ≥ 2.0 mg/L), and CMRNG (non-PPNG, non-TRNG, PEN 
MIC ≥ 2.0 mg/L and TET MIC ≥ 2.0 mg/L). An isolate can exhibit more than one resistance 
phenotype. For example, the phenotype of CMTR/CIP
R
/PPNG indicates a combination of 
chromosomally mediated resistances to TET, CIP resistance, and that it is β-lactamase positivity. 
 
For ceftriaxone, the susceptible (S) breakpoint is defined as having MICs ≤ 0.25 mg/L 
(CLSI 2006, 2009). Breakpoints for intermediate-levels of susceptibility (I) and resistance (R) 
have not been defined. The CLSI defines reduced susceptibility to ceftriaxone as having MICs > 
0.25 mg/L, whereas the European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
defines reduced susceptibility to ceftriaxone (CRO) as having MICs > 0.125 mg/L (Cole et al 
2010). In previous studies in N. gonorrhoeae clinical isolates, a variety of definitions for reduced 
(decreased) susceptibility to ceftriaxone have been used [e.g. 0.016-0.06 mg/L (Whiley et al 
2010); ≥ 0.12 mg/L (Lee et al 2010); 0.016-0.25 mg/L (Whiley et al 2007a/b); ≥ 0.125 mg/L (Ito 
et al 2005); and 0.064-0.125 mg/L (Lindberg et al 2007)]. Therefore, in this study I defined 
reduced susceptibility to ceftriaxone as having CRO MICs = 0.125-0.25mg/L. 
 
2.4 Chromosomal DNA Isolation from N. gonorrhoeae Isolates 
 
Chromosomal DNA from N. gonorrhoeae isolates was prepared at the Laboratory 
Diagnostic Centre of the SSDSH and shipped to the University of Saskatchewan, Canada for 
analysis. Chromosomal DNA of N. gonorrhoeae FA1090 was prepared at U of Saskatchewan for 
use as positive controls in PCR reactions.  
 
The Promega Wizard® Genomic DNA Purification Kit was used for isolating gonococcal 
genomic DNA (Promega USA, distributed by the Shanghai Promega Biological Products Ltd, 
Shanghai, China). Briefly, N. gonorrhoeae cells were grown overnight on GCBI plates. Bacterial 
suspensions were prepared from overnight culture in 0.9% saline to a turbidity equivalent to that 
of a 0.5 McFarland standard (Remel, Lenexa KS, USA, ~10
8
 cfu/mL). One milliliter of the cell 
suspension was used for chromosomal DNA extraction. Cells were pelleted by centrigugation at 
13,000–16,000 × g for 2 minutes. Cells were gently re-suspended in lysis solution (600 μL) and 
incubated at 80°C for 5 minutes to lyse the cells. After cooling to room temperature, RNase 
68 
 
solution (3 μL) was added to the cell lysate and incubated at 37°C for 15–60 minutes. The 
RNase-treated cell lysates were vigorously mixed with Protein Precipitation Solution and 
incubated on ice for 5 minutes. Proteins and debris were removed by centrifugation. DNA in the 
supernatant was precipitated by isopropanol (600 μL). Following centrifugation, DNA pellets 
were washed with 70% ethanol (600 μL), and DNA was rehydrated in ddH2O (100 μL). The 
rehydrated DNA samples were shipped at room temperature. 
 
2.5 Polymerase Chain Reactions and DNA Sequencing Analysis 
 
Targeted genes/loci were amplified from chromosomal DNA of N. gonorrhoeae isolates by 
polymerase chain reactions (PCR). Targeted genes/loci in this study included porB, tbpB, gyrA, 
parC, mtrR, penA and ponA (Figs. 1.5, 1.12 & 1.14). The amplicons were subjected to DNA 
sequencing analysis.  
 
2.5.1 Primers 
Primers used for PCR and DNA sequencing reactions are listed in Table 2.2. Primers were 
purchased from Invitrogen Canada (Burlington, ON). Primer stock solutions were prepared by 
dissolving individual primers in TE at a concentration of 100 μM. Primer stocks were stored at -
20
o
C. Primer pair porB-F/porB-R was used to amplify the entire porB gene and to sequence the 
extended-length of porB sequence (Unemo et al 2003). The DNA sequences of an internal 
segment of the porB gene are also used for N. gonorrhoeae Multi-Antigen Sequence Typing 
(NG-MAST) (Martin et al 2004). Primer pair tbpB-F/tbpB-R was used to amplify tbpB locus and 
to sequence the internal segment of tbpB for NG-MAST analysis. 
 
Primer pairs gyrA-F/gyrA-R and parC-F/parC-R were used to amplify and sequence the 
quinolone resistance determinant regions (QRDRs) in gyrA and parC, respectively (Belland et al 
1995, Trees et al 1999). Primer pair mtrR-F/mtrR-R was used to amplify MtrR coding sequences 
and the mtrR promoter regions (Hagman & Shafer 1995; Lucas et al 1997). Primer pair penA-
F/penA-R was used to amplify and sequence the coding sequences of the polymorphic regions of 
the penicillin binding protein 2 (PBP2) (Ochiai et al 2007; Ito et al 2005). Primer pair ponA-
F/ponA-R was used to amplify and sequence partial ponA gene (Ropp et al 1997, 2002).  
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Table 2.2 Primers used for PCR and DNA Sequencing Reactions 
 
*: nt- nucleotide positions. §: AA- amino acid 
Primer 
Name 
Sequence (5’ to 3’) Locus and GenBank 
accession number of 
the locus 
Sequenced regions References 
porB-F CCGGCCTGCTTAAATTTCTTA porB, J03017 nt
*
 72-933, coding for AA25-
311
§
 
Unemo et al 
2003, Martin et al 
2004 
porB-R TATTAGAATTTGTGGCGCAG 
tbpB-F CGTTGTCGGCAGCGCGAAAAC tbpB, 2286066 nt
 
1098-1686 Martin et al 2004 
tbpB-R TTCATCGGTGCGCTCGCCTTG 
gyrA-F ACTGTACGCGATGCACGAGC gyrA, U08817 nt 195-432,  coding for AA66-
144 
Belland et al 1994 
gyrA-R TCTGCCAGCATTTCATGTGAG 
parC-F GTTTCAGACGGCCAAAAGCC parC, U08907 nt 120-399, coding AA41-133 Belland et al 1994 
parC-R GGCATAAAATCCACCGTCCCC 
mtrR-F AACAGGCATTCTTATTTCAG mtrR, Z25796 nt -1 – 120 (promoter), nt 1-630 
coding sequences of full-length 
MtrR (AA 1-210) 
Hagman & Shafer 
1995, Lucas et al 
1997  
mtrR-R TTAGAAGAATGCTTTGTGTC 
penA-F CGATATGATCGAACCTGG penA, X07468 nt 1017-1725, coding AA340- 
575 
Ito et al 2005, 
Whiley et al 
2007a 
penA-R ACAATCTCGTTGATACTCG 
ponA-F CGCGGTGCGGAAAACTATATCGAT ponA, U72876 nt 987-1950, coding for 
AA330-650 
Ropp et al 1997, 
2002 ponA-R AGCCCGGATCGGTTACCATACGTT 
 
JDA-F 
 
TACTCAATCGGTAATTGGCTTC 
  
PCR amplification of β-
lactamase producing plasmids 
 
Dillon et al 1999 
JDB-R CCATATCACCGTCGGTACTG 
 
RM4-F 
 
CCAAATCCTTTCTGGGCT 
  
PCR amplification of tetM 
 
Xia et al 1995 
G1-R ATCACTCACAGTTAAT 
6
9
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2.5.2 Polymerase Chain Reactions 
The PCR mixture (50 μL) contained 2-5 μL of genomic DNA, 2.5 U of Taq DNA 
polymerase (Amersham Bioscience), 1 x PCR buffer with 1.5 mM MgCl2, 0.25 mM dNTPs, and 
0.5 μM of each primer. Amplification (Perkin Elmer 9600 Thermo Cycler, Wellesley, MA, USA) 
was performed as follows: an initial denaturing step at 94
0
C for 4 min, followed by 30 sequential 
cycles of 94
0
C for 1 min, 55
0
C for 45 s, 72
0
C for 45 s (for tbpB, gyrA and parC) or 1 min (for 
porB, mtrR, penA and ponA), and a final extension phase at 72
0
C for 10 min. PCR products were 
purified using the Qiagen PCR Purification Kit according to the manufacturer’s instructions 
(Qiagen, Mississauga, Ontario, Canada). DNA was eluted from the column in 50 μL ddH2O. 
DNA samples of the PCR products were analyzed by agarose gel electrophoresis (Shambrook & 
Russel 2001) and examined for purity and size as compared to DNA standards (1kb Plus DNA 
ladders, New England Biorad). DNA solutions were stored at -20
0
C for use in subsequent DNA 
sequencing analysis. 
 
2.5.3 DNA Sequencing 
DNA sequences of both strands for each locus amplified were determined using an Applied 
Biosystems 3730x1 DNA Analyzer (Plant Biotechnology Institute, National Research Council of 
Canada, Saskatoon, SK). Primers used for DNA sequencing reactions of the targeted loci were 
the same as the primers used in PCR reactions (Table 2.2). Primers were freshly prepared from 
stock solutions by diluting them in ddH2O to a final concentration of 4 μM. PCR product was 
also diluted in ddH2O to a final concentration of 10 ng/μL for amplicons with a length of less 
than 500 base pairs (bp) and to a concentration of 100 ng/μL for amplicons with a length of ≥ 
500 bp. Using the above-mentioned PCR conditions, purified PCR products were diluted 1:4 for 
amplicons of the gyrA, parC and tbpB genes, and 1:2 for amplicons of the porB, mtrR, penA and 
ponA genes. 
 
2.5.4 DNA Sequence Verification and Editing 
DNA sequences were verified and edited using online programs and occasionally by manual 
examination (Unemo et al 2002). Chromas Lite (http://www.softpedia.com/get/Science-
CAD/Chromas-Lite.shtml) was used to view and edit chromatograms. The Clustal W program 
(http://www.ebi.ac.uk/Tools/clustalw2/index.html) was used to align DNA sequences of both 
71 
 
complementary strands (Larkin et al 2007). Aligned DNA sequences were viewed and edited 
using the Jalview program (Clamp et al 2004). A reference sequence for each locus was used for 
trimming DNA sequences (Table 2.3). Flanking sequences corresponding to the reference 
sequence were removed or trimmed. After removing gaps introduced during the alignment, DNA 
sequences were output in a FASTA format. DNA sequences were copied and pasted in Notepad, 
creating DNA sequence databases for subsequent analysis.  
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Table 2.3 Reference DNA Sequences Used in This Study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NG-MAST: Neisseria gonorrhoeae multi-antigen sequence typing. 
QRDR: Quinolone resistance determinant region. 
nt: Nucleotides 
AA: Amino acid. 
PBP: Penicillin binding protein 
 
 
 
 
 
 
 
 
Locus Nucleotide (nt) position GenBank accession  
number 
 
porB (Extended-length) 
 
nt 72-933, gaps included J03017  
porB (for NG-MAST) 
 
 
Start at nt 350 extended for 490 bp 
exactly, gaps removed during alignment  
M21289  
tbpB Start at nt 1098 extended for 390 bp 
exactly, gaps removed during alignment 
 
2286066  
gyrA nt 220-360, QRDR coding sequences U08817  
parC nt 210-390, QRDR coding sequences U08907  
mtrR (N. gonorrhoeae 
FA1090) 
nt -1 to -120 promoter sequences and 
sequences coding for full-length MtrR 
(nt 1-630)    
 
YP_208426  
penA nt 1017-1725, coding for AA340-575 of 
PBP2 (full-length PBP2 581 AAs) 
 
NC_002946  
ponA nt 1050-1890 coding AA350-630 of 
PBP1 (full-length PBP1 798 AAs) 
U72876  
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2.6 Molecular Mechanisms of Antimicrobial Resistance in Neisseria gonorrhoeae 
 
2.6.1 Plasmid Typing of β-lastamase Producing and tetM-containing Plasmids 
 
β-lastamase-producing plasmids in N. gonorrhoeae were differentiated by PCR assays 
(Dillon et al 1999). PCR reactions were performed on extracted gonococcal DNA as templates 
using the primer pair JDA/JDB (Table 2.2). The amplified DNA products were analyzed by 
agarose gel electrophoresis followed by ethidium bromide staining and visualized under UV light 
(Shambrook & Russel 2001). PCR conditions were the same as described in Section 2.5.2, 
except for an extension time of 5 minutes in the reaction cycles (Dillon et al 1999). Controls 
included PCR on plasmid DNA pJD4, pJD5, and pJD7, which represent the Asia-, Africa- and 
Toronto-types of the β-lactamase-producing plasmids, respectively (Dillon et al 1999; Pagotto et 
al 2000). The sizes of PCR products of pJD4, pJD5, and pJD7 were 4.9 kilobases (kb), 3.1 kb, 
and 2.6 kb, respectively (Dillon et al 1999). Negative controls were comprised of distilled water 
and chromosomal DNA of Escherichia coli DH5α.  
 
To determine the tetM plasmid types in N. gonorrhoeae isolates, the tetM locus was PCR-
amplified from gonococcal DNA of isolates having a TET MIC ≥ 16.0 mg/L, using primer pairs 
RM4/G1 (Table 2.2; Xia et al 1995). PCR conditions were the same as described in Section 
2.5.2, except for an extension time of 2 minutes in the reaction cycles (Xia et al 1995). PCR 
products were analyzed by agarose gel electrophoresis followed by ethidium bromide staining 
and visualized under UV light (Shambrook & Russel 2001). The America-type tetM-containing 
plasmid has an amplicon size of 1600 bp and the Dutch-type tetM-containing plasmid exhibits a 
fragment of 700 bp (Xia et al 1995). 
 
2.6.2 Analysis of Antimicrobial Resistance Determinants in N. gonorrhoeae Isolates 
 
In this study, targeted loci (gyrA, parC, porB, mtrR, penA, ponA), implicated in quinolone, 
penicillin, tetracycline and third-generation cephalosporin resistances and described in Chapter 1 
(Figs. 1.5 for PorB, 1.12 for PBPs and MtrR & 1.14 for GyrA and ParC) were analyzed. PCR 
reactions and DNA sequencing have been described in Sections 2.5.2 and 2.5.3, respectively.  
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Deduced amino acid sequences for each gene were obtained using the Proteomics and 
Sequence Tools (http://ca.expasy.org/, last accessed on December 21, 2009). To identify 
mutations, amino acid sequences were aligned with their respective prototypes for which 
GenBank accession numbers were shown in Table 2.3.  
 
2.7 Phylogenetic Analysis of N. gonorrhoeae porB 
  
The porB DNA sequences determined in this study comprised 7 polymorphic regions 
encoding the surface-exposed loops (Loops I - VII) and 6 conserved intersapce regions (II - VII). 
This DNA fragment accounts for ~82% of the entire porB gene (Gotschlich et al 1987; Fudyk et 
al 1999; Fig. 1.5). The sequences of these regions were determined and used for analysis because 
they can be ascertained in a single DNA sequencing reaction of one strand of the amplicon, and 
because the discriminatory power is high enough for molecular epidemiological studies (van 
Looveren et al 1999; Dillon et al 1993; Hunter & Gaston 1988).  
 
porB genotypes were assigned as porB1a or porB1b based on the presence or absence of two 
nucleotide sequences in the loop V coding region, as described previously (van der Ley et al 
1991; Gotschlich et al 1987; Danielsson et al 1986; Olesky et al 2002); porB1a was characterized 
by the absence of ~50 nucleotides (nt) corresponding to the positions nt681-705 and nt718-736 
of porB1b. porB DNA sequences of two widely used N. gonorrhoeae strains were used as 
templates for porB1a and porB1b assignment. N. gonorrhoeae MS11 possessesses porB1a 
(GenBank #J03029), and N. gonorrhoeae FA1090 has porB1b (GenBank #J03017). 
 
Edited DNA sequences were separated into 2 data sets, i.e. porB1a and porB1b. DNA 
sequences in FASTA format were converted into a NEXUS format using the Clustal X program 
(http://bips.u-strasbg.fr/fr/Documentation/ClustalX; Thompson et al 1997) for subsequent use in 
the PAUP program. 
 
Phylogenetic analyses were conducted with PAUP version 4.0b10, according to the 
publisher’s instructions (Swofford 2002). Alignments were not stripped of gaps before 
phylogenic analysis (Unemo et al 2002, 2003). Maximum parsimony (MP) trees were generated 
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with 1000 heuristic searches. Parsimony-informative characters in random stepwise addition and 
tree bisection and reconstruction (TBR) were used as branch swapping algorithm. MAXTREES 
were set to 5000, branches of zero length were collapsed, and all most parsimonious trees were 
saved. Branch support for all parsimony analyses was estimated by performing 1000 bootstrap 
replicates (Felsenstein 1985) with a heuristic search consisting of 10 random-addition replicates 
for each bootstrap replicate. Trees were figured and viewed in Treeview (Page 1996; 
http://taxonomy.zoology.gla.ac.uk/rod/treeview.html). Some of the porB1b data sets were 
divided into subclasses based on phylogenetic trees generated using Clustal W. This division 
facilitated subsequent PAUP analysis because the PAUP program is only able to manipulate 
datasets of ~60-100 variable DNA sequences (Swofford 2002). 
 
2.8 Neisseria gonorrhoeae Multi-Antigen Sequence Typing (NG-MAST) 
 
The NG-MAST database and programs for assigning sequence types (ST) of N. 
gonorrhoeae isolates are available online (www.ng-mast.net, Martin et al 2004). 
 
Briefly, tbpB and porB loci were amplified by PCR methods and amplicons were sequenced 
using the primer pairs of tbpB-F/tbpB-R and porB-F/porB-R (Table 2.2) as described in Section 
2.5. porB and tbpB DNA sequences were trimmed using the template sequences specified in the 
NG-MAST database (www.ng-mast.net). The template DNA sequence for porB or tbpB 
comprises 490 bp (porB) and 390 bp (tbpB).  DNA sequences were input into the sequence input 
windows in the NG-MAST website. An allele type was assigned to either porB or tbpB of each 
isolate, and a sequence type (ST) was assigned to the isolate based on porB and tbpB types. The 
allele types and STs were deposited in the NG-MAST database. Allele types or STs which are 
novel to the database were indicated. Therefore, previously identified alleles of porB and tbpB, 
and STs were obtained by interrogating the NG-MAST website. Previously unrecognized NG-
MAST STs were submitted to the website in order to obtain an identity for new alleles and novel 
STs.  
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2.9 Concordance between Sexual Networks Established from Epidemiological 
Information and Revealed by DNA Sequence Types of porB 
 
Since molecular typing can complement contact tracing for reconstructing gonorrhoea 
sexual networks, the concordance between porB genotypes of dyads or triads of N. gonorrhoeae 
isolates from recent sexual contacts was examined. Components of sexual networks (dyads or 
triads) were constructed using the index-named contact data, and the recorded dates at which 
specimens were obtained from named sexual contacts (Bilek et al 2007). These epidemiological 
contacts were compared to the assigned STs in NG-MAST analysis to obtain congruent 
percentages between the results of the two study methods. To determine the congruence of porB 
sequence types and epidemiological linkages, a neighbor-joining tree of porB sequences from 
sexual relationships was constructed using the Clustal W program (Larkin et al 2007).  
 
 
2.10 Statistical Analysis 
 
Yates’ Chi-square tests were performed on differences of percentage distribution (Ury & 
Fleiss
 
1980; Yates 1934). Significance was set at a P value of < 0.05. The Yates' correction 
prevents overestimation of statistical significance for small data sets. This reduces the chi-square 
value obtained and thus increases its p-value. 
 
Correlation coefficients (R) between QRDR mutation rates (Y) and ciprofloxacin MICs (X) 
were determined using the formula:  
 
R = N(ΣXY) - (ΣX)(ΣY) / Sqrt([NΣX2 - (ΣX)2][NΣY2 - (ΣY)2]) 
  
N is the total number of isolates. The ―R‖ values represent the strength of association 
between two variables, X and Y. The R values were calculated using Excel Statistical Tools or 
an online program (http://easycalculation.com/statistics/correlation.php).  
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Simpson’s index of diversity (ID) was used to determine the discriminatory abilities of the 
molecular typing methods (Dillon et al 1993; Hunter & Gaston 1988). The numerical index is 
based on the probability that two unrelated isolates would be placed into different typing groups 
(Hunter & Gaston 1988). The calculation formula is: 
 
ID = 1 – [1/N(N-1)] [Σni(ni-1)] 
 
N equals the sum of all of the isolates, and ni is the size of the i
th
 group. ID is expressed as a 
percentage. An ID of 90% or greater is desirable for a typing scheme (Hunter & Gaston 1988), 
depending on the objectives of molecular epidemiological studies. 
 
 
2.11 DNA Sequence Deposit 
 
DNA sequences were submitted to the National Center for Biotechnology Information 
(NCBI) GenBank (http://www.ncbi.nlm.nih.gov/WebSub/?tool=genbank). GenBank accession 
numbers were reported for porB (EF540591 - EF540669, EU719202 - EU719208, HM481249 - 
HM481254 and HM490092 - 490124), gyrA (HM563745 - HM563747), parC (HM579826 - 
HM579837), mtrR (HM467704 - HM467711), penA (HM490125 - HM490141), and ponA 
(HM467700 - HM467704). The DNA sequences of porB and tbpB for NG-MAST analysis were 
stored in the NG-MAST database (http://www.ng-mast.net; Martin et al 2004). 
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RESULTS 
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At the Shanghai Skin Disease and STD Hospital, 5036 clinic patients were tested for 
gonorrhea infections in 2005. Among them, 1627 cases were N. gonorrhoeae culture positive 
(Gu and Liao, unpublished data). In our research, 402 male gonorrhea patients were asked to 
participate in the study in 2005, of whom 40 (10%) withdrew due to time constraints of the 
patients. In total 342 male gonorrhea patients were successfully interviewed as index patients 
who described 526 sexual partners. Subsequently, 106 sexual partners of the index cases were 
recruited and interviewed in our research. At the time I ended field work in this PhD project in 
the middle of 2008, the recruitment of participants were ongoing, and I used cases consecutively 
enrolled in the early 2008.  
 
N. gonorrhoeae isolates I studied were consecutively collected from gonorrhea patients in 
2005 and 2008 in Shanghai; among those isolates collected, there were 74 sexual links (74 
isolates from male index cases, 78 from female partners, forming 70 dyads and 4 triads). N. 
gonorrhoeae isolates were also obtained from the isolate collection in the Urumchi STD Center 
in 2007-2008. 
 
3.1 Antimicrobial Resistance in Neisseria gonorrhoeae  
 
Antimicrobial susceptibility of N. gonorrhoeae isolates consecutively collected from 
Shanghai (SH2005 and SH2008) and Urumchi (UQ2008) was tested against 5 antimicrobial 
agents [penicillin (PEN), tetracycline (TET), ciprofloxacin (CIP), ceftriaxone (CRO), and 
spectinomycin (SPT)]. To minimize clonal effects, only results of isolates collected from 
individual male patients were analyzed.  
 
3.1.1 Antimicrobial Resistance of 159 N. gonorrhoeae Isolates from Shanghai in 2005  
Part of these results was reported in J Antimicrob Chemother (Yang et al 2006). Permission 
to use has been obtained from the Oxford University Press License (Appendix A2.3). 
 
The antimicrobial susceptibilities of 159 N. gonorrhoeae isolates (SH2005) from male 
patients in Shanghai in 2005 (SH2005) are summarized in Table 3.1.  
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Penicillin (PEN) MICs ranged from 0.5 - ≥64 mg/L, with an MIC50 of 32 mg/L and an 
MIC90 ≥64 mg/L; 93.1% of the isolates were resistant to PEN and 6.9% demonstrated 
intermediate levels of susceptibility (MICs=0.5-1.0 mg/L). Plasmid mediated PEN resistance 
was observed in 51.6% of the isolates with 37.8% (n=60) being PPNG and 13.8% (n=22) being 
PP/TRNG. Chromosomal PEN resistance was observed in 41.5% of the isolates with 23.3% 
(n=37) classified as CMPR and 18.2% (n=29) as CMRNG.  
 
The total burden of tetracycline (TET) resistance was 56.5% and included isolates classified 
as TRNG (6.3%), PP/TRNG (13.8%), CMTR (18.2%), and CMRNG (18.2%). Isolates had TET 
MICs extending from 0.06 to ≥64.0 mg/L with an MIC50 of 2 mg/L and an MIC90 of 32 mg/L.  
 
The ciprofloxacin (CIP) MIC range of the isolates was 0.06-≥64 mg/L (MIC50 and MIC90 
values of 8 and 32 mg/L, respectively); 98.7% of the isolates were Cip
R
 while 1 (0.6%) isolate 
was susceptible, and 1 (0.6%) was classified at an intermediate (MIC=0.5 mg/L) susceptibility 
level.  
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Table 3.1 MICs of 159 N. gonorrhoeae isolates from Shanghai 2005 to 5 antimicrobial agents
§ 
 
 
§: This result has been published in J Antimicrob Chemother (Yang et al 2006). Permission to use has been obtained from the 
Oxford University Press. 
a. N: Number of isolates; Cum %: Cumulative percent. PEN-penicillin, TET-tetracycline, CIP-ciprofloxacin, SPT-spectinomycin, 
CRO-ceftriaxone. 
b. End of concentration range for PEN, TET and CIP MIC testing. 
c. Bold indicates isolates with MICs below breakpoint or available limits of susceptibility. Breakpoints have not been determined 
for CRO and MICs > 0.125 mg/L are considered having reduced susceptibility in this study. 
d. PPNG isolates. PEN MICs = 8 mg/L (1 isolate), 32 mg/L (2 isolates) and > 64 mg/L (79 isolates). 
 
Antibiotic
a 
 
 
MICs (mg/L) 
 
0.002 0.004 0.008 0.015 0.03 0.06 0.125 0.25 0.5 1.0 2.0 4.0 8.0 16.0 32.0 ≥64.0b
 
MIC50 MIC90 
PEN  
N 
Cum %
  
 
       
0 
0.0
c 
 
0 
0.0 
 
3 
1.9 
    
8 
6.9 
 
19 
18.8 
 
26 
35.2 
 
16
d 
45.3 
 
5 
48.4 
 
3
d 
50.3 
 
79
d 
100.0 
 
32.0 
 
≥64.0 
TET 
N 
Cum % 
 
      
2 
1.3 
 
9 
6.9 
 
16 
17.0 
 
15 
26.4 
 
27 
43.4 
 
34 
64.8 
 
17 
75.5 
 
7 
79.9 
 
11 
86.8 
 
12 
94.3 
 
9 
100.0 
 
2.0 
 
32.0 
CIP 
N 
Cum % 
 
 
0 
0.0 
 
0 
0.0 
 
0 
0.0 
 
0 
0.0 
 
0 
0.0 
 
1 
0.6 
 
0 
0.6 
 
0 
0.6 
 
1 
1.3 
 
6 
5.1 
 
27 
22.1 
 
35 
44.1 
 
47 
73.6 
 
23 
88.1 
 
16 
98.1 
 
3 
100.0 
 
8.0 
 
32.0 
SPT 
N 
Cum % 
 
           
0 
0.0 
 
8 
5.0 
 
16 
15.1 
 
72 
60.4 
 
60 
98.1 
 
3 
100.0 
 
16.0 
 
32.0 
CRO 
N 
Cum % 
 
0 
0.0 
 
3 
1.9 
 
10 
6.38 
 
22 
22.0 
 
57 
57.9 
 
48 
88.1 
 
18 
99.4 
 
1 
100.0 
         
0.03 
 
0.125 
8
1
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All isolates were susceptible to spectinomycin (SPT; MIC <128.0 mg/L) with 98.1% having 
MICs classified as susceptible and 1.9% (n=3) demonstrating intermediate (MIC=64.0 mg/L) 
levels of susceptibility. All isolates were susceptible to ceftriaxone (CRO; MICs=0.004-0.25 
mg/L; MIC50 and MIC90: 0.03 and 0.125 mg/L, respectively). Noticeably 11.9% (n=19) of the 
isolates exhibited reduced susceptibility to CRO, with an MIC of 0.125 mg/L (n=18) or 0.25 
mg/L (n=1), respectively. 
 
Isolates with multiple drug resistant (MDR) phenotypes were PPNG-CIP
R (
20.8%), CMPR-
CIP
R 
(16.4%), CMRNG-CIP
R
 (18.2%), PPNG-CMTR-CIP
R
 (17.6%), and PP/TRNG-CIP
R
 
(13.2%).  
 
3.1.2 Antimicrobial Resistance of 71 N. gonorrhoeae Isolates from Shanghai in 2008 
The antimicrobial susceptibility of N. gonorrhoeae isolates (SH2008) to PEN, TET, CIP, 
SPT, and CRO is summarized in Table 3.2.  
 
The percentages of N. gonorrhoeae isolates resistant to CIP, PEN or TET were 100%, 
88.7%, and 64.8%, respectively. Isolates with chromosomal resistance to PEN (CMPR), TET 
(CMTR), or both antibiotics (CMRNG) accounted for 32.4%, 8.5% and 5.6%, respectively. 
Seventy-nine percent of isolates carried plasmid-mediated resistance (PPNG - 22.5%, TRNG - 
22.5%, PP/TRNG - 33.8%).  
 
All isolates were susceptible to SPT, and SPT MIC50 and MIC90 were 32 and 64 mg/L, 
respectively. Seven isolates (9.9%) displayed an intermediate level of susceptibility to SPT 
(MIC=64.0 mg/L). All isolates were susceptible to CRO (MIC50 and MIC90: 0.06 and 0.125 
mg/L, respectively). Notably, 19.7% (n=14) isolates exhibited reduced susceptibility to CRO 
(MIC=0.125 mg/L).  
 
Isolates having MDR phenotypes comprised PPNG-CIP
R
 (22.5%), TRNG-CIP
R
 (22.5%), 
PP/TRNG-CIP
R
 (33.8%), CMPR-CIP
R
 (32.4%), CMRNG-CIP
R
 (5.6%), and CMTR-CIP
R
 (8.5%).  
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Table 3.2 MICs of 71 N. gonorrhoeae isolates from Shanghai in 2008 to 5 antimicrobial agents  
 
 
a. N: Number of isolates; Cum %: Cumulative percent. PEN-penicillin, TET-tetracycline, CIP-ciprofloxacin, SPT-spectinomycin, 
CRO-ceftriaxone. 
b. End of concentration range for PEN, TET and CIP MIC testing. End concentration for SPT was 128 mg/L, no isolates have a 
SPT MIC of 128 mg/L.  
c. Bold indicates isolates with MICs below breakpoint or available limits of susceptibility. Breakpoints have not been determined 
for CRO and MICs > 0.125 mg/L are considered having reduced susceptibility in this study. 
d. PPNG isolates. PEN MICs = 8 mg/L (1 isolate), 32 mg/L (4 isolates) and > 64 mg/L (33 isolates). 
 
 
Antibiotic
a 
 
 
MICs (mg/L) 
 
0.002 0.004 0.008 0.015 0.03 0.06 0.125 0.25 0.5 1.0 2.0 4.0 8.0 16.0 32.0 ≥64.0b
 
MIC50 MIC90 
PEN  
N 
Cum %
  
 
       
0 
0.0
c 
 
0 
0.0 
 
1 
1.4 
    
7 
11.3 
 
13 
29.6 
 
9 
42.3 
 
2
d 
45.0 
 
0 
45.0 
 
6
d 
53.5 
 
33
d 
100.0 
 
32.0 
 
≥64.0 
TET 
N 
Cum % 
 
      
0 
0.0 
 
1 
1.4 
 
2 
4.2 
 
6 
12.7 
 
16 
35.2 
 
6 
43.7 
 
0 
43.7 
 
0 
43.7 
 
4 
49.3 
 
12 
66.2 
 
24 
100.0 
 
16.0 
 
64.0 
CIP 
N 
Cum % 
 
 
0 
0.0 
 
0 
0.0 
 
0 
0.0 
 
0 
0.0 
 
0 
0.0 
 
0 
0.0 
 
0 
0.0 
 
0 
0.0 
 
0 
0.0 
 
2 
2.8 
 
2 
5.6 
 
14 
25.4 
 
25 
60.6 
 
25 
95.8 
 
3 
100 
 
0 
100.0 
 
8.0 
 
16.0 
SPT 
N 
Cum % 
 
           
0 
0.0 
 
1 
1.4 
 
2 
4.2 
 
19 
31.0 
 
42 
90.1 
 
7 
100.0 
 
32.0 
 
32.0 
CRO 
N 
Cum % 
 
0 
0.0 
 
0 
0.0 
 
2 
2.8 
 
4 
8.5 
 
26 
45.1 
 
25 
80.3 
 
14 
100.0 
 
0 
100.0 
         
0.06 
 
0.125 
8
3
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3.1.3 Antimicrobial Resistance of 44 N. gonorrhoeae Isolates from Urumchi 
The antimicrobial susceptibility of 44 N. gonorrhoeae isolates (UQ2008) to PEN, TET, CIP, 
SPT, and CRO is summarized in Table 3.3.  
 
The percentages of isolates resistant to CIP, PEN, or TET were 97.7%, 79.5%, and 61.4%, 
respectively. Isolates with chromosomal resistance to PEN (CMPR), TET (CMTR), or both 
antibiotics (CMRNG) accounted for 34.1%, 25.0%, and 11.9%, respectively. Sixty-three percent 
of isolates exhibited plasmid-mediated resistant phenotypes (PPNG – 15.9%, TRNG – 18.2%, 
PP/TRNG – 28.6%).  
 
All isolates were susceptible to SPT (MIC≤ 32.0 mg/L), and SPT MIC50 and MIC90 were 
32.0 mg/L, respectively. No isolates had intermediate levels of susceptibility to SPT. All isolates 
were susceptible to CRO (MIC50 and MIC90: 0.03 and 0.06 mg/L, respectively). A small 
percentage of isolates (4.5%, n=2) had reduced susceptibility to CRO (MIC=0.125 mg/L).  
 
Isolates having MDR phenotypes were (PPNG-CIP
R
 (13.6%), TRNG-CIP
R
 (18.2%), 
PP/TRNG-CIP
R
 (28.6%), CMPR-CIP
R
 (34.1%), CMTR-CIP
R
 (25.0%), and CMRNG-CIP
R
 
(11.9%).  
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Table 3.3 MICs of 44 N. gonorrhoeae isolates from Urumchi 2008 to 5 antimicrobial agents  
 
 
a. N: Number of isolates; Cum %: Cumulative percent. PEN-penicillin, TET-tetracycline, CIP-ciprofloxacin, SPT-spectinomycin, 
CRO-ceftriaxone. 
b. End of concentration range for PEN, TET and CIP MIC testing. End concentration for SPT was 128 mg/L, and no isolates have 
a SPT MICs of 128 mg/L.  
c. Bold indicates isolates with MICs below breakpoint or available limits of susceptibility. Breakpoints have not been determined 
for CRO and MICs > 0.125 mg/L are considered having reduced susceptibility in this study. 
d. PPNG isolates. PEN MICs = 16 mg/L (1 isolate) and > 64 mg/L (19 isolates). 
 
 
Antibiotic
a 
 
 
MICs (mg/L) 
 
0.002 0.004 0.008 0.015 0.03 0.06 0.125 0.25 0.5 1.0 2.0 4.0 8.0 16.0 32.0 ≥64.0b
 
MIC50 MIC90 
PEN 
N 
Cum %
  
 
       
0 
0.0
c 
 
2 
4.5 
 
1 
6.8 
    
6 
20.5 
 
8 
38.6 
 
7 
54.5 
 
0 
54.5 
 
1
d 
63.6 
 
0 
63.6 
 
19
d 
100.0 
 
4.0 
 
≥64.0 
TET 
N 
Cum % 
 
      
0 
0.0 
 
0 
0.0 
 
7 
15.9 
 
7 
31.8 
 
3 
38.6 
 
5 
50.0 
 
0 
50.0 
 
2 
54.5 
 
3 
61.4 
 
1 
63.6 
 
16 
100.0 
 
2.0 
 
64.0 
CIP 
N 
Cum % 
 
 
0 
0.0 
 
0 
0.0 
 
0 
0.0 
 
0 
0.0 
 
0 
0.0 
 
0 
0.0 
 
0 
0.0 
 
0 
0.0 
 
1 
2.3 
 
0 
2.3 
 
4 
11.4 
 
9 
31.8 
 
17 
70.5 
 
11 
95.5 
 
2 
100.0 
 
0 
100.0 
 
8.0 
 
16.0 
SPT 
N 
Cum % 
 
           
0 
0.0 
 
2 
4.5 
 
0 
4.5 
 
18 
45.5 
 
24 
100.0 
 
0 
100.0 
 
32.0 
 
32.0 
CRO 
N 
Cum % 
 
0 
0.0 
 
0 
0.0 
 
2 
4.5 
 
16 
40.9 
 
15 
75.0 
 
9 
95.5 
 
2 
100.0 
 
0 
100.0 
         
0.03 
 
0.06 
8
5
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3.1.4 Temporal Distribution of Antimicrobial Resistance of N.  gonorrhoeae Isolates in 
Shanghai: 2005/2008 
 
Percentages of N. gonorrhoeae isolates resistant to penicillin (PEN) were 93.1% (SH2005) 
and 88.7% (SH2008), to tetracycline (TET) 56.5% (SH2005) and 64.8% (SH2008), and to 
ciprofloxacin (CIP) 98.7% (SH2005) and 100% (SH2008). Resistance percentages (PEN, TET, 
and CIP) between SH2005 and SH2008 isolates were not significantly different (P>0.05).  
Resistance to spectinomycin (SPT) and ceftriaxone (CRO) was not observed in either 2005 or 
2008 (P>0.05, Fig. 3.1A).  
 
Percentages of PPNG declined from 37.8% (SH2005) to 22.5% (SH2008), whereas TRNG % 
increased from 6.3% (SH2005) to 22.5% (SH2008). PP/TRNG increased from 13.8% (SH2005) 
to 33.8% (SH2008). CMPR % increased from 23.3% (SH2005) to 32.4% (SH2008). CMTR % 
declined from 18.2% (SH2005) to 8.5% (SH2008).  CMRNG % decreased from 18.2% (2005) to 
5.6% (2008). In all cases, these differences between 2005 and 2008 were significant (P<0.05, Fig. 
3.1B). 
 
MIC distributions of CIP, SPT, and CRO were compared (Fig. 3.2). A significantly higher 
percentage of isolates with CIP MICs ≥ 8 mg/L was observed in 2008 isolates (74.6%) as 
compared to 2005 (45.9%; Fig. 3.2A). A significantly higher percentage of the SH2008 isolates 
(68.9%) had SPT MICs of ≥ 32 mg/L as compared to the SH2005 isolates (39.6%; Fig. 3.2B). 
Isolates classified as having intermediate susceptibility to SPT (MIC=64 mg/L) rose to 9.9% in 
SH2008 as compared to 1.9% in SH2005 isolates. The distribution curve for CRO MICs shifted 
to the right for the SH2008 isolates as compared to that for the SH2005 isolates (Fig. 3.2C). 
Approximately 19.7% of the SH2008 isolates had CRO MICs of ≥ 0.125 mg/L, whereas 11.9% 
of the SH2005 isolates had CRO MICs of ≥ 0.125 mg/L.  
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Fig. 3.1 Comparison of antimicrobial resistance of N. gonorrhoeae isolates from Shanghai: 2005/2008.  
A. Resistance percentages: PEN- penicillin, TET-tetracycline, CIP-ciprofloxacin, SPT-spectinomycin, CRO-ceftriaxone  
B. Plasmid or chromosomally-mediated resistance: PPNG-  Penicillanse-producing N. gonorrhoeae and TET MIC < 16.0 mg/L, 
TRNG- TET MIC ≥ 16.0 mg/L and non-PPNG, PP/TRNG- PPNG and TET MIC ≥ 16.0 mg/L, CMPR- PEN MIC ≥ 2.0 mg/L and 
TET MIC ≤ 1.0 mg/L and non-penicillinase producing, CMTR- TET MIC ≥ 2.0 mg/L and PEN MIC ≤ 1.0 mg/L and non-penicillinase 
producing, CMRNG- PEN MIC ≥ 2.0 mg/L and TET MIC ≥ 2.0 but ≤ 16.0 mg/L and non-penicillinase producing. 
Stars indicate percentage difference between isolates from 2005 and 2008 is significant.  
8
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3.1.5 Geographic Distribution of Antimicrobial Resistance of N.  gonorrhoeae Isolates: 
Shanghai/Urumchi 
 
The majority of N. gonorrhoeae isolates in both cities were resistant to PEN, TET, and CIP. 
All isolates remained susceptible to SPT and CRO. The percentages of resistant isolates were not 
significantly different between the UQ2008 and SH2008 isolates (P>0.05; Fig. 3.3A).  
  
The SH2008 isolates had higher percentages of plasmid mediated resistance than the 
UQ2008 isolates (Fig. 3.3B). Among the SH2008 isolates, PPNG, TRNG, and PP/TRNG 
accounted for 22.5%, 22.5%, and 33.8%, respectively. Among the UQ2008 isolates, PPNG, 
TRNG and PP/TRNG accounted for 15.9%, 18.2%, and 28.6%, respectively.  
 
The UQ2008 isolates had significantly higher percentages of CMTR (25.0%) and CMRNG 
(11.9%) as compared to the SH2008 isolates (CMTR 8.5%, CMRNG 5.6%). The percentages of 
CMPR isolates were not significantly different (32.4% for SH2008 vs 34.1% for the UQ2008 
isolates; P>0.05). 
 
The MIC distributions of CIP, SPT, and CRO of the SH2008 and UQ2008 isolates were 
compared. A higher percentage of SH2008 isolates had CIP MICs ≥ 8.0 mg/L (39.4%) as 
compared to the UQ2008 isolates (29.5%; Fig. 3.4A). A significantly higher percentage (69.0%) 
of the SH2008 isolates than the UQ2008 isolates (54.5%) had SPT MICs of ≥ 32 mg/L (Fig. 
3.4B). The CRO MIC curve for the SH2008 isolates was shifted to the right as compared to the 
UQ2008 isolates (Fig. 3.4C). Approximately 19.7% of the SH2008 isolates had CRO MICs of ≥ 
0.125 mg/L, whereas 4.5% of the UQ2008 isolates had CRO MICs of ≥ 0.125 mg/L. 
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Fig. 3.3 Comparison of antimicrobial resistance of N. gonorrhoeae isolates from Shanghai and Urumchi (2008).  
A. Resistance percentages: SH- Shanghai 2008 (SH2008, n=71), UQ- Urumchi 2007/2008 (UQ2008, n=44); PEN- penicillin, TET- 
tetracycline, CIP- ciprofloxacin, SPT- spectinomycin, CRO- ceftriaxone.  
B. Plasmid or chromosomally-mediated resistance: PPNG-  Penicillanse-producing N. gonorrhoeae and TET MIC < 16.0 mg/L, 
TRNG- TET MIC ≥ 16.0 mg/L and non-PPNG, PP/TRNG- PPNG and TET MIC ≥ 16.0 mg/L, CMPR- PEN MIC ≥ 2.0 mg/L and 
TET MIC ≤ 1.0 mg/L and non-penicillinase producing, CMTR- TET MIC ≥ 2.0 mg/L and PEN MIC ≤ 1.0 mg/L and non-penicillinase 
producing, CMRNG- PEN MIC ≥ 2.0 mg/L and TET MIC ≥ 2.0 but ≤ 16.0 mg/L and non-penicillinase producing. 
Stars indicate the difference of percentage between the SH2008 and UQ2008 isolates was significant.  
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3.1.6 Analysis of Gonococcal β-lactamase-producing and tetM-containing Plasmids 
 
Sixty-eight (SH2005) and 18 (SH2008) consecutive PPNG isolates were analyzed for types 
of β-lactamase producing plasmids using PCR methods (Dillon et al 1999). Three types of β-
lactamase producing plasmids were observed (Fig. 3.5). For the SH2005 PPNG isolates (n=68), 
the Asia-type accounted for 86.8%, the Africa-type for 10.3%, and the Toronto-type for 2.9%. 
For the 2008 PPNG isolates (n=18), the Asia-type accounted for 77.8%, the Africa-type for 
11.1%, and the Toronto-type for 11.1%. The distribution of plasmid types was not significantly 
different between the SH2005 and the SH2008 PPNG isolates (P>0.05).  
 
The types of tetM-containing plasmids (Xia et al 1995) were tested in 24 consecutive 
SH2005 and 14 consecutive SH2008 TRNG isolates. All tetM-containing plasmids exhibited a 
Dutch-type plasmid (data not shown).  
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Fig. 3.5 Differentiation of β-lactamase producing plasmids in PPNG N. gonorrhoeae isolates. 
The β-lactamase producing N. gonorrhoeae (PPNG) isolates were consecutively collected from 
the SH2005 or the SH2008 isolates. In total, 68 PPNG isolates from the SH2005 collection and 
18 PPNG isolates from the SH2008 collection were analyzed.  
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3.2 Molecular Mechanisms of Antimicrobial Resistance in Neisseria gonorrhoeae 
 
3.2.1 Gonococcal PorB Is Associated with Penicillin and Tetracycline Resistance  
These results have been published in J Antimicrob Chemother (Liao et al 2008). Permission 
to use has been obtained from the Oxford University Press (Appendix A2.4). 
 
3.2.1.1 Association between porB Genotypes and Antimicrobial Resistance 
One hundred and forty-three consecutive gonococcal isolates from male patients from 
Shanghai in 2005 were analyzed for association between porB genotypes and susceptibility to 
antimicrobial agents (Fig. 3.6).  
 
The N. gonorrhoeae isolates included 39 isolates with a porB1a and 104 isolates with a 
porB1b genotype. Percentages of PEN resistance were 89.8% in porB1a isolates and 95.3% in 
porB1b isolates; percentages of CIP resistance were 91.5%% in porB1a isolates and 99.2% in 
porB1b isolates. There was no significant difference in percentages of PEN and CIP resistance 
and carriage of porB alleles (P>0.05). porB1b isolates had higher MIC50s to PEN (64.0 mg/L) 
than porB1a isolates (8.0 mg/L). Both the MIC50 and MIC90 to CIP were higher in porB1b 
isolates (MIC50=8.0 mg/L and MIC90=32.0 mg/L) than porB1a isolates (MIC50=4.0 mg/L and 
MIC90=8.0 mg/L). Percentages of TET resistance were 62.5% for porB1b and 38.4% for porB1a 
isolates. The percentage of TET resistance was significantly higher in porB1b isolates than that 
in porB1a isolates (P=0.025).  
 
More than 95% of the isolates were susceptible to SPT and all isolates were susceptible to 
CRO. There was no significant difference for SPT or CRO resistant percentages between porB1b 
and porB1a isolates. porB1a and porB1b isolates had the same MIC50 to SPT (16.0 mg/L) or to 
CRO (0.03 mg/L). 
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Figure 3.6 Association of antimicrobial susceptibility and porB genoypes of 143 N. 
gonorrhoeae isolates from male patients. Bars indicate percentages of isolates which were 
classified as susceptible (white), intermediate (hatched) and resistant (black). PEN: penicillin, 
TET: tetracycline, CIP: ciprofloxacin, SPT: spectinomycin, and CRO: ceftriaxone. Stars indicate 
statistically significant difference of TET resistance between the two porB types.  porB1a, n=39. 
porB1b, n=104.  
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3.2.1.2 Mutations of G120 and A121 in Gonococcal PorB   
 
Mutations at codons G120 and A121 of gonococcal PorB proteins (i.e. PIB and PIA) are 
associated with decreased susceptibility to antibiotics (Olesky et al 2002, 2006). Of the 104 PIB 
isolates, 98.1% (102/104) carried mutations at codon G120: 84.6% (88/104) with a G120K 
mutation, 11.5% (12/104) with a G120D mutation, 1% (1/104) with a G120R, and 1% (1/104) 
with a G120N mutation. The majority of the PIB isolates (87.5%, 91/104) had mutations at 
codon A121: A121D (73.1%, 76/104), A121G (6.7%, 7/104), A121N (6.7%, 7/104), or A121H 
(1.0%, 1/104). Double mutations of PIB G120/A121 were observed in 86.5% (90/104) of the 
isolates, including G120K/A121D (71.1%, 74/104), G120K/A121G (6.7%, 7/104), 
G120K/A121N (5.7%, 6/104), G120K/A121H (1%, 1/104), G120R/A121D (1%, 1/104), and 
G120N/A121N (1%, 1/104). A single G120 mutation (G120D) was noted in 11.5% (12/104) of 
the sequences while a single A121 mutation, A121D, was observed in 1% (1/104). Two PIB 
isolates (2/104) did not carry any mutations at these two codons. Mutation G120R and A121N 
have not been reported previously (Table 3.4).  
 
In the 39 PIA isolates, the G120 mutation, G120D, was observed in 82.1% (32/39) of the 
sequences while the rest (7/39) did not exhibit this mutation. All PIA isolates had a mutation at 
codon A121 (A121G). Double mutations of G120D/A121G were observed in 82.1% of PIA 
isolates, while 17.9% of PIA isolates had a single A121G mutation (Table 3.4).  
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Table 3.4 Mutations at the residues G120 and A121 of porB in 143 N. gonorrhoeae isolates 
from Shanghai in 2005
§ 
 
 
Mutations in PorB Number of porB1b isolates (%) Number of porB1a isolates (%) 
G120K/A121D 74 (71.1) 0 
G120K/A121G 7(6.7) 0 
G120K/A121N 6 (5.7) 0 
G120R/A121D 1 (1.0) 0 
G120K/A121H 1 (1.0) 0 
G120N/A121N 1 (1.0) 0 
G120D/A121A 12 (11.5) 0 
G120G/A121D 1 (1.0) 0 
G120G/A121A 
 
1 (1.0) 0 
G120D/A121G 0 32 (82.1) 
G120G/A121G 0 7 (17.9) 
Total isolates (%) 104 (100.0) 39 (100.0) 
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3.2.2 Association between Mutations in Multiple Loci and Reduced Susceptibility to 
Ceftriaxone in N. gonorrhoeae 
3.2.2.1 Antimicrobial Resistance Phenotypes  
Ceftriaxone MICs of the CRO
Red
 and CRO
S
 N. gonorrhoeae isolates differed by at least 4 
fold. The MIC50s and MIC90s to penicillin (PEN), tetracycline (TET), ciprofloxacin (CIP), or 
spectinomycin (SPT) for the two groups were within 2-fold dilutions (data not shown). All 
isolates were susceptible to SPT. There was no significant difference (P>0.05) in the percentages 
of isolates resistant to PEN (CRO
Red
100% vs CRO
S
 84.8%), TET (CRO
Red
 64.3% vs CRO
S
 
54.3%), and CIP (CRO
Red
 100% vs CRO
S
 100%). Likewise, there was no significant difference 
(P>0.05) in percentages of resistant phenotypes [PPNG (CRO
Red
 67.9% vs CRO
S
 50.0%), TRNG 
(CRO
Red 
32.1% vs CRO
S
 31.3%), PP/TRNG (CRO
Red
 21.4% vs CRO
S
 18.8%), CMPR (CRO
Red
 
42.9% vs CRO
S
 31.2%), CMTR (CRO
Red 
31.3% vs CRO
S
 25.0%), and CMRNG (CRO
Red
14.3% 
vs CRO
S
 9.4%)].  
3.2.2.2 N. gonorrhoeae porB1b is associated with CRO
Red
 
The percentage of isolates carrying a PIB phenotype (Table 3.5) was significantly higher in 
CRO
Red
 (89.3%, 25/28) isolates than that in CRO
S
 (59.4%, 19/32) isolates (P=0.02). In CRO
Red
 
PIB isolates (n=25), the amino acid substitutions observed at codons G120 and/or A121 included 
G120K/A121D (68.0%), G120K/A121N/G (20.0%), and G120D alone (12.0%). In CRO
S
 PIB 
isolates (n=19), similar amino acid substitutions were observed –i.e. G120K/A121D (84.2%), 
G120K/A121N/G (5.3%), and G120D alone (5.3%). One CRO
S
 PIB isolate had no mutations at 
codons G120 and A121. The mutation patterns at G120 and A121 were not significantly 
different between CRO
Red
 and CRO
S
 isolates which were PIB (P=0.78) or PIA (P=0.92).  
 
3.2.2.3 MtrR Mutations Differ between CRO
Red
 and CRO
S
 N. gonorrhoeae Isolates 
 The distribution of mutation patterns in MtrR was significantly different (P<0.001) 
between CRO
Red
 and CRO
S
 isolates (Table 3.6). Notably, 50% of CRO
Red 
isolates (14/28) 
exhibited a MtrR protein sequence identical to N. gonorrhoeae FA1090 MtrR (GenBank 
accession #YP_208426, referenced to as wild type - WT), while only one CRO
S
 isolate (3.6%, 
1/32) displayed a WT MtrR.  
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Table 3.5 Association between gonococcal PorB and reduced susceptibility to ceftriaxone 
(CRO) in N. gonorrhoeae isolates from Shanghai 
 
a. CRO
Red
: Reduced susceptibility to ceftriaxone (MIC=0.125–0.25 mg/L) 
b. CRO
S
: susceptible to ceftriaxone (MIC=0.004–0.016 mg/L) 
P: P values were determined by Chi-square tests.
36
 
*: P value for differences of percentages of PIA and PIB isolates among CRO
Red
 and CRO
S
 
isolates.  
 
  
 
 
 
 
 
 
 
 
 
 
 
Mutations at residues G120 
and A121 of PorB 
CRO
Red
 isolates 
 n (%)
a
 
CRO
S
 isolates   
n (%)
b
 
 
P 
PIB    
   G120K/A121D 17 (68.0) 16 (84.2)  
 
0.78 
   G120K/A121N/G 5 (20.0) 1 (5.3) 
   G120D 3 (12.0) 1 (5.3)  
   No mutation 0 (0.0) 1 (5.3)  
   Subtotal 25 (100.0) 19 (100.0) 
PIA    
   G120D/A121G 3 (100.0) 10 (76.9)  
0.92    A121G 0 3 (23.1) 
   Subtotal  3 (100.0) 13 (100.0) 
    
Overall (PIB vs PIA) 
 
28 (100.0) 
 
32 (100.0) 
 
0.02* 
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Table 3.6 Specific amino acid substitutions in gonococcal MtrR are associated with reduced 
susceptibilityof N. gonorrhoeae isolates to ceftriaxone 
 
a. CRO
Red
: Reduced susceptibility to ceftriaxone (MIC = 0.125–0.25 mg/L) 
b. CRO
S
: susceptible to ceftriaxone (MIC = 0.004–0.016 mg/L) 
c. One isolate had a single nucleotide deletion at nt341 of mtrR, resulting in a truncated MtrR. 
This truncated MtrR also had an A39T/H105Y double mutation. 
d. A deletion of 5 nucleotides at nt189-193 of mtrR, resulting in a truncated MtrR protein. This 
truncated MtrR also had an A39T mutation. 
e. ND: Not determined because of small number of isolates. 
†. WT- wild type using MtrR from N. gonorrhoeae FA1090 as a template 
*. To facilitate Chi-sqaure tests, isolates with an A39T or G45D mutation were combined 
because both mutations were at the DNA binding domain of MtrR. Similarly, A39T/H105Y and 
G45D/H104Y were combined.  
Mutations in MtrR CRO
Red
 isolates, n (%)
a
 CRO
S
 isolates, n (%)
b
 P 
Overall (PIA and PIB)    
  WT
†
 14 (50.0) 1 (3.6)  
 
<0.001
*
 
   A39T/H105Y or G45D/H105Y 10 (35.7)
c,d
 0 (0.0) 
   T86A 3 (10.7) 0 (0.0) 
   A39T or G45D 1 (3.6) 15 (46.9) 
   H105Y 0 14 (43.8) 
   T86A/H105Y 0 (0.0) 2 (6.3) 
   Total 28 (100.0) 32 (100.0) 
PIA    
   WT 2 (66.7) 1 (7.7)  
 
ND
e
 
   A39T/H105Y 1 (33.3) 0 (0.0) 
   A39T or G45D 0 (0.0) 3 (23.1)
d
 
   H105Y 0 (0.0) 7 (53.8) 
   T86A/H105Y 0 (0.0) 2 (15.4) 
    Subtotal 3 (100.0) 13 (100.0)  
PIB    
   WT 12 (48.0) 0 (0.0)  
 
<0.001 
   A39T/H105Y or G45D/H105Y 9 (36.0) 0 (0.0) 
   T86A 3 (12.0) 0 (0) 
   A39T or G45D 1 (4.0) 12 (63.2) 
   H105Y 0 (0) 7 (36.8) 
    Subtotal 25 (100.0) 19 (100.0)  
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A39T/H105Y or G45D/H105Y mutations were present in CRO
Red
 isolates (35.7%), but not 
in CRO
S
 isolates. A T86A mutation was present in 3 CRO
Red
 isolates, but not in CRO
S
 isolates. 
CRO
S
 isolates often carried a single A39T or G45D mutation (46.9%) in the DNA binding 
domain of MtrR, in contrast with only 1 CRO
Red
 isolate. An H105Y single mutation was present 
in 43.8% of CRO
S
 isolates, but was not present in CRO
Red
 isolates. 
 
Frame-shift mutations of gonococcal mtrR were observed in 3 isolates; 2 CRO
Red
 isolates 
had a single nucleotide deletion at nt341 of mtrR, which would produce a truncated protein of 
113 amino acids (this truncated protein also had an A39T/H105Y mutation). A CRO
S
 isolate had 
a deletion of 5 nucleotides (nt189-193) in mtrR, which would produce a truncated MtrR of 62 
amino acids, which also carried an A39T substitution. 
 
The presence of a single nucleotide deletion (-A) in the 13bp inverted repeat of the mtrR 
promoter did not differentiate CRO
Red
 from CRO
S
 isolates (P>0.05). It was observed in 92.9% 
(26/28) of the CRO
Red 
(2 CRO
Red
 isolates without an ―-A‖ deletion carried a truncated MtrR 
protein). This deletion was also observed in 90.6% (29/32) of the CRO
S
 isolates [3 CRO
S
 isolates 
without ―-A‖ deletion had a G45D mutation (n=2) or carried a truncated MtrR (n=1)]. 
 
PorB type (i.e. PIA and PIB) was stratified in order to determine its association with MtrR 
mutations. Two of the 3 PIA CRO
Red
 isolates had a WT MtrR and 1 isolate carried an 
A39T/H105Y mutation in its truncated MtrR, whereas most PIA CRO
S
 isolates had A39T or 
G45D (23.1%, 3/13) or H105Y (53.8%, 7/13) single mutations in MtrR. The distribution of MtrR 
mutation patterns between CRO
Red
 and CRO
S
 isolates was significantly different (P < 0.001) for 
isolates which were PIB. Most PIB CRO
Red
 isolates had either a wild type (48.0%, 12/25), or 
double mutations of A39T/H105Y or G45D/H105Y (36.0%, 9/25) in MtrR, whereas the majority 
of PIB CRO
S
 isolates carried A39T or G45D (63.2%, 12/19), or H105Y (36.8%, 7/19) single 
mutations.    
 
3.2.2.4 Mutation Patterns in PBP2 (penA) 
Mutations in the transpeptidase domain of PBP2 (AA340-570) have been implicated in 
reduced susceptibility to third-generation cephalosporins. All isolates in this study had an Asp-
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346 insertion in PBP2 and all other amino acids between AA340 and AA500 of PBP2 were 
identical in both groups of isolates (data not shown).  
 
There was considerable diversity between amino acid 501 and 570 of the PBP2 
transpeptidase domain. Mutations in the region of AA501-570 were observed at 12 codons (Fig. 
3.7): Ala-501, Phe-504, Ala-510, Ala-516, His-541, Gly-542, Pro-551, Pro-552, Lys-555, Ile-556, 
Ile-563, and Ile566. The A501V/T mutation was present more frequently in the CRO
Red
 isolates 
(78.6%) as compared to isolates which were CRO
S
 (46.9%; P=0.02). However, when stratified 
by PorB type (i.e. PIA or PIB), the percentages of A501V/T mutations were similar between the 
CRO
Red 
and the CRO
S 
isolates (P > 0.05, Fig. 3.7). All isolates of both groups contained F504L, 
A510V, and A516G mutations. Although mutations at the other 8 codons were present, their 
percentages between the CRO
Red
 and CRO
S
 isolates were not significantly different (P > 0.05).  
 
Twenty-four polymorphism patterns (I-XXIV) of PBP2 between AA340-AA570 have been 
described previously (Ito et al 2005; Lee et al 2010; Whiley et al 2007a/b). Pattern X has been 
described as mosaic PBP2 (Ito et al 2005) but was not observed in either CRO
Red
 or CRO
S 
isolates in this study.  
 
As shown in Table 3.7, the patterns encountered in our study included 6 novel patterns 
(XXV-XXX). CRO
Red
 isolates (n=28) exhibited 11 polymorphism patterns: Pattern II/XVI 
(7.1%), V (10.7%), XIII (17.9%), XVII/XVIII (25.0%), XXI (10.7), XXVII (10.7%), and XXIV, 
XXV, XXVI, XXVIII, XXIX (3.6% each). CRO
S
 isolates (n=32) exhibited 8 polymorphism 
patterns: Pattern II/XVI (15.6%), V (21.9%), IX (12.5%), XXI (25.0%), XXVII (15.6%), and 1 
(3.1%) isolate each for patterns IV, XVII/XVIII, and XXX.  
 
Patterns XIII (17.9%), XXV (3.6%), XXVI (3.6%), XXVIII (3.6%) and XXIX (3.6%) were 
only present in CRO
Red
 isolates, while Patterns IV (3.1%) and XXX (3.1%) were only present in 
CRO
S
 isolates.  
 
Notably, Patterns XIII (17.9%) and XVII/XVIII (25.0%) were more prevalent in the CRO
Red
 
isolates than in the CRO
S
 isolates (P<0.001), and these patterns contained combinations of 
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mutations of A501V/P551S or A501V/G542S. Patterns V and XXI accounted for a larger 
proportion of CRO
S 
isolates (46.9%, 15/32) as compared to CRO
Red
 isolates (21.4%, 6/28) 
(P=0.04). Patterns V and XXI did not have combined mutations of A501V/P551S or 
A501V/G542S (pattern V did not have A501V although it had G542S, and pattern XXI did not 
have P551S/L or G542S although it had A501V). 
 
Isolates (CRO
Red
 or CRO
S
) were stratified by PorB type to analyze whether mutations in 
PBP2 were associated with PorB type. Forty-four percent of PIB CRO
Red
 isolates (n=25) 
exhibited mutation patterns XIII (16.0%, 4/25) or XVII/XVIII (28.0%, 7/25), while the PIB 
CRO
S
 isolates (n=19) were mostly pattern XXI (31.6%, 6/19). The 3 PIA CRO
Red
 isolates 
exhibited patterns IX, XIII and XXV, respectively, while13 PIA CRO
S
 isolates were pattern II or 
XVI (23.1%, 3/13), V (30.8%, 4/13), IX (7.7%, 1/13), XXI (15.4%, 2/13), and XXVII (23.1%, 
3/13).  
 
3.2.2.5 L421P Mutation in PBP1 (ponA) Is Not Associated with CRO
Red
 
 
All the CRO
Red 
isolates and 97.0% of the CRO
S
 isolates carried a L421P mutation in PBP1 
(P>0.05). One CRO
S
 isolate had double L421P/A375T mutations as well as a PIA phenotype. 
Another CRO
S
 isolate did not have mutations in PBP1 and exhibited a PIA phenotype. No other 
amino acid substitutions were observed in gonococcal PBP1 in this study. 
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Fig. 3.7 Amino acid mutations in the transpeptidase domain of gonococcal PBP2. Amino 
acid substitutions between AA340 to AA570 were determined. Percentages of mutations at 
various residues were presented for CRO
Red
 (MICs=0.125–0.25 mg/L, closed bars) or CROS 
isolates (MICs=0.004–0.016 mg/L, open bars). P values were determined using the Yates Chi-
square test and P < 0.05 was in bold.  
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Table 3.7 Mutation patterns of gonococcal PBP2 in CRO
Red
 and CRO
S
 isolates from Shanghai 
 
 
Mutation patterns 
in PBP2
a
 
 
Amino acid substitutions at the transpeptidase domain CRO
Red
 Isolates   
n (%) 
CRO
S
 Isolates  
n (%) 
Total 
n (%) 
 
II OR XVI
b
 
 
F504L, A510V, A516G 2 (7.1) 5 (15.6) 7 (11.7) 
IV F504L, A510V, A516G, G542S 0 (0) 1 (3.1) 1 (1.7) 
V F504L, A510V, A516G, G542S, I566V 3 (10.7) 7 (21.9) 10 (16.7) 
IX F504L, A510V, A516G, P551L 1 (3.6) 4 (12.5) 5 (8.3) 
XIII A501V, F504L, A510V, A516G, P551S 5 (17.9) 0 (0) 5 (8.3) 
XVII/XVIII  A501V, F504L, A510V, A516G, G542S, I566V 7 (25.0) 1 (3.1) 8 (13.3) 
XXI 
 
A501V, F504L, A510V, A516G, H541N, P552V, 
K555Q, I556V, I566V 
3 (10.7) 
 
8 (25.0) 
 
11 (18.3) 
 
XXV A501T, F504L, A510V, A516G, G542S 1 (3.6) 0 (0) 1 (1.7) 
XXVI A501V, F504L, A510V, A516G, G542S, P551S, I566V 1 (3.6) 0 (0) 1 (1.7) 
XXVII A501V, F504L, A510V, A516G 3 (10.7) 5 (15.6) 8 (13.3) 
XXVIII A501V, F504L, A510V, A516G, I566V 1 (3.6) 0 (0) 1 (1.7) 
XXIX A501V, F504L, A510V, A516G, H541Y 1 (3.6) 0 (0) 1 (1.7) 
XXX A501T, F504L, A510V, A516G, G542S,I563V 0 (0) 1 (3.1) 1 (1.7) 
Total 
 
28 (100) 32 (100) 60 (100) 
 
a: Mutation patterns were determined based on amino acid substitutions in the regions of AA340 to AA570 of N. gonorrhoeae PBP2.  
b: Pattern II and XVI, and pattern XVII and XVIII had identical amino acid substitutions within the region of AA340-AA570 of PBP2.  
CRO
Red
: Reduced susceptibility to ceftriaxone (MIC=0.125–0.25 mg/L) 
CRO
S
: Susceptible to ceftriaxone (MIC=0.004–0.016 mg/L) 
 
 
 
 
 
1
0
5
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3.2.2.6 Clustering of CRO
Red 
Isolates Based on porB DNA Sequence and NG-MAST 
Analysis 
 
To determine whether isolates having reduced susceptibility to ceftriaxone are clonal, 
extended-length porB-based sequence analysis and N. gonorrhoeae Multi-Antigen Sequence 
Typing (NG-MAST) were performed as described in the Method section.  
 
The porB sequence types and NG-MAST sequence types of the N. gonorrhoeae isolates, 
either exhibitng reduced susceptibility (CRO
Red
) or being susceptible (CRO
S
) to ceftriaxone, 
were diverse (Fig. 3.8). The 3 porB1a CRO
Red
 isolates exhibited 2 different porB sequences and 
3 NG-MAST STs, while the 13 proB1a CRO
S
 isolates exhibited 10 porB sequences and 10 NG-
MAST STs. The 25 porB1b CRO
Red
 isolates displayed 20 different porB sequences, dispersing 
along the entire porB 1b phylogenetic tree and 21 NG-MAST STs with the largest ST (#270) 
comprising 3 isolates. The 19 porB1b CRO
S
 isolates included 16 porB1b sequences, which were 
dispersed among the porB1b sequences of the CRO
Red
 isolates along the phylogenetic tree, and 
18 NG-MAST STs (ST421 comprising 2 isolates while all other STs had a single isolate). Three 
STs (ST1691, ST1972 and ST2288) were present in both the CRO
Red
 and the CRO
S
 isolates, 
while other STs were observed only in one susceptibility class or the other. Therefore, the 
CRO
Red
 and the CRO
S
 isolates are non-clonal. 
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Fig. 3.8 Clonality analysis of gonococcal isolates with reduced susceptibility to ceftriaxone.  
A. porB1a isolates (n=16); 3 isolates were CRO
Red
 and 13 isolates were CRO
S
.  
B. porB1b isolates (n=44); 25 isolates were CRO
Red
 and 19 were CRO
S
.  
Analysis was conducted using porB-based typing and NG-MAST analysis as described in the 
method section. Phylogenetic trees were generated based on porB DNA sequences using the 
Clustal X program.  
CRO
Red
 isolates (MICs = 0.125–0.25 mg/L) were highlighted by hatched boxes while CROS 
(MICs = 0.004–0.016 mg/L) isolates were on white background.  
Isolate number is shown at the tip of the tree branches, and NG-MAST ST is indicated for each 
isolate on the right. The distance of horizontal lines was proportional to nucleotide variations of 
porB sequences. Isolates on the same vertical lines had identical porB sequences.  
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3.2.3 Analysis of Quinolone Resistant Determinant Regions (QRDRs) in N. gonorrhoeae 
Isolates 
 
3.2.3.1 Mutation Patterns in QRDRs in N. gonorrhoeae Isolates in Shanghai in 2005 
Part of these results has been published in J Antimicrob Chemother (Yang et al 2006). 
Permission to use has been obtained from the Oxford University Press (Appendix A2.3).  
 
A total of 103 consecutive N. gonorrhoeae isolates collected in 2005 from male patients in 
Shanghai were analyzed. The isolates include 1 susceptible (S), 1 intermediately susceptible (I) 
and 101 resistant (R) to ciprofloxacin (CIP).  
 
The QRDR mutation profiles are shown in Table 3.8. The single CIP
S
 isolate tested did not 
carry mutations in its QRDRs of gyrA or parC (mutation pattern P0), while the CIP
I
 isolate 
carried a D95A mutation in gyrA and an S87N mutation in parC (pattern P1). All CIP
R 
isolates 
carried an S91F mutation in the QRDR of gyrA, while others also contained A92P (3/103, 2.9%) 
and D95A/G (85/103, 82.5%) mutations. Single, double, or triple mutations in gyrA accounted 
for 15.5%, 83.5%, and 0.1% of the 103 N. gonorrhoeae isolates, respectively. parC mutations 
occurred in 74.8% of the isolates tested at codons S87 and E91 including S87R (45/103, 43.7%) 
or S87N/I/C (27/103, 26.2%). Single substitutions at S87 were more commonly found in isolates 
with parC mutations (69/103, 67.0%), while mutations at E91 accounted for 7.8% of the isolates 
(8/103).  
 
Mutations in QRDRs were grouped into 19 patterns (Table 3.8). The most predominant 
patterns, accounting for 65.0% of the 103 isolates tested, included P3, P8, P9, and P15, with 
mutations at S91 and D95 of gyrA and a single or no mutation at S87 of parC. Isolates with 
patterns P2, P3, P4, and P16 (24.3%) contained gyrA but no parC mutations. Other patterns were 
characterized by either one substitution in both gyrA and parC (P1, P5 and P6), 2 mutations in 
gyrA and 1 mutation in parC (P7, P8, P9, P10, P11, P14, P15 and P17), double mutations in both 
gyrA and parC (P12, P13), 3 gyrA and 1 parC mutations (P18), or 1 gyrA and 2 parC mutations 
(P19).  
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Table 3.8 QRDR mutation patterns in 103 N. gonorrhoeae Isolates from Shanghai 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
QRDR: Quinolone resistance determinant region 
a: No mutation at that residue. 
b: The ciprofloxacin susceptible isolate without a mutation in the QRDRs was defined as Pattern 
P0. 
c: The isolate having an ―intermediate‖ MIC to ciprofloxacin exhibiting a QRDR mutation 
pattern P1. 
Predominant patterns P3, P8, P9 and P15 are in bold. 
 
 
 
 
 
 
Mutation  GyrA ParC No. of 
isolates (%) 
Ciprofloxacin 
MIC (mg/L) patterns S91 A92 D95 S87 E91 
P0 -
a
 - - - - 1(1.0) 0.06
b
 
P1 - - A N - 1(1.0) 0.5
c
 
P2 F - - - - 4(3.9) 1-16 
P3 F - A - - 13(12.6) 1-32 
P4 F - G - - 7(6.8) 2-32 
P5 F - - R - 5(4.8) 16-32 
P6 F - - I - 5(4.8) 2-≥64 
P7 F - A - A 3(2.9) 1-32 
P8 F - A R - 24(23.3) 2-32 
P9 F - A N - 16(15.5) 2-16 
P10 F - A I - 1(1.0) 8,16 
P11 F - A C - 1(1.0) 2 
P12 F - A I A 1(1.0) 32 
P13 F - A N G 1(1.0) 2 
P14 F - G - G 2(1.9) 2,8 
P15 F - G R - 14(13.6) 2-≥64 
P16 F P - - - 1(1.0) 2 
P17 F P - R - 1(1.0) 32 
P18 F P G R - 1(1.0) 2 
P19 F - - N G 1(1.0) 16 
 
Total 
      
103(100.0) 
 
0.06-≥64 
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3.2.3.2 Quantitative Association between MIC to Ciprifloxacin and Mutations in the 
Quinolone Resistant Determinant Regions 
 
Regression correlation analysis was conducted to quantitatively determine the association 
between mutation patterns in QRDRs and the CIP MICs in N. gonorrhoeae isolates (Fig. 3.9). 
The correlation coefficient, represented as R
2
, was 0.1759 for isolates having a single amino acid 
mutation, 0.328 for isolates with 2 amino acid mutations, and 0.0038 for isolates having 3 amino 
acid substitutions in GyrA QRDR. There was no association between the number of amino acid 
mutations in GyrA QRDR and CIP MICs (P>0.05).  The presence of mutations in ParC QRDR 
was significantly associated with high CIP MICs (R
2
 = 0.9258, P<0.01).  
 
3.2.3.3 Temporal Trends of QRDR Mutation Patterns in N. gonorrhoeae Isolates in 
Shanghai: 2005/2008 
  
 QRDR mutation patterns in CIP
R
 N. gonorrhoeae isolates collected from Shanghai in 2008 
(n=68) were compared to those in CIP
R
 isolates from Shanghai in 2005. All CIP
R
 isolates 
collected in 2008 (SH2008) contained a mutation at codons S91 and D95 of GyrA, and 75% of 
the SH2008  CIP
R
 isolates had mutations at codon S87. The percentages of mutations at codons 
S91, D95 of GryA, and S87 of ParC were similar to the SH2005 CIP
R
 isolates (P>0.05). The 
S88P mutation in ParC was observed in the SH2008 CIP
R
 isolates but not in the SH2005 CIP
R
 
isolates (Fig. 3.10A).  
 
 In the SH2008 CIP
R
 isolates, 10 QRDR mutation patterns were observed, with an average of 
6.8 isolates per mutation pattern (Fig. 3.10B). By comparison, 17 QRDR mutation patterns were 
observed in the SH2005 CIP
R
 isolates (n=101), with an average of 5.9 isolates per mutation 
pattern. Several common patterns were observed in both surveys (P3, P4, P8, P9, P14, and P15), 
but other patterns observed in the SH2005 CIP
R
 isolates were not observed in the SH2008 CIP
R
 
isolates. Nine SH2008 CIP
R
 isolates had 4 new mutation patterns as compared to the mutation 
patterns of the SH2005 CIP
R
 isolates; these new patterns included mutations of S91F/D95A in 
GyrA and S87R/S88P in ParC (5 isolates), or S91F/D95N in GyrA and none or S87/or E91G in 
ParC (4 isolates).  
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Fig. 3.9 Correlation of Ciprofloxacin MICs and Mutations of QRDRs in N. gonorrhoeae 
Isolates.  
QRDR: quinolone resistance determinant region. 
ParC mt indicated any mutations in ParC QRDRs. GyrA 1mt, 2mt and 3m indicated as isolates 
having 1, 2 or 3 amino acid substitutions in GyrA QRDR, respectively.  
R: correlation coefficient generated with logarithmic regression.  
Bold lines represent CIP MIC distributions of the isolates. Projected regression associations are 
shown in regular or dashed lines.  
Red open box: Significant association. 
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Fig. 3.10 Trends of QRDR mutations in ciprofloxacin resistant N. gonorrhoeae isolates in 
Shanghai: 2005/2008.  
A. Comparison of residue mutation percentages. Others- A92P (SH2005) in GyrA, S88P 
(SH2008) and E91G (both SH2005 and SH2008) in ParC. No Mut.- no mutations.     
B. Comparison of QRDR mutation patterns. Other mutation patterns of QRDRs for SH2005 
isolates were shown in Table 3.8, including P5-7, P10-13, P16-19. There are 4 new mutation 
patterns of QRDRs for the SH2008 CIPR isolates as compared those for the SH2005 CIPR 
isolates 
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3.3 Molecular Epidemiology of Neisseria gonorrhoeae in China 
 
3.3.1 Phylogenetic Analysis of N. gonorrhoeae Isolates Based on porB DNA Sequences 
N. gonorrhoeae isolates used in this study included 174 isolates (143 from male index 
patients and 31 from female sex partners) from Shanghai in 2005 (SH2005), 81 isolates (68 from 
male index patients and 13 from female sex partners) from Shanghai in 2008 (SH2008), and 44 
isolates (male patients only) from Urumchi in 2007-2008 (UQ2008).  
 
Isolates from patients with sexual contacts revealed at the interview were described as ―dyad‖ 
(two isolates from a male patient and one female patient, respectively, who reported having 
sexual contact.) or ―triad‖ (three isolates from a male patient and two female patients, 
respectively. Both female patients had sexual contact with the male patient reported at the 
interview). 
 
3.3.1.1 porB-based Strain Diversity of 174 N. gonorrhoeae Isolates in Shanghai in 2005 
These results have been published in J Antimicrob Chemother (Liao et al 2008). Permission 
for use has been obtained from the Oxford University Press (Appendix A2.4). 
  
The index of discrimination (ID) of the porB-based typing method for the 174 isolates from 
2005 was 95.0%. 
 
Among the 174 N. gonorrhoeae isolates (SH2005), 47 isolates (27.0%) had a porB1a 
genotype and 127 isolates (73.0%) exhibited a porB1b genotype (Table 3.9). In total 77 unique 
porB DNA sequences were identified, with an average of 2.3 isolates per porB sequence.  
 
The 47 porB1a isolates exhibited 15 porB DNA sequences. Two large clusters of N. 
gonorrhoeae isolates were identified: one comprised 15 isolates with 2 dyads, and the other one 
contained 14 isolates including 2 dyads and 1 triad. Two other clusters comprised 5 isolates 
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including a dyad and 2 isolates (a dyad), respectively. Eleven isolates, all from male patients, 
each had a distinct porB1a sequence. 
 
The 127 porB1b isolates exhibited 62 sequences. A large cluster was identified which 
comprised 33 isolates including 5 dyads. Two clusters each comprised 5 isolates. Another two 
clusters each comprised 4 isolates. Nineteen porB sequences each comprised 2 isolates including 
13 dyads. The other 38 isolates each exhibited a distinct porB sequence. 
 
 Phylogenetic analysis of the 15 porB1a sequences revealed that there were 3 nodes along the 
main trunk of the lineages and a node within the branches, based on a bootstrap value of higher 
than 50. Thus 4 clades formed in this group of 47 isolates, and the largest clade comprised 78.7% 
(37/47) of the porB1a isolates (Fig. 3.11 A). 
  
DNA sequences of the 127 porB1b isolates were first divided into two groups (Group 1 and 
2) based on clustering of neighbor joining trees in Clustal W analysis. porB DNA sequences of 
these 2 groups were separately subjected to phylogenetic analysis using the PAUP program. In 
Group 1, there were 7 nodes along the main trunk of the lineages and 2 nodes within the 
branches with a bootstrap value of higher than 50 (Fig. 3.11 B). There were 10 clades in Group 1 
porB1b isolates; the largest clade comprised 38 isolates (29.9%, 38/127), 33 of which had an 
identical porB1b sequence. In Group 2, there were 5 nodes along the main trunk of the lineages 
and 2 nodes within the branches with a bootstrap value of higher than 50 (Fig. 3.11 C). There 
were 7 clades in Group 2 porB1b isolates. Therefore, the 127 porB1b isolates were 
phylogenetically divided into 16 clades based on a bootstrap value of > 50.  
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Table 3.9 porB-based clustering of 174 N. gonorrhoeae isolates from Shanghai in 2005 
 
 
Isolates underlined were from gonorrhea patients having sexual contact. F - females. 
 
 
Sequence  Assigned isolate number 
 
porB1a (47 isolates, 15 sequences) 
 
1 sequence comprised 14 isolates 
 
 
2,9,54, 56,56F, 61,61F, 75,75F1,75F2, 86,129,160, 166 
1 sequence comprised 15 isolates 26,26F3,30,82,113,120,123,124,125,126,132,145, 156, 
162,162F 
 
1 sequence comprised 5 isolates 
 
18,35,115, 164,164F 
1 sequence comprised 2 isolates 63,63F 
11 sequences each comprised a single 
isolate (11 isolates) 
57,91,94,146,112,122,143,153,159,163,165 
 
porB1b (127 isolates, 62 sequences) 
 
1 sequence comprised 33 isolates 
 
5,17,25, 34,34F, 42,52,  64,64F, 71,70, 74, 81,87, 89,89F, 
90,92,93, 97, 101,101F, 104,109,110, 134,134F, 135,135F, 
140,147,152,151 
  
2 sequences each comprised 5 isolates 
(10 isolates) 
10,29, 53,53F,148 
12,16,23,67,169 
2 sequences each comprised  
4 isolates (8 isolates) 
58,41F,46,130,60, 118,118F, 161 
 
19 sequences each comprised  
2 isolates (38 isolates) 
 
 
8, 8F,72,72F,  78,78F, 83,83F,107,107F,  
116,116F, 158,158F, 11,11F, 32,32F, 37,37F, 103,103F, 
150,150F, 73,73F; 
(155,108),(79,44),(106,7),(45,141F),(80,157),(149,65) 
 
38 sequences each comprised  
a  single isolate (38 isolates) 
 
4F,19,39,50,68,76,114,117F,121,137,139,141, 
144,3,27,28,31,38,41F,47,55,66,119,127,131, 
13,20,21,22,33,43,77,95,102,105,133,136,138 
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Fig. 3.11 porB-based phylogenetic analysis of 174 N. gonorrhoeae isolates from 2005. 
A. porB1a sequences  
Phylogenetic analysis was conducted using the PAUP program. Tree was figured and presented 
in Treeview. Branch lengths are shown proportional to the amount of change along the branches. 
The scale distance bar indicates the number of nucleotide substitutions per site. Bootstrap values 
greater than 50% are shown in circles over the branches. A representative isolate number for 
porB sequences is shown at the tips of branches; and the number of isolates with identical 
sequences is shown adjacent to the representative isolate.  
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Fig. 3.11 porB-based phylogenetic analysis of 174 N. gonorrhoeae isolates from 2005. 
B. Group 1 of porB1b sequences, C. Group 2 of porB1b sequences.  
Phylogenetic analysis was conducted using the PAUP program. Tree was figured and presented 
in Treeview. Branch lengths are shown proportional to the amount of change along the branches. 
The scale distance bar indicates the number of nucleotide substitutions per site. Bootstrap values 
greater than 50% are shown in circles over the branches. A representative isolate number for 
porB sequences is shown at the tips of branches; and the number of isolates with identical 
sequences is shown adjacent to the representative isolate.  
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3.3.1.2 porB-based Strain Diversity of 81 N. gonorrhoeae Isolates in Shanghai in 2008 
  
 The index of discrimination (ID) of porB DNA sequence typing for these N. gonorrhoeae 
isolates was 96.8%. Among the 81 N. gonorrhoeae isolates, 10 isolates (12.3%) were identified 
to have a porB1a genotype and 71 isolates (87.7%) had a porB1b genotype (Table 3.10). In total, 
39 porB sequences were identified, with an average of 2.1 isolates per porB sequence.  
  
 The 10 porB1a isolates exhibited 6 unique DNA sequences. A cluster of 3 isolates had an 
identical porB1a sequence, and two other clusters each comprised 2 isolates. The other 3 isolates 
each had a distinct porB1a sequence. The 71 porB1b isolates exhibited 33 sequences. Each of 18 
DNA sequences comprised a single isolate, whereas the remaining 15 sequences comprised ≥ 2 
isolates. Two large clusters comprised 10 isolates and 6 isolates (including a dyad), respectively. 
There were 3 sequences that each comprised 4 isolates. Five sequences each had 3 isolates, and 
another 5 sequences each comprised 2 isolates. The remaining 18 isolates each displayed a 
distinct sequence. 
 
 Phylogenetic analysis of 6 porB1a sequences revealed that there were 3 nodes along the main 
trunk of the lineages with a bootstrap value of higher than 50. Thus 4 clades formed in this group 
of 10 isolates (Fig. 3.12 A). Among the 33 porB1b sequences, there were 8 nodes along the main 
trunk of the lineages and 5 nodes within the branches with a bootstrap value of higher than 50 
(Fig. 3.12 B). Therefore, the 71 porB1b isolates were phylogenetically divided into 13 clades 
based on a bootstrap value of higher than 50.  
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Table 3.10 porB-based clustering of 81 N. gonorrhoeae isolates from Shanghai in 2008  
 
 
Isolates underlined were from gonorrhea patients having sexual contact. F – isolates from female 
patients. 
Sequence  Assigned isolate number 
 
porB1a (10 isolates, 6 sequences) 
 
1 sequence contained 3 isolates 
 
 
200824, 200832,200832F1 
2 sequences each comprised 2 
isolates (4 isolates) 
 
SH200811,SH200836F1, SH200835,SH200835F1 
3 sequences each contained a single 
isolate (3 isolates) 
SH200896,SH200855,SH200852 
 
porB1b (71 isolates, 33 sequences) 
 
 
1 sequence contained 10 isolates 
 
SH200891,SH200893,SH200836,SH200825,SH200818, 
SH200815,SH200814,SH200813,SH20089,SH20082 
 
1 sequence contained 6 isolates 
 
SH20088,SH20088F2, SH200817,SH200840,SH200842, 
SH200882 
 
3 sequences each contained 4 isolates  
(12 isolates) 
 
SH20083, SH300839,SH200839F1, SH200810 
SH200889, SH200897,SH200897F1, SH200881F1 
SH200887,Sh200888,SH200890,SH200892 
 
5 sequences each contained 3 isolates 
(15 isolates) 
 
SH20085,SH200826,SH200851 
SH20087, SH200886,SH200886F1 
SH200822,SH22F1,SH22F2 
Sh200853, SH200856,SH200856F1 
SH200894,SH200894F1,SH200894F7 
 
5 sequences each contained 2 isolates 
(10 isolates) 
SH20081,SH20081F1 
SH200819,SH200838 
SH200812,SH200841 
SH200820,SH200820F1 
SH200828,SH200848 
18 sequences each comprised  
a  single isolate (18 isolates) 
SH200850,SH200821,SH200816,SH200884,SH200844, 
SH200810,SH200881,SH200847,SH200843,SH200845F1, 
SH200830,SH200895,SH200834,SH200854,SH200831, 
SH200884,SH20086,SH200846 
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Fig. 3.12 porB-based phylogenetic analysis of 81 N. gonorrhoeae isolates from Shanghai in 
2008. 
A. porB1a sequences, C. porB1b sequences  
Phylogenetic analysis was conducted using the PAUP program. Tree was figured and presented 
in Treeview. Branch lengths are shown proportional to the amount of change along the branches. 
The scale distance bar indicates the number of nucleotide substitutions per site. Bootstrap values 
greater than 50% are shown in circles over the branches. A representative isolate number for 
porB sequences is shown at the tips of branches; and the number of isolates with identical 
sequences is shown adjacent to the representative isolate.  
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3.3.1.3 porB-based Strain Diversity of 44 N. gonorrhoeae Isolates in Urumchi 
  
 The index of discrimination (ID) of porB DNA sequence typing for these N. gonorrhoeae 
isolates was 93.2%. 
 
Among the 44 N. gonorrhoeae isolates, 16 isolates (36.4%) had porB1a genotypes and 28 
isolates (63.6%) had porB1b genotypes (Table 3.11). In all, 23 porB sequences were identified, 
with an average of 1.9 isolates per porB sequence.  
  
The 16 porB1a isolates exhibited 6 sequences. A large cluster of 8 isolates had an identical 
porB sequence. Two sequences comprised 3 and 2 isolates, respectively. The remaining 3 
porB1a sequences each comprised a single isolate. 
 
The 28 porB1b isolates displayed 17 porB1b sequences. A large cluster of 8 isolates had an 
identical porB1b sequence. Four sequences each comprised 2 isolates. The remaining 12 
sequences each comprised a single isolate. 
 
Phylogenetic analysis of the 6 porB1a sequences revealed that there was 1 node with a 
bootstrap value of higher than 50. Thus 2 clades formed for the 16 porB1a isolates (Fig. 3.13). 
Among the 17 porB1b sequences, there were 7 nodes along the main trunk of the lineages and 3 
nodes within the branches, which had bootstrap values of higher than 50.  
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Table 3.11 porB-based clustering of 44 N. gonorrhoeae isolates from Urumchi in 2007-2008  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sequence  Assigned isolate number 
 
porB1a (n=16 isolates, 6 sequences) 
 
1 sequence comprised 8 isolates 
 
 
XJH1,XJY1,XJY9,XJY11,XJY16,XJY13+,XJY15,XJQ19 
1 sequence comprised 3 isolates 
 
XJZ7,XJZ8,ZJY21 
1 sequence comprised 2 isolates 
 
XJH5,XJH7 
3 sequences each comprised a single 
isolate (3 isolates) 
XJZ33,XJQ8,XJY6 
 
porB1b (n=28 isolates, 17 sequences) 
 
1 sequence comprised 8 isolates 
 
XJQ11,XJQ22,XJQ10,XJY24,XJY20,XJY3,XJZ34,XJZ21 
 
4 sequences each comprised 2 isolates 
(8 isolates) 
 
XJZ29,XJZ30 
XJY12,XJY19 
XJZ22,XJZ23 
XJY22,XJQ4 
 
12 sequences each comprised  
a  single isolate (12 isolates) 
XJY23,XJY18,XJZ35,XJY8,XJZ9,XJW4,XJY7,XJQ3, 
XJY4,XJH6,XJQ9,XJQ5 
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Fig. 3.13 porB-based phylogenetic analysis of 44 N. gonorrhoeae isolates from Urumchi in 
2007-2008. 
       Phylogenetic analysis was conducted using the PAUP program. Tree was figured and 
presented in Treeview. Branch lengths are shown proportional to the amount of change along the 
branches. The scale distance bar indicates the number of nucleotide substitutions per site. 
Bootstrap values greater than 50% are shown in circles over the branches. A representative 
isolate number for porB sequences is shown at the tips of branches; and the number of isolates 
with identical sequences is shown adjacent to the representative isolate.  
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3.3.1.4 Temporal Strain Distribution of N. gonorrhoeae in Shanghai: 2005/2008  
 
To determine temporal trends of N. gonorrhoeae strain distribution, porB sequences for the 
SH2005 and SH2008 isolates were combined (SH2005/2008 porB1a and SH2005/2008 porB1b) 
for phylogenetic analysis using the PAUP software.  
 
All porB1a sequences for the SH2008 isolates were distinct from those observed in the 
SH2005 isolates. porB1a sequences of the two surveys dispersed along the phylogenetic tree. 
However, the largest porB1a clusters for the SH2005 and the SH2008 isolates were placed in 
distant clades (Fig. 3.14 A).  
 
porB1b sequences for SH2005 and SH2008 isolates were divided into 3 data sets based on 
Clustal W neighbor joining trees for ease of analysis using the PAUP program. porB1b 
sequences of the two surveys dispersed along the phylogenetic trees (Fig. 3.14 B-D). 
Approximately 76% of the SH2008 sequences (25/33) differed from the SH2005 sequences; only 
8 SH2008 sequences (24%, 8/33) comprising 14 isolates (20%, 14/71) were also present in the 
SH2005 isolates. The largest porB1b cluster, comprising 10 SH2008 isolates (12.3%), was 
unique as compared to the SH2005 isolates (Fig. 3.14 B). The largest porB1b cluster for the 
SH2005 isolates (19%, 33/174) was only observed in 3 SH2008 isolates (3.7%, 3/81).  
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Fig. 3.14 Temporal strain distribution of N. gonorrhoeae in Shanghai based on porB DNA 
sequences: 2005/2008 
A. porB1a sequences, B. Group 1 porB1b sequences 
Phylogenetic analysis was conducted using the PAUP program. Tree was figured and presented 
in Treeview. Branch lengths are shown proportional to the amount of change along the branches. 
The scale distance bar indicates the number of nucleotide substitutions per site. Bootstrap values 
greater than 50% are shown in circles over the branches.  
The SH2005 sequences are highlighted in blue and the SH2008 sequences highlighted in pink. 
Dashed arrows indicate the sequence contained highest number of isolates for porB1a isolates (a) 
and porB1b isolates (b-d).  
Stars on the SH2008 sequences indicate that those sequences were also present in the SH2005 
isolates. The SH2008 sequences without a star indicate a novel sequence as compared to the 
SH2005 isolates.  
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Fig. 3.14 Temporal strain distribution of N. gonorrhoeae in Shanghai based on porB DNA 
sequences: 2005/2008 
C. Group 2 porB1b sequences, D. Group 3 porB1b sequences.  
Phylogenetic analysis was conducted using the PAUP program. Tree was figured and presented 
in Treeview. Branch lengths are shown proportional to the amount of change along the branches. 
The scale distance bar indicates the number of nucleotide substitutions per site. Bootstrap values 
greater than 50% are shown in circles over the branches.  
The SH2005 sequences are highlighted in blue and the SH2008 sequences highlighted in pink. 
Dashed arrows indicate the sequence contained highest number of isolates for porB1a isolates (a) 
and porB1b isolates (b-d).  
Stars on the SH2008 sequences indicate that those sequences were also present in the SH2005 
isolates. The SH2008 sequences without a star indicate a novel sequence as compared to the 
SH2005 isolates.  
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3.3.1.5 Spatial Strain Distribution of N. gonorrhoeae Isolates: Shanghai/Urumchi 
 
To determine geographic strain distribution, porB DNA sequences for the SH2008 and the 
UQ2008 isolates were combined into two datasets: SH2008/UQ2008 for porB1a and 
SH2008/UQ2008 for porB1b. Each dataset was subjected to phylogenetic analysis using the 
PAUP program.  
 
The 6 porB1a sequences for the SH2008 isolates were distinct from the porB1a sequences 
observed in the UQ2008 isolates. Isolates of the two surveys were dispersed along the 
phylogenetic tree. Similarly, the porB1b sequences in the SH2008 and the UQ2008 isolates 
differed, and were dispersed along the phylogenetic tree was as well. (Fig. 3.15). 
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Fig. 3.15 Spatial strain distribution of N. gonorrhoeae based on porB DNA sequences: 
Shanghai/Urumchi  
A. porB1a sequences, B. porB1b sequences 
Phylogenetic analysis was conducted using the PAUP program. Tree was figured and presented 
in Treeview. Branch lengths are shown proportional to the amount of change along the branches. 
The scale distance bar indicates the number of nucleotide substitutions per site. Bootstrap values 
greater than 50% are shown in circles over the branches.  
The SH2008 sequences are highlighted in pink, and the UQ2008 sequences are highlighted in 
yellow. 
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3.3.2 NG-MAST Analysis of N. gonorrhoeae Isolates 
 
3.3.2.1 NG-MAST Analysis of the SH2005 N. gonorrhoeae Iosolates (see Section 3.3.3) 
 
3.3.2.1 NG-MAST Analysis of the SH2008 N. gonorrhoeae Isolates 
 
NG-MAST analysis was performed for the 81 isolates collected from Shanghai in 2008. The 
index of discrimination (ID) for the NG-MAST analysis was 98.1%. There were 50 NG-MAST 
sequence types (STs) among the 81 N. gonorrhoeae isolates; 27 of them (43 isolates) were new 
to the NG-MAST database. The largest cluster (ST# 1866) comprised 6 isolates (7.4%). One 
cluster (ST# 3288) comprised 4 isolates. Two clusters (ST# 3356 and 3361) each comprised 4 
isolates. Five ST clusters each comprised 3 isolates, and six clusters each comprised 2 isolates. 
The remaining 35 STs each comprised a single isolate.  
 
3.3.2.2 NG-MAST Analysis of the UQ2008 N. gonorrhoeae Isolates 
NG-MAST analysis was performed for 44 N. gonorrhoeae isolates collected from Urumchi 
in 2007-2008. The ID for the NG-MAST analysis was 94.6%. There were 25 NG-MAST STs 
among the 44 N. gonorrhoeae isolates; 13 of them (15 isolates) were new to the NG-MAST 
database. The largest cluster (ST# 1866) comprised 8 isolates (18.2%). One cluster (ST# 436) 
comprised 6 isolates. Seven ST clusters each comprised 2 isolates. The remaining 16 STs each 
comprised a single isolate.  
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3.3.3 Comparison of the modified porB-based and NG-MAST Analysis for Differentiating 
N. gonorrhoeae Isolates 
 
These results have been reported in J Clin Microbiol (Liao et al 2009). Permission for use has 
been obtained from the American Society for Microbiology (Appendix A2.6). 
 
One hundred and ninety-nine N. gonorrhoeae isolates, consecutively collected from 
Shanghai in 2005, were analyzed using the NG-MAST typing method. Among these isolates, 
157 were from male patients and 42 were from female partners with gonorrhea infections. These 
isolates comprised 40 sexual connections, including 39 dyads (one male index patient and one 
female partner) and 1 triad (one male with 2 female partners).   
 
The index of discrimination (ID) of the NG-MAST analysis for the 199 isolates was 0.982. 
Among the 199 N. gonorrhoeae isolates, 114 NG-MAST STs were identified (i.e. 1.7 isolates 
per NG-MAST ST). Sixty-two percent of the 114 STs had not been previously reported. NG-
MAST ST421 was the largest cluster among the isolates, containing 13.6% of the isolates 
(27/199). The second largest cluster of isolates (n=6) exhibited NG-MAST ST1691.   
 
The ID of porB-based DNA sequence typing for the 199 isolates was 0.942. Among the 199 
N. gonorrhoeae isolates, 81 porB sequence types (PSTs) were identified (2.5 isolates per PST).  
 
The 199 isolates were divided into 9 groups (I-IX) based on the number of isolates with 
identical porB DNA sequences (Fig. 3.16). There were 46 isolates in Group I and each isolate 
exhibited a distinct porB sequence. Forty-eight isolates were classified in Group II, representing 
24 porB sequences (each porB sequence comprised 2 isolates). Twelve isolates in Group III 
exhibited 4 porB sequences, with each sequence containing 3 isolates. The 10 isolates in Group 
V displayed 2 porB sequences, each containing 5 isolates. N. gonorrhoeae isolates in Group IV 
(n=4), Group VI (n=6), Group VII (n=14), Group VIII (n=17), and Group IX (n=42) each 
exhibited a distinct porB sequence. Group IX isolates formed the largest cluster based on porB 
sequence analysis, accounting for 21.1% of the 199 isolates. 
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Fig. 3.16 porB-based groups of 199 N. gonorrhoeae isolates (SH2005). N. gonorrhoeae 
isolates were grouped based on the number of isolates with identical porB DNA sequences. 
Group I: forty-six porB sequences each comprised a single isolate (n=46). Group II: twenty-four 
porB sequence each contained 2 isolates (n=48). Group III: four porB sequences each comprised 
3 isolates (n=12). Group IV: 4 isolates have an identical porB DNA sequence. Group V: two 
porB sequences each comprised 5 isolates (n=10). Group VI: 6 isolates have an identical porB 
DNA sequence. Group VII: 14 isolates have an identical porB DNA sequence (n=14). Group 
VIII: 17 isolates have an identical porB DNA sequence. Group IX: 42 isolates have an identical 
porB DNA sequence. Percentages represent the proportion of total isolates.  
 
 
 
 
  
132 
Clusters of N. gonorrhoeae isolates identified by the porB-based analysis and NG-MAST 
typing were compared (Table 3.12). Each isolate in Group I (n=46) with a distinct porB 
sequence type (PST) also exhibited a distinct NG-MAST ST. Twenty-one of the 24 PSTs  in 
Group II had identical NG-MAST STs, while the remaining PSTs each displayed a different ST 
(i.e. 6 STs). Isolates in Group III (n=12) with 4 PSTs were further differentiated into 8 NG-
MAST STs, with 3 of the PSTs further differentiated by NG-MAST. Group V isolates (n=10) 
with 2 PSTs were differentiated into 8 STs with each PST cluster split into 4 NG-MAST STs. 
Isolates with a single PST in Group IV (n=4), Group VI (n=6), VII (n=14), VIII (n=17), or IX 
(n=42) were further differentiated into 2, 5, 6, 10, and 7 NG-MAST STs, respectively. A few 
isolates with identical NG-MAST STs were further differentiated by porB DNA sequence 
analysis. For example, NG-MAST ST#567 (2 isolates), ST#641 (4 isolates), ST#1691 (6 
isolates), and ST#2066 (3 isolates) were each differentiated into 2 porB PSTs.  
 
Thirty porB PSTs and 36 NG-MAST STs were identified among 81 isolates which 
comprised 40 sexual contacts (39 dyads and 1 triad). Isolates of the triad and 37 dyads had 
identical porB PSTs (95.0%, 38/40) and 2 dyads exhibited different PSTs between the 
epidemiologically connected isolates. The concordance rate between NG-MAST analysis and 
epidemiological connections was 95.0% (38/40). As expected, the 2 dyads with different PSTs 
also had different NG-MAST STs.  
 
3.3.4 Summary of the Modified porB-based Typing Scheme and the NG-MAST 
 
The modified porB-based typing scheme and the NG-MAST method were used to 
differentiate N. gonorrhoeae isolates in 3 strain collections in China (Table 3.13). The indexes 
of discrimination were 0.932-0.968 and 0.946-0.982 for the modified porB-based scheme and the 
NG-MAST, respectively. Each porB sequence comprised 1.9 – 2.8 isolates whereas each NG-
MAST ST comprised 1.6 – 1.8 isoaltes. The largest cluster of N. gonorrhoeae isolates identified 
by the porB-based analysis comprised 12.3 – 21 isolates, whereas the largest NG-MAST cluster 
comprised 7.4-18.2 isolates.  
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Table 3.12 Distribution of porB DNA sequences and NG-MAST sequence types (STs) in 199 
N. gonorrhoeae isolates from Shanghai in 2005 
 
 
*: Some of the NG-MAST STs overlapped across the porB DNA sequence based groups. 
PST: porB-based sequence type. 
NG-MAST ST: sequence type (ST) of the N. gonorrhoeae multi-antigen sequence (NG-MAST). 
 
 
 
 
 
 
 
Group Number of 
isolates (%) 
Number of porB 
sequences (PST) 
Number of NG-
MAST STs 
    
I 46 (23%) 46 46
 
 
II 48 (24%) 24 26
 
 
III 12 (6%) 4 7 
IV 4 (2%) 1 2
 
 
V 10 (5%) 2 8 
VI 6 (3%) 1 5
 
 
VII 14 (7%) 1 6
 
 
VIII 17 (9%) 1 10
 
 
IX 42 (21%) 1 7 
Total 199 (100%) 81 114* 
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Table 3.13 Index of discrimination of the modified porB-based DNA sequence and NG-
MAST analysis for differentiating N. gonorrhoeae isolates 
 
NG-MAST: Neisseria gonorrhoeae Multi-Antigen Sequence Typing 
*: Initially the 199 SH2005 isolates were tested for indexes of discrimination of porB-based 
analysis and NG-MAST.  
§: ID- Simpson’s index of discrimination. 
NA: Not analyzed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
City/Year 
 
# of 
isolates 
tested 
  ID (%)
§
 # of types # of isolates per 
type 
% of isolates for 
the largest cluster 
NG-
MAST 
porB NG-
MAST 
porB NG-
MAST 
porB NG-
MAST 
porB 
Shanghai/2005 199 98.2 94.2 115 81 1.7 2.5 13.6 21.0 
Shanghai/2008 81 98.1 96.8 50 39 1.6 2.1 7.4 12.3 
Urumchi/2007-
2008  
44 94.6 93.2 25 23 1.8 1.9 18.2 19.5 
  
135 
3.3.5 Concordance between Patient-reported Sexual Contacts and porB Genotypes 
  
 To determine the concordance between N. gonorrhoeae porB genotypes recovered from 
known sexual contacts, all isolates from patients having sexual contacts in Shanghai in 2005 
were analyzed using the modified porB-based DNA typing method. The N. gonorrhoeae isolates 
included a total of 152 N. isolates (74 isolates from male index patients and 78 isolates from their 
female sex partners), which formed 74 sexual connections: 70 dyads (140 isolates) and 4 triads 
(12 isolates).  
  
 Twenty-nine isolates (19.1%, 29/152) had porB1a genotypes which comprised 7 porB1a 
sequences (Fig. 3.17A). Two large clusters with identical porB1a sequences were identified; one 
cluster comprised 10 isolates from 5 dyads, and the other comprised 9 isolates from 3 dyads and 
1 triad. The remaining 5 porB1a sequences comprised 10 isolates (4 sequences each comprised a 
dyad, and 1 sequence comprised 2 isolates from two female partners).  
  
One hundred and twenty-three isolates (80.9%, 123/152) exhibited porB1b genotypes which 
comprised 46 sequences. The porB1b isolates were grouped into 3 clades based on phylogenetic 
trees generated using the Clustal W program. The porB1b Clade 1 comprised 68 isolates having 
20 porB sequences (Fig. 3.17B). The porB1b Clade 2 comprised 15 isolates having 8 distinct 
sequences (Fig. 3.17C), whereas the porB1b Clade 3 had 40 isolates with 19 distinct sequences 
(Fig. 3.17D).  
  
 In total, 74 sexual connections were reported epidemiologically and these were linked by 
solid lines. Among them isolates from 69 sexual connections had identical porB sequences and 
the concordance rate was 93.2% (69/74). The incongruent relationships (Fig. 3.17, black squares 
or black circles) included 4 dyads (D1-D4) and 1 triad (T1). In 2 dyads (D1, D2), the isolates 
from female partners had porB1a sequences while the isolates from the corresponding male 
index patients exhibited porB1b sequences. Two isolates in one dyad (D3) had different porB1b 
sequences but they belonged to the same porB1b clade; and another incongruent dyad (D4) had 
different porB sequences in different clades. In the triad (T1), the isolate from one female partner 
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had a unique porB sequence, while the porB sequences of the other two (male index and female 
partner) were identical.  
 
Large clusters having identical porB sequences and comprising multiple sexual connections 
were identified for both porB1a and porB1b isolates. For example, two clusters were identified in 
porB1a isolates, comprising 4 (9 isolates) and 5 (10 isolates) sexual contacts, respectively (Fig. 
3.17A). The largest cluster comprised 13 sexual relationships (27 isolates) (Fig. 3.17B); clusters 
with 2 or 3 sexual contacts were also observed for the porB1b isolates (Fig. 3.17B-D). 
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Fig. 3.17 Sexual networks identified by proB typing. porB1a and porB1b genotypes and clades were defined based on sequence 
alignments and phylogenetic trees generated by Cluastal W as described in Section 2.5 (Larkin et al 2007). Squares- male index 
patients. Circles- female sexual partners. Isolates having sexual contacts were linked with a solid line. Isolates having different 
sequences in sexual dyads or triads were shown in black squares (from males) or black circles (from females). All other sexual 
contacts had identical porB sequences. Isolates inside rectangles with dashed line had an identical porB sequence. 
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4.1 Prevalence of Antimicrobial Resistance in Neisseria gonorrhoeae  
 
4.1.1 Prevalence of Reduced Susceptibility to Third-generation Cephalosporins in N. 
gonorrhoeae Isolates 
 
The global spread of N. gonorrhoeae isolates resistant to different classes of antibiotics 
resulted in the removal of inexpensive antimicrobials such as penicillins, tetracyclines, 
macrolides and quinolones from gonorrhea treatment guidelines worldwide (Tapsall 2002, 2005, 
2006, 2009; Workowski et al 2008). After the spread of quinolone resistant N. gonorrhoeae 
(QRNG) strains worldwide, third-generation cephalosporins have become the antibiotics of 
choice for the treatment of gonococcal infections (Wang & Zhang 2007; PHAC 2006; CDC 2006, 
2007a).  
 
Oral third-generation cephalosporins used for the treatment of gonorrhea included cefixime 
(400 mg single dose), recommended by the WHO, Canada, the United States and the United 
Kingdom (WHO 2003; PHAC 2006; BASHH 2005; CDC 2006), ceftibuten in Hong Kong and 
cefditoren and cefdinir in Japan before 2006 (Lo et al 2010; Jap Soc STD 2006). Among the 
parental cephalosporins, ceftriaxone is the recommended first line antimicrobial for the treatment 
of gonorrhea in the United States (CDC 2007a; CDC2006), Canada (PHAC 2006), the United 
Kingdom (BASHH 2005), China (Wang & Zhang 2007), Japan (Yakoi et al 2007; Jap Soc STD 
2006) and is recommended by the WHO (WHO 2003). The dose of ceftriaxone is the subject of 
debate with 125 mg recommended in the United States and by the WHO (Newman et al 2007; 
WHO 2003). Many countries recommended a dose of 250 mg (Barry & Klausner 2009). In Japan 
and China, a single dose of 1000 mg is recommended (Wang & Zhang 2007; Yakoi 2007).  
 
Results from my research, for the first time, indicated that N. gonorrhoeae isolates with 
reduced susceptibility to ceftriaxone are highly prevalent in Shanghai, the social economic centre 
of China. In 2005 in Shanghai, 11.9% (19/159) of N. gonorrhoeae isolates exhibited reduced 
susceptibility to ceftriaxone (MICs = 0.125 - 0.25 mg/L), and this rate increased to 19.7% (14/71) 
in 2008. In Urumchi 2007, there was also a small percentage of isolates (4.5%, 2/44) that 
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exhibited reduced susceptibility to ceftriaxone (MIC = 0.125 mg/L). Isolates with elevated 
ceftriaxone MICs during the 1990s have been reported in China; however, these results were not 
confirmed at the national reference laboratory and MIC values were not specified (Ye et al 2002, 
2004). 
 
Recent reports have also demonstrated that gonococci with reduced susceptibility to third-
generation cephalosporins are emerging and spreading globally (Ito et al 2004; Martin et al 2006; 
WHO-WPR 2006; Tapsall et al 2009; Barry & Clausner 2009). In Australia, N. gonorrhoeae 
isolates with reduced susceptibility to ceftriaxone (MICs = 0.05-0.5 mg/L) was present in 2001 
which and were possibly imported by international travelers and their sex partners (Tapsall et al 
2008). Sporadic isolates with ceftriaxone MIC ≥ 0.5 mg/L have been observed in Vietnam (Cao 
et al 2008), the Philippines and Thailand (Clendennen et al 1992a/b), though further testing from 
a reference laboratory were not performed. In India, Bala et al recently reported 9 isolates with 
ceftriazone MICs = 0.064 – 0.094 mg/L among 382 isolates collected in New Delhi during 2002-
2006 (Bala et al 2007).  
 
Recently, the European Surveillance of Sexually Transmitted Infections (ESSTI) has 
identified isolates with ceftriaxone MICs of ≥ 0.125 mg/L (Martin et al 2006; Cole et al 2010). 
Other reports from national surveillance programs in Europe such as the UK (HPA 2008), Spain 
(Vazquez et al 2007), Italy (Martin et al 2006), Sweden (Olsen et al 2008), and Greece (Tzelepi 
et al 2008) have also documented isolates with increased ceftriaxone or cefixime MICs. The 
decreased susceptibility to cefixime (MIC ≥ 0.25 mg/L) first observed in gonococcal isolates in 
2007 (0.2%) continued to increase, reaching 1.5% in 2008 in UK (HPA 2009). 
 
In the United States, a few isolates with increased ceftriaxone MICs were reported since 
1986 when the National Gonococcal Isolate Surveillance Program (GISP) was established (CDC 
2008b). In 2001, three isolates were identified in Hawaii with multidrug resistance and having 
cefixime MIC of 0.25-0.5 mg/L and ceftriaxone MIC of 0.125 mg/L (Wang et al 2003). 
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A recent report from Canada (Allen et al 2011) observed that 9.4% of 149 isolates in Ontario 
had reduced susceptibility to cefixime (MICs = 0.125 – 0.25 mg/L), or ceftriaxone (MICs = 
0.032 – 0.125 mg/L) though all isolates (up to 2006) examined by the Public Health Agency of 
Canada were susceptible to ceftriaxone (PHAC 2008a).  
 
Limited data from Africa have not reported isolates with cefixime MICs of 0.25 - 0.5 mg/L 
and ceftriaxone MIC of 0.125 mg/L (Barry & Klausner 2009).  
 
Recently, a few isolates with ceftriaxone MIC of > 0.25 mg/L were reported in Brazil in 
2007, although confirmation of reference laboratory testing is needed (Dillon et al, unpublished 
data). 
 
Treatment failures with third-generation cephalosporins have primarily reported with use of 
oral cephalosporins (Barry & Klausner 2009). In 2000, treatment failures with the oral 
cephalosporins cefpodoxime and cefdinir were reported in Japan (Akasaka et al 2001). 
Subsequent reports from various regions in Japan documented the rapid spread and increase of 
resistance to oral third-generation cephalosporins (Tanaka et al 2002, 2006; Ito et al 2004; 
Takahata et al 2006; Ameyama et al 2002). Beginning in 2006, cefixime was no longer 
recommended as first line therapy for gonorrhea in Japan (Yakoi et al 2007). Treatment failures 
were also reported in Hong Kong (Lo et al 2008). Among 1228 gonorrhea cases during 2006-
2007 in Hong Kong, 3.7% (42 cases) were with ceftibuten treatment failure (400mg single dose)  
(Lo et al 2008).  
 
Treatment failure coupled with reduced susceptibility to third-generation cephalosporins 
indicates that the current recommendations for the treatment of gonorrhea need to be reviewed 
and that on-going surveillance is highly warranted.  
 
Breakpoints for susceptibility to ceftriaxone in N. gonorrhoeae have not been well defined. 
The term ―reduced susceptibility‖ is commonly used. The Clinical and Laboratory Standards 
Institute (CLSI 2006, 2009) defines ceftriaxone MICs >0.25 mg/L as having reduced 
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susceptibility, whereas the European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) defines ceftriaxone MICs > 0.125 mg/L as having decreased susceptibility (Cole et al 
2010). In previous studies of susceptibility to ceftriaxone in N. gonorrhoeae clinical isolates, a 
variety of definitions for reduced (decreased) susceptibility have been used [e.g. 0.016-0.06 
mg/L (Whiley et al 2010), >= 0.12 mg/L (Lee et al 2010), 0.016-0.25 mg/L (Whiley et al 
2007a), >= 0.125 mg/L (Ito et al 2005), 0.064-0.125 mg/L (Lindberg et al 2007), and 0.032 – 
0.125 mg/L (Allen et al 2011)]. Given the above history, in my research, I defined isolates 
having ceftriaxone MICs of 0.125-0.25 mg/L as ―reduced susceptibility to ceftriaxone‖ which 
will be helpful comparing my results with other reports.  
 
4.1.2 Susceptibility of N. gonorrhoeae Isolates to Spectinomycin 
 
We did not observe spetinomycin resistant isolates (MICs ≥ 128.0 mg/L; CLSI 2006, 2009) 
in Shanghai and Urumchi. However, isolates with intermediate levels of susceptibility (MIC = 
64.0 mg/L; CLSI 2006, 2009) were observed in Shanghai and the percentage of intermediate 
susceptible isolates increased from 1.9% (3/159) in 2005 to 9.9% (7/71) in 2008. Spectinomycin 
is being used as an alternative regimen for the treatment of uncomplicated urogenital gonorrhea 
in China (Wang & Zhang 2007), therefore, close monitoring of trends of susceptibility in N. 
gonorrhoeae to this antibiotic is warranted. 
 
In the mid-1980s, clinical treatment failures caused by spectinomycin-resistant strains began 
to be present in US military personnel in the Republic of Korea (Boslego et al 1987). 
Gonococcal resistance to spectinomycin has also been reported from the Western Pacific regions 
(WHO-WPR 2001) and from the Latin American countries (Dillon et al 2006). No resistant 
isolates have been identified in Europe according to published reports (WHO 2001; Olsen et al 
2008; Cole et al 2010; Starnino et al 2008).  
 
Resistance to spectinomycin has been rare in the United States, with a reported resistant rate 
of < 1% (CDC 2005; Newman et al 2007). In Canada, it was reported that one PPNG isolate was 
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also resistant to spectinomycin (Dillon 1981, 1989; Dillon et al 1978). Since 1990s, 
spectinomycin-resistant isolates have not been reported in Canada (PHAC2008a).   
 
In a landmark report with regards to the antimicrobial susceptibility of N. gonorrhoeae 
isolates in Latin America and the Caribbean (LAC), sporadic spectinomycin-resistant isolates 
were identified in the LAC region during the 1990s (Dillon et al 2006). Unfortunately data on 
trends of spectinomycin susceptibility were limited after 2000 in the LAC region.  
 
Spectinomycin is an alternative regimen for treating urogenital gonorrhea patients who do 
not tolerate cephalosporins. However, spectinomycin has limited effectiveness for the treatment 
of pharyngeal infection, and it is not currently commercially available for gonococcal treatment 
in the United States (CDC 2006). Cautions of wide use of spectinomycin were executed because 
high levels of resistance developed when this antimicrobial was widely used in the mid-1980s 
(Boslego et al 1987).  
 
4.1.3 N. gonorrhoeae Isolates Are Resistant to Quinolones 
 
Ciprofloxacin, a fluoroquinolone antibiotic, had been recommended for the treatment of 
gonorrhea in China in 1990s and early 2000s. Almost all isolates examined in our study (97.7% - 
100%) were resistant to ciprofloxacin (MICs ≥ 1.0 mg/L). Furthermore, percentages of high 
levels of ciprofloxacin resistance (MICs ≥ 8.0 mg/L) increased over time from 55.9% in 2005 to 
76.4% in 2008 in Shanghai. High percentages of ciprofloxacin resistance N. gonorrhoeae had 
been observed since it was introduced for gonorrhea treatment in early 1990s (Ye et al 2002; 
15.5% in 1993 to 55.8% in 1998). In spite of the high prevalence of resistant isolates, 
ciprofloxacin continued to be a recommended antimicrobial for the treatment of gonorrhea in 
China until 2007 (Wang & Zhang 2007). It is imperative to promptly review and modify 
treatment guidelines based on scientific information.  
 
A similar trend of the high prevalence of quinolone resistance has being noted in other parts 
of the world. In the Western Pacific Region, quinolone non-susceptible isolates (including 
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resistant and intermediate) were in excess of 90% of all isolates examined in Hong Kong, 
Mongolia, India, Thailand and Sri Lanka, and between 75% and 90% of all isolates tested in 
Brunei, Japan, Korea, Malaysia, Singapore and Vietnam (WHO-WPR 2008, 2010). Percentages 
of quinolone-resistant isolates in Japan increased from 6.6% in 1993-1994 to 24.4% in 1997-
1998
 
(Tanaka et al 2000a), further to 27.5% in 1999-2000 and 78.3% in 2002 and 78.1% in 2007 
(Ito et al 2004; WHO-WPR 2010).  
 
A recent report from the ESSTI (Cole et al 2010) revealed that the overall level of 
ciprofloxacin resistance was high in many European countries (42% to 51% for 2006 - 2008), 
and that all countries displayed more than 5% resistance rates each year. In Italy, the resistance 
percentage of N. gonorrhoeae isolates was 34.2% in 2003-2005 (Starnino et al 2010). In the UK, 
ciprofloxacin resistance is prevalent in England and Wales, having risen steadily since 2000 and 
apparently stabilising at 28% in 2008. The burden of ciprofloxacin resistance remains 
disproportionately high in MSM, increasing from 11% in 2003 to 46% in 2008 (HPA 2009). 
 
Based on data from Gonococcal Isolate Susceptibility Project (GISP) in the United States, 
the emergence of quinolone-resistant N. gonorrhoeae was first identified in Hawaii in 1991. 
Resistant percentages of N. gonorrhoeae isolates to ciprofloxaxin exceed 5% in many areas of 
the USA, and over 27% of isolates from patients with male-to-male sex are ciprofloxacin-
resistant (Newman et al 2007).  
 
In Canada, the proportion of ciprofloxacin resistance in N. gonorrhoeae isolates has 
increased from less than 1% in the early 1990s, to 2.4% in 2003, 6.2% in 2004, 15.7% in 2005, 
28.8% in 2006 and 30% in 2007 (PHAC; http://www.phac-aspc.gc.ca/std-mts/report/sti-
its2008/04-eng.php#Fig9, accessed on February 27, 2011). Separate reports showed similar 
trends in gonococcal ciprofloxaxin resistance in Alberta (1.5% in 2001 to 27.7% in 2007; Plitt et 
al 2009) and Ontario (4% in 2002 to 27.8% in 2006; Ota et al 2009). Thus, quinolones are no 
longer recommended for the treatment of gonorrhea in Canada (PHAC 2006).  
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In Africa, most studies for isolates before 2000 showed that N. gonorrhoeae remained 
susceptible to the flouroquinolones (Dan 2004; WHO 2001). However, recent studies have 
shown that quinolone resistant N. gonorrhoeae have emerged and spread in Africa. For example, 
the prevalence of ciprofloxacin resistance was 7% in Cape Town in 2004 and 11% in 
Johannesburg, whereas in 2007, percentages of resistance isolates were 27% in Cape Town 
isolates and 32% Johannesburg (Lewis et al 2008), respectively.  
 
Gonococcal quinolone resistance in Latin America and the Caribbean (LAC) was rare in 
1990s although low level resistance were noted in several regions of the LAC (Dillon et al 2006; 
Dillon et al 2001b; Ison et al 1998; Dillon et al 1997, Swanston et al 1997), which may reflect 
the more limited use of these drugs in the region (Dillon & Pagotto 1999; Dillon et al 2001a/b). 
In 2009, resistant percentages ranged from 22% to 90% in most countries participating in the 
Gonococcal Susceptibility Surveillance Program in Latin America and the Caribbean (Dillon et 
al, unpublished data).   
 
4.1.4 N. gonorrhoeae Isolates Are Persistently Resistant to Penicillin and Tetracycline 
 
The overall burden of N. gonorrhoeae resistance to penicillin (MIC ≥ 2.0 mg/L) was 93.1% 
(Shanghai 2005), 88.7% (Shanghai 2008) and 79.5% (Urumchi 2008), respectively. Resistance 
percentages to tetracycline (MIC ≥ 2.0 mg/L) were 56.5% (Shanghai 2005), 64.5% (Shanghai 
2008) and 61.4% (Urumchi 2008), respectively. These findings indicate that the prevalence of N. 
gonorrhoeae resistance to penicillin or tetracycline is persistently at very high levels in China, 
reflecting that gonococcal resistance to penicillin and tetracycline is long established in the 
world. Penicillin is no longer recommended for the treatment of gonorrhea and tetracycline is 
used for treating Chlamydia trachomatis co-infections in gonorrhea patients, together with 
macrolides (erythromycin or azithromycin). 
 
4.1.4.1 Penicillin Resistance in the World 
From 2000 through 2007 in China, penicillin-resistant isolates, defined as having MICs ≥ 
1.0 mg/L (WHO-WPR 2001), accounted for 80% - 93% of isolates examined (WHO-WPR 2001, 
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2002, 2003, 2005, 2006a/b, 2008, 2010). In the 1990s (between 1993 and 1998), 66.7% of 
isolates tested were resistant to penicillin (Ye et al 2002). The high prevalence of penicillin-
resistant gonococcal isolates remains a major problem in many parts of the Western Pacific 
countries/regions (WHO-WPR 2010). The proportion of isolates with penicillin resistance in 
2007 was 38.3% (Australia), 64.3% (Brunei), 17.5% (Japan), 55.4% (Korea), 61.0% (Malaysia), 
21.6% (New Zealand), 89.9% (the Philippines), 56.3% (Singapore), 37.2% (Vietnam) and 47.2% 
(India). In Japan from 1993 through 2002, the proportion of isolates with penicillin resistance 
(MIC ≥ 2.0 mg/L) ranged from 13.5% to 29.9% in 2002 (Tanaka et al 2004).  
 
A recent report from the European Gonococcal Antimicrobial Surveillance Programme of 
the European Surveillance of Sexually Transmitted Infections (Euro-GASP of ESSTI) 
demonstrated an overall burden of 21% penicillin resistance during 2006 and 2008 (Cole et al 
2010). The percentage of penicillin resistant isolates (2003-2005) in Italy was 25.5% (Starnino et 
al 2010).  
 
In Latin America and the Caribbean (LAC) in the 1990s, percentages of penicillin-resistant 
isolates (MIC ≥ 2.0 mg/L) varied between 48.5% in 1993 and 25.3% of isolates tested in 1999 
(Dillon et al 2006). In 2009, the percentage of isolates resistant to penicillin ranged from 8% to 
90% (Dillon et al, unpublished data). 
 
In the USA, the Gonococcal Isolate Surveillance Project (GISP) reported that (CDC 2004, 
2007 GISP reports), approximately 10% of N. gonorrhoeae isolates were resistant to penicillin 
since the late 80s. 
 
In Canada, the percentage of penicillin resistant N. gonorrhoeae isolates rose from 8.7% in 
1992 to 15% to 22% in 2003 (Dillon 1992; Ng et al 2003). The penicillin resistance percentage 
for N. gonorrhoeae isolates nationwide in 2006 was 17% (PHAC 2008, http://www.phac-
aspc.gc.ca/publicat/2008/sti-its/gonorrhe-eng.php, accessed on February 27, 2011).  
 
4.1.4.2 Tetracycline Resistance in the World 
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The total burden of tetracycline resistance (MIC ≥ 2.0 mg/L) in Shanghai was 56.5% (2005) 
64.8% (2008) and 61.4% in Urumchi (2007-2008). The majority of tetracycline resistant N. 
gonorrhoeae isolates had high level resistance (i.e. TRNG). In the 1990s (between 1993 and 
1998), 92.0% isolates tested were resistant to tetracycline (MIC ≥ 1.0%) (Ye et al 2002). The 
higher prevalence in 1990s could be explained by the interpretation criteria which was lower 
than that used in my study.  
 
In China, since 2000, only TRNG is reported to the national center of the gonococcal 
antimicrobial susceptibility program in Nanjing. Most antimicrobial susceptibility surveillance 
programs only reported TRNG as well. Some individual studies suggested that the prevalence of 
tetracycline resistance is high in many areas of the world (Cole et al 2010, WHO 2001, Starnino 
et al 2008).  
 
Studies in Latin America and the Caribbean (LAC) in the 1990s reported that the total 
burden of tetracycline-resistance (MIC ≥ 2.0 mg/L) in the region ranged from 28.6% (1994) to 
52.5% (1993) of isolates tested, with an average percentage of tetracycline-resistant isolates of 
43.4% over the decade (Dillon et al 2006; Dillon et al 2001b; Sosa et al 2003). In 2009, the 
percentage of isolates resistant to tetracycline ranged from 24% to 100% (Dillon et al, 
unpublished data). 
 
Twenty-nine percent of isolates tested in 2006 in Canada were resistant to tetracycline 
(PHAC 2008, http://www.phac-aspc.gc.ca/publicat/2008/sti-its/gonorrhe-eng.php, accessed on 
February 27, 2011).   
 
In the USA, the Gonococcal Isolate Surveillance Project (GISP) reported that approximately 
10% of N. gonorrhoeae isolates were resistant to tetracycline since the late 80s (CDC 2007). 
 
4.1.5 Plasmid-mediated Antimicrobial Resistance in N. gonorrhoeae 
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4.1.5.1 Prevalence of Plasmid-mediated Resistance in N. gonorrhoeae 
 
The emergence of high-level, plasmid-mediated resistance to penicillin (PPNG) were first 
reported in 1976 (Percival et al 1976; CDC 1976) and to tetracycline (TRNG) in mid-1980s 
(CDC 1985; Roberts et al 1988).  
 
Approximately 50% of the isolates tested in this study were PPNG, TRNG or PP/TRNG. 
Noticeably, TRNG including PP/TRNG significantly increased in Shanghai, from 20.1% for 
2005 to 56.3% for 2008. In China between 1993 and 1998, PPNG or TRNG accounted for 48.8% 
and 34.2% of the isolates tested, respectively (Ye et al 2004). In Nanjing China, the rate of 
PPNG rose from 8.0% to 57.36% in 2004, and declined to 44.44% in 2006, and the prevalence of 
TRNG increased from 1.8% in 1999 to 32.82% in 2006 (Su et al 2007). In many other parts of 
the Western Pacific regions, PPNG and TRNG has also been high for many years and ranged 
between 35% and 55% (WHO 2001, WHO-WPR 2006, 2010). In a recent report in India, the 
rates of PPNG, TRNG and PP/TRNG were 16.5%, 8.9% and 4.7%, respectively (Bala et al 2008). 
 
In the Latin American and the Caribbean region (LAC), high percentages of plasmid-
mediated resistance to penicillin (i.e. PPNG) had been noted in 1990s, ranging from 17.9% to 
38.8% (Moreno et al 1987; Dillon et al 2006). Between 1990 and 1998, PPNG represented more 
than 28% of all isolates tested, falling to 17.9% in 1999 (Dillon et al 2006). Percentages of 
TRNG were high in 1990s although they varied by year and by country, ranging from 1.4% to 
89.5% (Dillon et al 2006). Recent survey demonstrated that percentages of plasmid-mediated 
resistance ranged from 10% to 62% for PPNG and 4% to 16% for TRNG among 10 countries in 
2008 or 2009 (Dillon et al, unpublished data), showing a decreasing trend from 1990s. 
 
The Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in UK 
reported that the combination of PPNG/TRNG remained relatively stable up until 2006, 
increasing from 2.1% in 2006 to 7.6% in 2008. High percentage of patients with PP/TRNG 
reported sex abroad in the past three months, indicating that PPNG/TRNG is likely to be 
imported in many cases (HPA 2008).  
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The number of PPNG strains isolated in Canada 1976-1984 comprised < 1% of all 
gonococcal isolates (Dillon et al 1986), it increased to 5% in 1985, 9.6% in 1990 (Yeung et al 
1990; Dillon 1992; Yeung et al 1991). Between 1986 and 1997, 6,306 TRNG isolates were 
cultured and identified in Canadian laboratories, representing 29.1% of all N. gonorrhoeae 
isolates (Greco et al 2003). Combined plasmid-mediated resistance of PPNG and TRNG was 
common in Canada (Carballo et al 1990; Dillon and Carballo 1990). 
 
4.1.5.2 Types of gonococcal β-lactamase-producing and tetM-containing plasmids 
 
Penicillinase-producing N. gonorrhoeae (PPNG) comprised plasmids encoding a TEM-1-
type β-lactamase (Pagotto et al 2000; Dillon et al 1989; Yeung & Dillon 1988). Several types of 
related penicillinase-producing plasmids have been described, including the Asia, Africa, 
Toronto, Rio, Nîmes and New Zealand plasmids (Dillon et al 1989, 1999). The Asia, Africa and 
Toronto types have been associated with epidemic outbreaks (Dillon & Yeung 1989). During 
1976-1984, out of the 501 analyzed PPNG isolates from Canada, 402 (80.2%) carried the Asia 
type β-lactamase plasmids, followed by 79 (15.8%) and 20 (4%) isolates with the Africa and 
Toronto type, respectively (Dillon et al 1986). In South Africa, the Toronto and Africa types 
were predominant (Fayemiwo et al 2010).  
 
In my study, a majority (> 77%) of PPNG isolates in Shanghai carried Asia-type plasmids, 
whereas the Toronto-type and the Africa-type were also present. No other types were observed. 
The distribution of plasmid types was similar to that found in Canada in 1980s (Dillon et al 
2006). However; only Asia type was observed in PPNG isolates  collected in Nanjing China, a 
nearby city of Shanghai (Su et al 2007), indicating the geographic dynamics of resistant plasmids. 
 
High-level tetracycline resistance in N. gonorrhoeae (TRNG) is the result of the acquisition 
of plasmids carrying the streptococcal tetM determinant (Morse et al 1986; Carballo et al 1994). 
tetM-containing plasmids in TRNG are differentiated into the American type and Dutch type 
(Ison et al 1993, Xia et al 1995; Greco et al 2003). Initially, the American type was described in 
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the UK and Africa and the Dutch type in Asia and South America (Gascoyne-Bini et al 1994). A 
higher prevalence of Dutch type plasmids (79.3%) in TRNG than the American type (20.7%) has 
been reported in Canada (Greco et al 2003). Of the 78 TRNG isolates collected in Scotland in 
1990s, 55% were the Dutch type (Beattie et al 1999). In South Africa, the America type was 3-
fold more frequent as compared with the Dutch type (Fayemiwo et al 2010).  
 
In my results, TRNG isolates from Shanghai exhibited a Dutch-type plasmid. In Nanjing 
China, a nearby city of Shanghai, 99.23% (258 of 260) of TRNG isolates comprised the Dutch 
type plasmid (Su et al 2007).  The Dutch type plasmid is the prevalent type in many areas of the 
world. The absence of the American type plasmid in N. gonorrhoeae isolates in my study could 
be due to the small number of isolates examined.   
 
4.1.6 Conclusion 
 
Antibiotic treatment is the hallmark of curing gonococcal infections and controlling the 
spread of gonorrhea. According to the accepted definition of gonococcal treatment efficacy, a 
cure rate of over 95% is desired if an antibiotic be recommended for the treatment of gonorrhea. 
Thus, an antibiotic should not be used in situations where resistance is observed in greater than 3% 
to 5% of gonococcal isolates tested.  
 
My research provides longitudinal (2005 and 2008) and spatial (Shanghai and Urumchi) 
information on the antimicrobial resistance of N. gonorrhoeae in China. It is the first study 
showing a high prevalence of reduced susceptibility to ceftriaxone in China, a third-generation 
cephalosporin currently the first-line antimicrobials for the treatment of gonorrhea in China and 
elsewhere. This study also demonstrates that N. gonorrhoeae is persistently resistant to 
ciprofloxacin, penicillin and tetracycline, antibiotics had been used for treating gonococcal 
infections in China and are no longer recommended. Spectinomycin is currently an alternative 
regimen for the treatment of gonorrhea in China, and the increasing number of isolates with 
intermediate levels of susceptibility in Shanghai over time indicates the need of close monitoring 
on gonococcal antimicrobial susceptibility. 
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4.2 Molecular Mechanisms of Antimicrobial Resistance in Neisseria gonorrhoeae 
  
Mechanisms of antibiotic resistance in N. gonorrhoeae have been genetically divided into 
two types, i.e. chromosomally mediated (CMR) and plasmid-mediated resistance (Dillon & 
Pagotto 1999). CMR mechanisms involve reduced access of antibiotic to the target sites and 
alteration of the target sites by mutations of various resistance determinants (Dillon & Pagotto 
1999; Tapsall 2001). Multiple resistance determinants may coexist in a single isolate conferring 
additive resistance to a single or a number of different antibiotics (Tapsall 2001). Plasmid-
mediated resistance in N. gonorrhoeae is conferred by β-lactamase-producing plasmids (i.e.  
penicillinase-producing N. gonorrhoeae, PPNG) or by tetM-containing plasmids (e.g. high levels 
of tetracycyline resistance N. gonorrhoeae, TRNG) (Dillon & Pagotto 1999). 
 
4.2.1 Mechanisms of Reduced Susceptibility to Ceftriaxone in N. gonorrhoeae 
 
I studied a panel of ceftriaxone susceptible (CRO
S
, MIC=0.004-0.016 mg/L, n=32) and 
reduced susceptible (CRO
Red
, MIC=0.125–0.25 mg/L, n=28) N. gonorrhoeae isolates from 
Shanghai that were collected in 2005 and 2008. I performed sequencing and bioinformatic 
analysis to determine if mutations in certain genes or possession of a particular PorB type are 
associated with reduced susceptibility to ceftriaxone.  
 
My results show that the porB1b allele (expressing PIB) is required but is insufficient for 
conferring reduced susceptibility to ceftriaxone in N. gonorrhoeae isolates. Approximately 40% 
of the CRO
S
 isolates (13/32) also exhibited a porB1b genotype (expressing PIB), suggesting that 
other loci in porB1b isolates are involved in mediating increasing ceftriaxone MICs.  
 
G120K/A121D double mutations in PIB (porB1b) have been associated with reduced 
susceptibility of N. gonorrhoeae isolates to ceftriaxone (Lindberg et al 2007). Tanaka et al (2006) 
reported that G120/A121 mutations were only found in the one ceftriaxone resistant strain (MIC 
= 0.5 mg/L), but not in the 4 ceftriaxone susceptible strains tested (MIC ≤ 0.004 mg/L). I did not 
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find this to be the case with the isolates studied from Shanghai. The G120/A121 mutations of 
PorB were not associated with increasing ceftriaxone MICs, supporting other reports (Takahata 
et al 2006).  
  
The transpeptidase domain of gonococcal PBP2 (penA) was polymorphic and exhibited 15 
mutation patterns, but the ―mosaic‖ PBP2 (Pattern X), which was first associated with reduced 
susceptibility to oral cephalosporins (i.e. cefixime) (Ameyama et al 2002), was not present in the 
N. gonorrhoeae isolates of the present study. Six of the 15 mutation patterns in PBP2 identified 
in the present study are new. The most common mutation patterns for all isolates combined 
(n=60) were Patterns V, XXI and XXVII. By comparison, the most common mutation patterns in 
isolates from Sydney, Australia were Patterns XII, X and XIII (Whiley et al 2007a/b), whereas in 
Korea, Pattern XIII was most common (Lee et al 2010). Interestingly Patterns XIII and 
XVII/XVIII were only present in CRO
Red
 isolates in both the study by Whiley et al (MIC=0.06-
0.12 mg/L; 17.9% of 28 isolates) (Whiley et al 2007a/b) and in the present study (MIC=0.125–
0.25 mg/L; 21.4% of 28 CRO
Red
 isolates). These 2 patterns comprised combinations of A501V 
and P551S (Pattern XIII) or A501V and G542S (Pattern XVII/XVIII) mutations which have 
been associated with increased ceftriaxone MIC (Whiley et al 2010). I conclude that a 
combination of A501V/T and G542S or A501V/T and P551S/L mutations, and probably 
mutations at other codons in PBP2 are required for increasing ceftriaxone MICs. Genetic 
confirmation and structure/function analysis of these mutations are warranted. 
 
Over 90% of both CRO
Red
 and CRO
S
 N. gonorrhoeae isolates I examined contained an ―-A‖ 
deletion in the 13bp inverted repeat sequence of the mtrR promoter, indicating that such a 
deletion is not implicated in reduced susceptibility to ceftriaxone. However A39T/H105Y or 
G45D/H105Y double mutations in MtrR were only present in CRO
Red
 isolates in my study. 
Mutation A39T or G45D, either singly or in combination, diminishes binding of the MtrR 
repressor to the mtrC/D/E promoter and thereby increases resistance to hydrophobic agents 
(Hagman et al 1995; Lucas et al 1997; Shafer et al 1995). The H105Y mutation might inhibit 
MtrR dimerization and subsequently further reduce MtrR DNA binding (Shafer et al 1995), or it 
could enhance binding of ceftriaxone to MtrR which could then serve as a sink for the antibiotic 
  
153 
(W.M Shafer, Department of Microbiology and Immunology, Emory University School of 
Medicine, Atlanta, GA, USA; personal communication). A single H105Y mutation was 
exclusively present in the CRO
S
 isolates and the wild type MtrR (N. gonorrhoeae FA1090) was 
observed mainly in the CRO
Red
 isolates in the present study. It is reasonable to further 
hypothesize that a single H105Y mutation may be a ―gain-of-function‖ mutation, enhancing 
MtrR repression activity and that the enhanced activity of the H105Y MtrR is diminished when 
mutations A39T and or G45D occur. Again, follow-up studies for genetic confirmation and 
structure/function analyses of H105Y mutation in MtrR are warranted. 
 
It has been reported that the L421P mutation in PBP1 is present in N. gonorrhoeae isolates 
which have reduced susceptibility or are susceptible to cefixime (Takahata et al 2006) as well as 
in isolates with reduced susceptibility to ceftriaxone (Lindberg et al 2007). The L421P mutation 
is also present in N. gonorrhoeae isolates with various penicillin MICs although it may play a 
role in resistance to penicillin (Shigemura et al 2005). The majority of both the CRO
Red
 (100%) 
and the CRO
S
 (97.0%) N. gonorrhoeae isolates in the present study carried a L421P mutation in 
PBP1 (P>0.05). Therefore, the L421P mutation in PBP1 is not associated with reduced 
susceptibility of N. gonorrhoeae to ceftriaxone in the present study.  
 
Previous reports suggest that cephalosporin resistant N. gonorrhoeae may be clonal (Lo et al 
2008; Ameyama et al 2002; Lindberg et al 2007).
 
It has been reported that the ceftibuten resistant 
N. gonorrhoeae isolates (n=11) from Hong Kong shared identical NG-MAST types (Lo et al 
2008). Most isolates with the mosaic PBP2 and cefixime MICs > 0.125 mg/L from Japan were 
closely related in pulse-field gel electrophoresis analysis (Ameyama et al 2002), indicating a 
close genetic identity among the isolates with reduced susceptibility to third-generation 
cephalosporins. The majority (11/18) of N. gonorrhoeae isolates from Sweden with reduced 
susceptibility to cephalosporins belonged to 2 NG-MAST types (e.g. ST326 and ST925; 
Lindberg et al 2007). However, others have reported that CRO
Red
 isolates are not clonal (Whiley 
et al 2007a/b; Takahata et al 2006; Lee et al 2010). The results of my research too demonstrated 
that CRO
Red
 isolates from Shanghai were non-clonal; 28 CRO
Red
 isolates displayed 22 porB 
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sequence types and 24 NG-MAST STs, whereas the 32 CRO
S
 isolates exhibited 26 porB 
sequences and 28 NG-MAST STs.  
 
Therefore from my research, it can be concluded that porB1b alleles are more frequently 
associated with N. gonorrhoeae CRO
Red
 isolates, that these strains more frequently have 
missense mutations in the DNA binding domain of MtrR, and that the CRO
Red
 isolates do not 
have defining mutations in PBP1. Specific patterns in the transpeptidase domain of PBP2 which 
are associated with the CRO
Red 
phenotype are identified in the present study. The mosaic PBP2 
first characterized in isolates with reduced susceptibility to cefixime, Pattern X was not present 
in the Shanghai isolates. porB-based DNA sequence and NG-MAST analyses revealed that the 
CRO
Red
 isolates are non-clonal. These findings have impact in gonorrhea control by providing 
scientific information for development and modification of treatment guidelines, since third-
generation cephalosporins are the first-line antibiotics recommended for the treatment of 
gonorrhea in China (Wang & Zhang 2007) and other countries (PHAC 2007, 2008a/b; Sexual 
Health Society of Victoria 2008; CDC USA 2006, 2007a; HPA UK 2005; Jpn Soc STD 2006). 
 
4.2.2 Role of PorB in Chromosomal Resistance to Penicillin or Tetracycline in N. 
gonorrhoeae 
 
PorB, a porin, allows the passage of small molecules, such as β-lactams and tetracyclines, 
through the outer membrane (Danielsson et al 1986; Scudamore et al 1979). There are two 
isoforms of PorB in N. gonorrhoeae, e.g. PIA and PIB (Gotschlich et al 1987; Unemo et al 2002). 
A PorB protein comprises 8 surface exposed-loop regions interspaced by conserved 
transmembrane domains (van der Lay et al 1991). The surface exposed-loop regions of PorB 
have a high frequency of amino acid variations (Ison et al 1988; Smith et al 1995). 
 
The PIA phenotype is associated with higher susceptibility to β-lactams and tetracyclines 
(Olesky et al 2006; Liao et al 2008). Amino acid substitutions at Gly-120 and Ala-121 of loop 3 
of PorB are associated with decreased susceptibility to β-lactams and tetracyclines (Olesky et al 
2002), and recently, G120K/A121D mutations in PorB were found to be associated with 
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decreased susceptibility of N. gonorrhoeae isolates to penicillins or third-generation 
cephalosporins (Zhao et al 2009; Tanaka et al 2006; Tapsall 2009a/b).   
 
4.2.3 Mechanisms of Quinolone Resistance in N. gonorrhoeae 
 
Quinolone resistance in N. gonorrhoeae is exclusively mediated by chromosomal mutations 
(Tapsall 2001), although plasmid-mediated quinolone resistance has been frequently reported in 
other microorganisms (Martínez-Martínez et al 2008). 
 
4.2.3.1 Quinolone Resistance Determinant Regions (QRDRs) 
 
The subunits of DNA gyrase (GyrA) and topoisomerase IV (ParC) which are encoded by 
gyrA and parC respectively, are the targets for quinolones (Blondeau 2004). In N. gonorrhoeae, 
GyrA is the primary target and ParC is the secondary target (Belland et al 1994). Specific regions 
in GyrA and ParC have been defined as the quinolone resistant determinant regions (QRDRs) of 
N. gonorrhoeae. Mutations in QRDRs cause N. gonorrhoeae isolates resistant to quinolones such 
as fluoroquinolone resistance (CIP
R
; Belland et al 1994; Deguchi et al 1996).  
 
The present research demonstrates that amino acid (AA) substitutions at codons Ser-91 and 
Asp-95 of GyrA determine quinolone resistance phenotypes of N. gonorrhoeae, consistent with 
reports from others (Trees et al 1999; Ng et al 2002a; Su et al 2001; Tanaka et al 2001). Other 
AA substitutions in GyrA reported in the present study and by others include AA mutations at 
codons Ala-67, Ala-75, Ala-84, His-88, Ala-92, Gln-102, Asn-103 and Val-120 (Trees et al 1999; 
Yang et al 2006; Giles et al 2004; Tanaka et al 2000b). The most frequent mutations in 
gonococcal ParC occur at residue Asp-86 or Ser-87, as observed in the present study and by 
others. Other ParC mutations at residues Ala-29, Gly-85, Ser-88, Glu-91, Ala-92, Phe-100 and 
Arg-116 have been observed (Trees et al 1999; Yang et al 2006; Giles et al 2004; Tanaka et al 
2000b).  
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The combinations of the AA substitutions in GyrA and ParC of gonococcal QRDRs form 
diverse mutation patterns (Su et al 2001; Tanaka et al 1998). For example, nine mutation patterns 
were found in 66 ciprofloxacin resistant (CIP
R
) isolates in the USA (Trees et al 1999), and 17 
mutation patterns were found in the 99 CIP
R
 isolates from Shanghai, China in the present 
research. The majority of the QRDR mutation patterns have a double mutation in GyrA (e.g. 
Ser91-to-Phe and Asp95-to-Ala/Gly), which is frequently combined with a single mutation (e.g. 
Ser87-to-Arg/Asn) in ParC (Yang et al 2006; Trees et al 1999).  
 
In my research, the association between mutations in ParC QRDR and gonococcal quinolone 
MICs was quantitatively analyzed. My results revealed that the presence of mutations in 
gonococcal ParC is correlated with higher ciprofloxacin MICs, suggesting that ParC mutations 
play a role in high level resistance to quinolones in N. gonorrhoeae isolates. In the present study 
GyrA mutations were present in all ciprofloxacin resistant
 
but not in the only ciprofloxacin 
susceptible isolate, supporting the hypothesis that GyrA mutations are essential for a quinolone 
resistance phenotype in N. gonorrhoeae (Trees et al 1999). Thus, my research supports the 
hypothesis that GyrA mutations determine whether a gonococcal isolate is resistant to quinolones, 
while mutations in ParC are correlated with high-level quinolone resistance (Tanaka et al 1998). 
 
4.2.3.2 Trends of QRDR Mutation Patterns in Shanghai: 2005/2008 
 
Quinolones (i.e. fluoroquinolone) had been the antibiotic of choice for the treatment of 
gonorrhoeae during the early 1990s and the mid-2000s in China and other part of the world 
(Workoski et al 2008). The long history and intensive use of quinolones contributed to a 
significant selection pressure with the potential to cause high mutation rates in QRDRs of N. 
gonorrhoeae and subsequently resulting in the development and spread of resistant clones to 
quinolones. Previous studies reported that QRDR mutations are diverse among N. gonorrhoeae 
isolates from various locales and over time; however, predominate QRDR mutation patterns 
consistently contained GyrA mutations at codons S91 and D95 and ParC mutations at codon S87 
(Yang et al 2006; Giles et al 2004; Su 7 Lind 2001; Yoo et al 2004; Ng et al 2002a; Trees et al 
1999, 2001).  
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In the present study, for the first time, the QRDR mutation patterns in the post-quinolone era 
were compared to those when quinolones were commonly used for the treatment of gonorrhea. 
We observed that the predominant QRDR mutation patterns remain although new codon 
mutations and mutation patterns were observed in 2008 as compared to 2005. Moreover, the 
percentages of CIP
R
 were similar between 2005 and 2008; and more 2008 isolates (74.6%) had 
high ciprofloxacin MICs (≥ 8 mg/L) than the 2005 isolates (45.9%). This finding suggests that 
quinolone resistant N. gonorrhoeae (QRNG) is stable both phenotypically and genetically. 
QRNG may last a long time even though selection pressure has been removed (Wang & Zhang 
2007). The QRNG persistency may also be due to the continual wide use of quinolone drugs for 
the treatment of other infectious diseases in Shanghai and in China. Continuing observation of 
QRNG and surveillance of quinolone use in the overall communities is warranted.   
  
 
4.2.4 Conclusion 
 
My research systemically examined mutations in various loci in association with gonococcal 
resistance to different antibiotics. It is the first report with regards to molecular mechanisms of 
reduced susceptibility to third-generation cephalosporins in N. gonorrhoeae isolates from China. 
Our results revealed that the molecular factors associated with reduced susceptibility to 
ceftriaxone include a porB1b (expressing PIB) genotype, a wild-type MtrR protein or double 
mutations in MtrR, and certain mutation combinations in PBP2. The present study demonstrated, 
for the first time, that molecular determinants of quinolone resistant N. gonorrhoeae are stable 
genetically and could remain for a long time in the post-quinolone era.  
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4.3 Molecular Epidemiology of N. gonorrhoeae in China 
 
4.3.1 porB-based DNA Sequence Analysis is a Useful Tool for Molecular Epidemiological 
Studies in N. gonorrhoeae 
 
Molecular typing methods should possess the characteristics of typeability (able to type all 
strains), reproducibility of results, ease of use, ease of interpretation and high discriminatory 
powers (Maslow et al 1993; Unemo & Dillon 2011).  
 
DNA sequence analyses of appropriately selected gene(s) are currently the methods of 
choice for distinguishing N. gonorrhoeae isolates as it provides unambiguous and reproducible 
information, high discriminatory powers. DNA sequence data can be stored or shared 
electronically, permitting reliable comparisons to be made between laboratories (Maiden 2006; 
O’Rouke et al 1995; Viscidi et al 2000). Among them, NG-MAST and porB-based analyses have 
been widely applied in molecular epidemiological studies in N. gonorrhoeae (Unemo & Dillon 
2011). NG-MAST utilizes internal fragments of two variable genes, porB and tbpB, to achieve 
high discriminatory abilities. The porB-based typing schemes use either the entire porB gene or a 
fragment of the porB gene (Viscidi et al 2000; Unemo et al 2002, 2003; Liao et al 2008). 
Furthermore, porB DNA sequences are associated with two gonococcal porB isoforms (i.e. 
porB1a and porB1b) and would additionally provide isolate information with clinical relevance 
(Unemo et al 2002). porB-based typing, both full-length and extended-length typing schemes, 
can be correlated to serovar types (Unemo et al 2003); however, the association between porB 
sequence types and serovar types remains to be confirmed by  further comparison studies 
(Unemo & Dillon 2011). 
 
This research established a modified porB-based molecular typing scheme using an 
extended length of the porB gene, covering ~82% and most variable regions of the entire porB 
gene. As compared to the typing scheme based on the sequences of the entire porB gene, this 
typing scheme is less costly and quicker to perform as it can be determined by one PCR reaction 
and 2 DNA sequencing reactions (one reaction for each strand). To obtain sequences of the entire 
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porB gene, two DNA sequencing reactions for each strand are often needed to achieve 
unambiguous sequence results. NG-MAST typing involves 2 PCR and 4 DNA sequencing 
reactions.  
 
The index of discrimination (ID) for this new scheme is similar to the IDs of the NG-MAST 
analysis. It has been shown that NG-MAST analysis has high discriminatory power sufficient to 
distinguish N. gonorrhoeae isolates in short-term molecular epidemiological studies (Unemo and 
Dillon 2011). Using the typing scheme developed in this study, IDs of 0.932-0.968 was 
achieved, which is similar to the IDs (0.946-0.982) for the NG-MAST analysis of the same N. 
gonorrhoeae populations. Therefore, our results validated the use of this porB-based typing 
scheme in epidemiological studies, providing high discriminatory abilities similar to those of the 
NG-MAST analysis as well as full-length porB-based typing scheme used by others (Bash et al 
2005; Fredlund et al 2004; Martin et al 2004; Olsen et al 2008; Unemo et al 2002, 2004, 2007; 
Ward et al 2000). NG-MAST had a slightly higher discriminatory power for typing N. 
gonorrhoeae isolates and further differentiated porB types. This additional differentiation ability 
is due to the sequence variations present in tbpB alleles (Harrison et al 2008; Choudhury et al 
2006) which contributed to different NG-MAST STs. However, it is uncertain whether the 
differences detected in tbpB using NG-MAST are indicative of epidemiologically distinct groups 
of isolates and further study is required.  
 
The extended-length porB-based typing scheme established in this study has the ability to 
confirm epidemiological sexual connections of gonorrhea cases. In this study, we observed a 
concordance rate of 93.2% between porB genotypes of isolates and epidemiologically reported 
sexual connections of patients (dyads and triads), which was confirmed by the NG-MAST 
analysis. Similar congruence rate (90.3%) was also reported by others using the NG-MAST 
typing method (Bilek et al 2007). However, a small number of patient self-identified sexual 
contacts harboured N. gonorrhoeae isolates with different porB sequences or NG-AMST STs, 
suggesting that the corresponding male and/or female patients might have had multiple sex 
partners infected with different N. gonorrhoeae strains, or that the patients might have mixed 
strain infections. Mixed strain infections are present in sexually active groups. To detect multiple 
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strains from cultures, porB-sequence typing of multiple individual colonies from the primary 
isolation plate is required (Unemo et al 2002). Alternatively, opa-typing of multiple individual 
colonies (O’Rourke et al 1995; Martin & Ison 2003) or porB variable region (VR) typing from 
clinical noncultured samples (Lynn et al 2005; Thompson et al 2000) can be used; however these 
methods may still only detect the predominant strain in a mixed infection. 
 
 Furthermore, large clusters, based on the modified porB-based typing or NG-MAST analysis 
was identified. For example, 42 isolates exhibited an identical porB sequence, and 27 of these 
isolates also displayed a single NG-MAST ST. Thus the modified porB-based typing scheme is 
able to identify epidemiologically unrevealed transmission networks, and this is confirmed by 
NG-MAST analysis. Further epidemiological investigation is warranted to determine whether the 
isolates clustered based on molecular typing are truly related in this study. 
 
A molecular typing method should be able to retain information of epidemiological 
relatedness and sameness, such as observing a single genotypic type for different isolates from a 
single host and identifying epidemiological outbreaks (Riley 2004). Therefore, for short-term 
molecular epidemiological studies of N. gonorrhoeae, the porB-typing scheme developed in this 
study is appropriate and highly cost-effective. 
 
Standardized guidelines should be established if porB DNA sequence analysis is to be used 
for widely studying N. gonorrhoeae molecular epidemiology to facilitate inter-laboratory 
comparisons and to differentiate N. gonorrhoeae clusters from different geographical regions. 
An independent N. gonorrhoeae porB DNA sequence database has not yet been established; a 
publicly accessible N. gonorrhoeae porB database is needed for sequence deposition, sequence 
type assignment, as well as spatial and temporal characterizations of N. gonorrhoeae isolate 
distribution. Further, some common porB type assignments should be established between NG-
MAST assigned types and porB types based on larger porB segments. Overall, porB DNA 
sequence analysis is a useful tool for N. gonorrhoeae molecular epidemiology, particularly in 
resource-limited settings. The NG-MAST analysis can be used if higher discrimination is 
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required for further differentiating large porB-based clusters of N. gonorrhoeae (Choudhury et al 
2000; Unemo & Dillon 2011).  
4.3.2 Construction of porB-based Gonorrhea Transmission Networks in Shanghai 
 
porB-based phylogentic analysis may reveal potential connectors in gonorrhea transmission 
networks. As illustrated in Fig 3.17 of Section 3.3.4, the incongruent dyads or triads might serve 
as connectors between core groups in transmission chains. For example, the dyads D1 and D2 
might connect sexual networks harboring porB1a or porB1b N. gonorrhoeae genotypes, 
respectively; dyad D4 might connect sexual networks harboring N. gonorrhoeae isolates with 
distinct porB1b genotypes. The triad T1 is important, in which one female partner (f1) carried a 
N. gonorrhoeae strain different from her male partner who had a N. gonorrhoeae strain identical 
to his other female partner (f2). Therefore, patient f1 must have obtained gonorrhea from other 
sexual partner(s) who are unrevealed in the epidemiological survey. Furthermore, there are 
several clusters identified by porB sequence analysis, linking several epidemiological dyads and 
triads. These clusters are potential sexual networks, which are broader than sexual networks 
revealed by contact tracing in this study. The large clusters with identical porB sequences could 
be the core groups of gonorrhea transmission networks in Shanghai in 2005.  
  
Because discussion of sex is not well accepted in China, the patient self-reported sexual 
linkages are likely underestimated and thus sexual networks created using the patient-reported 
information cannot be readily observed. It also should be noted that isolates with identical porB 
sequences could possibly be further differentiated using different typing methods, such as opa-
typing and MLST typing (O’Rourke et al 1995; Viscidi et al 2000, 2003; Bennett et al 2007; Tazi 
et al 2010). Therefore, future in-depth analysis of demographic, social and geographical data, 
coupled with genotypic data, would reveal better information of sexual networks in communities 
and better define specific transmission clusters.  
 
It has been shown that the identification of a cluster of identical gonococcal isolates from 
individuals within a particular area and within a short time period can be used as an indicator that 
these individuals may be sexual contacts or part of a closely related chain of transmission, if the 
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typing method indexes genetic variation that accumulates rapidly (O;Rourke et al 1995; Ison 
1998; Ward et al 2000; Martin et al 2004; Choudhury et al 2006; Risley et al 2007). Thus, my 
research has important implications in formulating gonorrhea control programs by identifying 
transmission networks otherwise unrevealed. However, in practice, caution should be taken in 
the interpretation of these results. This type of approach in constructing sexual networks requires 
careful validation to ensure that clusters of identical gonococcal genotypes typically identify 
clusters of individuals with chains of transmission. In-depth comparison of concordance of 
clusters defined by molecular typing to those identified by empirical epidemiological surveys is 
warranted (Risley 2004).  
  
4.3.3 Strain Diversity of N. gonorrhoeae Revealed by porB-based Sequence Analysis 
 
N. gonorrhoeae population is highly diverse in their genetic characteristics. This is 
particularly reflected in surface-exposing protein-coding loci such as porB (Fudyk et al 1999; 
Pérez-Losada et al 2005). This study confirms the extent and nature of porB heterogeneity by 
phylogeneitc analysis of porB in 3 independent population-based studies of N. gonorrhoeae 
isolates, e.g. SH2005, SH2008 and UQ2008. The average number of isolates per NG-MAST ST 
was 1.6 to 1.7; the number of isolates per porB sequence was 1.9 to 2.5 (Table 4.1). These results 
are generally consistent with the few reported gonococcal population studies by others. The 
reported number of isolates per NG-MAST ST ranged from 1.9 (Olsen et al 2008; Unemo et al 
2007) to about 2.4 isolates (Martin et al 2004; Abu-Rajab et al 2009; Palmer et al 2006). As high 
as 4.6 isolates per NG-MAST ST (2045 isolates having 449 NG-MAST STs) was observed 
(Choudhury et al 2006); these isolates were collected in a one-year period in a gonorrhea 
prevalent city London, UK. The reported number of isolates per porB sequence ranged from 1.24 
(Unemo et al 2003) to about 2.0 isolates (Unemo et al 2007; Olsen et al 2008). Gonorrhea 
occurrence rates can significantly affect the degrees of heterogeneity in gonococcal populations 
(Tazi et al 2010). In endemic populations, gonococcal isolates may be highly heterogeneous 
while in epidemic populations the gonococci may be more homogenous showing predominant 
circulating strains (Choudhury et al 2006). The slight differences in porB heterogeneity observed 
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from different studies may be due to the various gonorrhea prevalence rates in communities or is 
because of different typing schemes used. 
 
The study demonstrated, for the first time, that the porB1b genotype of N. gonorrhoeae is 
predominant in Shanghai and Urumchi, by showing that in all the 3 gonococcal populations 
studied, porB1b isolates accounted for over 63%. It has been reported that the porB1b type is 
more prevalent than the porB1a type in N. gonorrhoeae populations in Germany (Sandström et al 
1982), Russia (Il’ina et al 2003, Unemo et al 2007), Sweden (Berglund et al 2001; Olsen et al 
2008), and the United States (McKnew et al 1987, 2003). Prior to DNA sequence analysis to 
establish the prevalence of porB types, serological analysis was also used to indicate temporal 
and geographic differences between PIA and PIB phenotypes. For example, the PIB type 
(serogroups WII/III) was predominant in non-PPNG strains in Jamaica (Knapp et al 1984) and in 
Greece (Tzanakaki et al 1989), while PIA was prevalent in the Philippines and Singapore (Tam 
et al 1982). However, these studies used highly selected isolates and may not be fully 
representative of the broader N. gonorrhoeae population. The reason for type differences in 
different regions is not well understood, although host physiological factors, behavioral 
characteristics, and control programs such as antibiotic use, may play roles in evolutionary 
selection (Derrick et al 1999; Posada et al 2000, 2002).  
 
The gonococcal isolates from Urumchi (UQ2008) comprised much higher proportion of 
porB1a type (36.4%) as compared to the gonococcal populations in Shanghai (12.3% - 27.0%). 
This could be due to the small sample size of the UQ2008. The collection of the UQ2008 isolates 
is presumed to be highly selective at the local STD clinics, resulting in lack of representative of 
gonococcal population within the region. However, it has been documented that porB1a 
gonococci are more likely to cause invasive and complicated infections (Sandström et al 1984; 
Tapsall et al 1992). Therefore, clinical investigation of gonorrhea in Urumchi would be 
warranted to observe differences of clinical manifestations and outcomes of gonorrhea between 
Shanghai and Urumchi and among porB1a- or porB1b-isolate harboring patients. 
 
4.3.4 Temporal Strain Distributions of N. gonorrhoeae in Shanghai 
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The dynamics of temporal strain distribution of N. gonorrhoeae have been reported in other 
geographic locales by others. Using a probe-hybridization method of porB variable regions 
(VRs), McKnew et al (2003) studied gonococcal populations over a 10-year period (1991-2000) 
in Baltimore, Maryland. The most common porB1b strains varies from year to year; while the 
most common porB1a strains tend to persist across the 10-year period. Further, Sarafarin et al 
(1994) characterized a total of 432 PPNG strains from Honolulu, Hawaii during a 10-year period 
(1982-1991) using the auxotype/serovar (A/S) typing methods and reported that there was no 
evidence of endemic persistence of any strains during the study period. In the present study, we 
observed that both porB1a and porB1b gonococcal strains were diverse over time (2005 and 
2008) in Shanghai although few common porB1b clusters persisted over the 3 year period. The 
largest porB-based clusters in the 2005 isolates were not present in the SH2008 isolates; instead, 
the SH2008 isolates had predominant strains which are significantly genetically different from 
the SH2005 isolates. A small portion of the SH2008 isolates carried porB sequences which were 
present in the SH2005 isolates. However, there is no tendency of strain clustering among 2005 
and 2008 N. gonorrhoeae isolates in Shanghai. 
 
However, particular predominant strain types which persist over time in a community have 
been observed by using other typing methods. Using the opa-typing method, Martin et al (2003) 
examined the genetic diversity over a 2-year study period of isolates from all consecutive 
patients with gonorrhea attending the Genitourinary Medicine clinic in Sheffield, United 
Kingdom. Two opa genotypes were detected throughout the 2-year time period and comprised 
41% of all isolates tested. Using a serovar typing method, Young et al (1992) examined N. 
gonorrhoeae isolates from Edingburgh for a 14-year period (1986 and 1990) and reported that 
frequency of isolates with serovar types Bajk (IB-3/IB-6) and Aedgkih (IA-1/IA-2) declined in 
parallel with an overall fall in the prevalence of gonorrhea, whereas isolates with serovar type 
Bacejk (IB-1/IB-2) persisted at a fairly constant level.  
 
The discrepancy may reflect differences of temporal dynamics of N. gonorrhoeae 
populations in different communities, such as in Shanghai, Baltimore and Sheffield. The 
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discrepancy can also be resulted from different typing methods which have various 
discriminatory abilities. In the Baltimore study (McKnew et al 2003), only certain variable 
regions (VRs) of porB were targeted by the probes, and particularly the hyper-variable region 
VR-4 of porB (Unemo et al 2003) was not included. The discriminatory ability of serotyping 
method alone which was used in the Edingburgh study (Young et al 1992) was not high enough 
for investigating temporal trends of strain distribution (Unemo & Dillon 2011).  
 
4.3.5 Spatial Strain Distribution of N. gonorrhoeae 
 
Comparative study on strain types of N. gonorrhoeae populations among distant geographic 
locations has been sparse. Using a MLST typing scheme, Tazi et al (2010) found that there were 
no shared allelic profiles between the Shanghai and the Baltimore N. gonorrhoeae populations. 
Extensive variation in the repertoire of porB alleles was also observed between isolates from a 
gonorrhoea core group population (Nairobi, Kenya) and the N. gonorrhoeae isolates originated 
elsewhere (United Kingdom and North America) (Fudyk et al 1999).  
 
The results of the present comparative study revealed that N. gonorrhoeae isolates from 
Urumchi were genetically distinct from those from Shanghai, confirming the findings of others. 
In the present study, N. gonorrhoeae isolates were collected during a similar time period for both 
populations. The implication in disease control is that using porB typing, introducing isolates can 
be identified, although this result needs to be validated using larger sample sizes.  
 
4.3.6 Conclusion 
 
In this study, a modified porB DNA sequence-based typing scheme has been developed and 
applied to short-term epidemiological studies. This typing scheme has been validated by 
comparing with the NG-MAST typing method and by examining concordance with 
epidemiologically revealed sexual contacts. Using this porB-based typing method, patterns of 
gonococcal strain distributions have been revealed in Shanghai and in Urumchi. Our results 
revealed that predominant strains differ over time and across geographical locations. The 
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majority of strains in 2005 and 2008 in Shanghai carried distinct porB sequences, and only a 
small proportion of strains shared common porB sequences over time. This study also revealed 
sexual contacts and sexual networks unrevealed in traditional contact tracing. The identification 
of large clusters, which may represent the ―core‖ groups and the potential connectors in the 
gonorrhea transmission chains in Shanghai will help to design and modify control measures.  
 
To globally track strain distribution and transmission of N. gonorrhoeae, an international 
database of gonococcal porB sequences is needed. One limitation of my research is the small 
sample sizes of gonococcal populations studied, in particular the SH2008 and UQ2005. 
Recruitment of more N. gonorrhoeae isolates in Shanghai 2008 or in Urumchi may reveal some 
common strains although in low frequency, be shared between the cities or over time in Shanghai. 
Further analysis by combining the genetic data with patients’ demographic information may 
confirm the sexual networks established on the genetic bases, and may reveal a clearer picture of 
sexual networks in the communities.  
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Gonorrhea is a heavy public health burden worldwide. It has been estimated that the number 
of new cases each year increased from 62 million cases in 2001 to 82 million infections in 2010. 
Control of gonorrhea relies on comprehensive strategies, including safe sex, early diagnosis and 
effective treatment of the infection, partner notification and identification of sexual networks for 
targets of prevention programs. Antibiotic treatment is one of the hallmarks in gonorrhea control 
programs. However, the causative pathogen of gonorrhea, Neisseria gonorrhoeae, has developed 
resistance to almost all antimicrobial agents used for the treatment, which has limited treatment 
options to only one class of antibiotics, third-generation cephalosporins.   
 
Antibiotic treatment is the hallmark in curing gonococcal infections and controlling the 
spread of gonorrhea. According to the accepted definition of gonococcal treatment efficacy, a 
cure rate of over 95% is required for an antibiotic to be recommended for gonorrhea treatment. 
Thus, an antibiotic should not be used in situations where resistance is observed in greater than 3% 
to 5% of gonococcal isolates tested.  
 
Surveillance systems are crucial to identify resistant infections for intervention and critically 
important in setting treatment guidelines. Currently, sentinel surveillance systems, so called the 
Gonococcal Antimicrobial Susceptibility Surveillance Programs (GASP), have been established 
and used for decades at local, national and international levels, and these systems are exemplified 
by the GASP in Western Pacific Region and in Southeast Asia Region, the GASP in Latin 
America and the Caribbean, the GASP in South Africa, the Gonococcal Isolate Susceptibility 
Project (GISP) in the United States, the GASP of the European Surveillance of Sexually 
Transmitted Infections (Euro-GASP of ESSTI) and the GASP in the Public Health Agency of 
Canada. 
 
My research provides temporal (2005 and 2008) and spatial (Shanghai and Urumchi) 
information on gonococcal antimicrobial resistance in China. It is the first study showing a high 
prevalence of reduced susceptibility to ceftriaxone, a third-generation cephalosporin currently 
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the first-line antimicrobials for the treatment of gonorrhea in China. This study also demonstrates 
that N. gonorrhoeae is persistently resistant to ciprofloxacin, penicillin and tetracycline, 
antibiotics which had been used for treating gonococcal infections in China and are no longer 
recommended. Spectinomycin is currently an alternative regimen for the treatment of gonorrhea 
in China, and the increasing number of isolates with intermediate levels of susceptibility in 
Shanghai over time indicates the need of close monitoring.  
 
 Over their long history of evolution, bacteria have developed various ways to protect 
themselves from antimicrobial attacks. Some mechanisms mediate cross-resistance to multiple 
unrelated drugs, whereas more than one resistant mechanism can co-exist in a microorganism 
against a particular antibiotic. Gonococcal resistance to antimicrobial agents is generally 
classified as plasmid-mediated or chromosomally mediated resistance or both. Plasmid-mediated 
resistance confers high levels of resistance to penicillin (i.e. PPNG) or tetracycline (i.e. TRNG). 
PPNG isolates harbor β-lactamase producing plasmids; TRNG isolates contain tetM-containing 
plasmids. Mutations at various loci, singularly or in combination, are associated with 
chromosomally mediated resistance. The potential molecular determinants for antimicrobial 
resistance in N. gonorrhoeae include the quinolone resistance determining regions (gyrA and 
parC) and various mutations in the porB, penA, mtrR and ponA genes. The accumulation of 
chromosomal mutations can confer resistance to multiple antibiotics or higher levels of 
resistance to single antibiotics. 
 
The present research systemically examined mutations in various loci in association with 
gonococcal resistance to difference antibiotics. It is the first report with regards to molecular 
mechanisms of reduced susceptibility to third-generation cephalosporins in N. gonorrhoeae 
isolates from China. My results revealed that the molecular factors associated with reduced 
susceptibility to ceftriaxone include a porB1b (expressing PIB) genotype, a wild-type MtrR 
protein or double mutations in MtrR, and certain mutation combinations in PBP2 (penA). The 
present study demonstrated, for the first time, that molecular determinants of quinolone resistant 
N. gonorrhoeae are stable genetically and could remain long time in the post quinolone era.  
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Gonorrhea control strategies, as for other sexually transmitted infections, is achieved by a 
coordinated approach involving minimizing organism transmissibility, decreasing rate of partner 
exchange and reducing duration of infectiousness. Thereby identification of ―core‖ groups of 
transmission, sexual networks and transmission patterns in communities is crucial for setting 
appropriate intervention. Molecular epidemiology, combinational application of molecular tools 
and traditional epidemiological studies provides many advantages for this purpose. The selection 
of molecular methods in molecular epidemiology mostly depends on study purposes, availability 
of resources and factors of cost-effective relationships. 
 
In this cross sectional molecular epidemiological study, a modified porB DNA sequence-
based typing scheme has been developed and applied. This typing scheme has been validated by 
comparing it with the NG-MAST (N. gonorrhoeae Multi-Antigen Sequence Typing) method, an 
internationally accepted molecular method for short-term molecular epidemiological studies, and 
also by examining concordance with epidemiologically revealed sexual contacts. Using the 
porB-based typing method, patterns of gonococcal strain distributions have been revealed in 
Shanghai and in Urumchi. My results revealed that predominant strains differ over time and 
across geographical locations. Majority of strains in 2005 and 2008 in Shanghai carried distinct 
porB sequences, and only a small proportion of strains shared common porB sequences over 
time. This study also revealed sexual contacts and sexual networks unrevealed by traditional 
contact tracing. The identification of large clusters, which may represent the ―core‖ groups and 
the potential connectors in the gonorrhea transmission chains in Shanghai will help to design and 
modify control measures.  
 
An international database of gonococcal porB sequences is needed for globally tracking 
strain distribution and transmission of N. gonorrhoeae. Recruitment of more N. gonorrhoeae 
isolates in Shanghai 2008 or in Urumchi may reveal some common strains although in low 
frequency, be shared between the cities or over time in Shanghai. Further analysis by combining 
the genetic data with patients’ demographic information may confirm the sexual networks 
established on the genetic bases, and may reveal a clearer picture of sexual networks in the 
communities.  
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A1 Questionnaire for Patient Recruitment of Male Gonorrhea Patients 
 
To interviewer; by sex or sexual intercourse we mean oral, vaginal or anal sex.  Frottage 
(rubbing together) or mutual masturbation without insertion do not usually transmit STI and 
hence we do not ask questions about them.  Also, sex includes all sex within a love relationship 
and within a trade relationship. 
 
1.0 Administration 
 
ADMIN1 Client ID number_________________________________ 
 
ADMIN2 Interviewer’s name________________________________ 
 
ADMIN3 Centre  Shanghai       
    ChengDu       
Urumqi       
 
Date of interview: __ __ /__ __/__ __ __ __ 
    Day/month/year 
 
 DEM1 What is the highest level of education you have received?  
 
1 No school      
2. Below primary school     
3. Primary school       
4. Middle school       
5. High school      
6. Above High School     
 
DEM2  How much money did you earn in the last three months on average? 
 
_________________________________________________ 
 
DEM3 What kind of work do you do most often?  Mark 1 for the work done most often 
in the past three months 
1. Public servant           
2. Company manager or owner          
3. Commercial representatives (sales representatives)      
4.         Workers (manual labourers, including migrants)                                                        
5. Student                                                                 
6.          Taxi; truck, company driver  
7.          Waiters  
8. Teachers, professors and health professionals      
9.          Farmers  
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10.       Army personnel  
11.       No job      
12. Small business/store manager, owner.       
13 . Retired           
14. Company staff          
15. Other           
____________________________________________________________________________ 
 
DEM4  Who are you living with now? Mark only one. 
1. Alone           
2. Girlfriend           
3. Girlfriend with whom you have lived for longer than one year   
4. Wife           
5. Parent           
6. Room mate, share         
5. Other, specify:         
____________________________________________________________________________ 
    
DEM5  Does your house have...? for ChengDu and Urumqi 
1. Running water from a tap     
2. Television       
3. Cell phone       
 
DEM6  Do you have any religious beliefs? 
1.Yes       Specify;    
2. None    
   
 
HIST  STI history 
  
HIST1  Did you experience any symptoms from your current STD now? Read from list 
below.   
If HIST1 is No go to question HIST5,  
 
Yes   No   Unsure           Refuse 
  
HIST2 Mark all which apply (Read from list:)       
1.Redness at tip of penis      
2.Discharge from penis       
3.Pain or burning on passing urine     
4.Swelling or pain of testicles/balls     
5.Itching of genitals       
6.Other, specify______________________________ 
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HIST3  When did the symptoms begin? 
 __ __ /__ __/__ __ __ __ 
 Day/month/year   
 
HIST4  Did you have sex while you had symptoms? 
 Yes   No   Unsure   Refused 
 
HIST5  When you were diagnosed with this STI now, why did you go to see the doctor or 
nurse?      Check the most important reason only.  
 
1  Symptoms       
2  Contact of case       
3  For a check-up in case you had risky sex   
4  Other, specify 
________________________________________________________________________ 
    
HIST6. What treatment did you have for the current STI now?  Mark all which 
apply. If unsure write the name of the drug(s) 
1. Penicillins         
2. Cephalosporins        
3. Aminoglycosides        
4. Tetracyclines         
5. Macrolides         
6. Quinolones         
7. Sulfonamides         
8. Azathioprine         
9. Antifungals         
10. Other, specify 
______________________________________________________________________________ 
 
HIST7  How many days did you take the current treatment? 
Mark number of days______________________ 
 
HIST8 Just before you got the current STI, where did you meet the sex partner(s)?  The 
one immediately before you came here? 
  
1. This city. Specify district ______________________________________________ 
   
2 Mainland China        
  Specify province, city: _________________________________________ 
 
3. Taiwan, Hong Kong          
4 Other country 
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  Specify:__________________________________________________________ 
 
HIST9  Have you ever had an STI before? 
If No then go to PRACT1 
Yes   No   Unsure   Refused 
 
If  HIST9  is yes, then  
 
HIST10 which ones in the past 12 months? Mark all that are applicable, and how many 
times. 
1. Syphilis      how much time  
2. Gonorrhea      how much time   
3. Chlamydia      how much time   
4. Condyloma, genital warts    how much time   
5. Herpes       how much time   
6. HIV/AIDS      how much time   
7. Mycoplasma      how much time   
8. Other, specify__________________________ 
 
HIST11 When was the last time you had an STI? 
  
/__ __/__ __ __ __ 
/month/year  
      
HIST12 Where did you see a doctor for the previous STI? Not the current one. 
1. Public or government hospital      
2. Private hospital        
3. Private practitioner        
4. Self-diagnosed       
 
HIST13 Which drug did you have for the previous STI?  Mark all of which apply.  
 1. Oral          
2. Injection         
3. Douche, vaginal wash        
4. Suppository (Candida albicans)      
5. Ointment (external use)       
6. Laser surgery (HPV)        
7. Other          
 
PRACT Health knowledge, attitudes and practice relating to sex and STI 
 
PRACT1 Do you usually…? Mark all that apply       
1. Use lubricant         
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2. Use any topical disinfectant       
3. Use any topical sexual enhancer      
4. Wash genitals before sex       
5. Wash genitals after sex       
6. Take regular doses of antibiotics (over the counter)    
7. Take over the counter antibiotics if you think you have an STI  
8. Take over the counter of antibiotics when you have risky sex  
9. None of the above        
 
PRACT2 Are you circumcised?  
Yes      No    Refused 
 
PRACT3 Do you have sex with…?     
1. People of the same sex      
2. People of the opposite sex      
3. Both         
4. Refused        
   
PRACT4 What birth control method did you use at most recent sex?  
 
1. Condoms        
2. Vasectomy          
3. Withdrawal        
4. None         
5. Refused        
6. Other, specify        
_________________________________________________________________ 
   
PRACT5 In the past 12 months how often have you used alcohol before or during sexual 
activities? 
1. Always      
2 More than 1/2 the time    
3 About 1/2 the time     
4 Less than 1/2 the time     
5 Never       
6 Refused to answer       
 
PRACT6 In the past 12 months how often have you used psychogenic drugs (ones that 
make you high), before or during sexual activities? 
1. Always      
2. More than 1/2 the time    
3. About 1/2 the time     
4. Less than 1/2 the time     
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5. Never       
6. Refused to answer     
 
Remember, all the answers you give us will remain confidential between you and me.  We 
will use your answers only to count how many people may get STIs 
 
PRACT7 In the past 12 months have you ever injected street drugs, or been injected with 
drugs?   
1. Yes       
2. No       
3. Refused to answer     
 
PRACT8 At what age did you first voluntarily (willingly) have sex ? 
 Give age       
 Refused to answer     
 
PRACT9 In the past 3 months, how many sex partners have you had? 
 Give number:      
 Unsure       
 Refused to answer    

PRACT10 In your lifetime, how many sexual partners have you had? Give your best guess.   
 Give number:      
 Unsure       
 Refused to answer     
 
 
Now, we want to ask you some more personal information.  Remember, we will not give 
this information to anyone, and we will only use it to count the number of people of what 
age, or which cities they are from. 
 
 
DEM Personal information of client   
 
DEM7 Date of birth  __ __ /__ __/__ __ __ __ 
    Day/month/year 
 
DEM8 Where do you live in this city? 
 
District___________________________________________________________ 
 
Refused         
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DEM9 Are you or official permanent resident(s) of this city? (Have official registration?) 
If DEM9 is YES then go to DEM12 
IF DEM9 is NO then go to DEM10 

Yes                        No                 Refused 
 
DEM 10 Have you lived in this city longer than 6 months?  
 
Yes                       No                  Refused 
 
DEM11  Which Chinese province or country did you live in before this city? 
 
1. Mainland China 
2. Hong Kong, Taiwan 
3. Other country or province 
Specify:______________________________________________________________________ 
 
DEM12  What ethnic group do you belong to? (For ChengDu and Urumqi) 
 
1. Han 
2. Uigur 
3. Other, specify 
___________________________________________________________________________
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Section II.  Sexual partner information for named partners:     
    
 
We will note the alias, initial or name of up to 10 partners with whom you had sex in the last 3, so 
that you can remember which partner we are talking about.  Start with the sex partners with whom 
you had sex immediately before the onset of symptoms.  Then write in the partners with whom 
you had sex after your symptoms started.   
 
1. ___________________________________________________________________________ 
2. ___________________________________________________________________________ 
3. ___________________________________________________________________________ 
4. ___________________________________________________________________________ 
5. ___________________________________________________________________________ 
6. ___________________________________________________________________________ 
7. ___________________________________________________________________________ 
8. ___________________________________________________________________________ 
9. ___________________________________________________________________________ 
10. ___________________________________________________________________________ 
 
1.0 Administration 
 
ADMIN1 Index client ID number ________________________________________ 
 
ADMIN2 
 
Partner’s name, alias or initials (from the previous sheet) 
 
PARTID__________________________________________ PARTNO   ________________ 
 
2.0 Partner information  
 
PART1 Is this partner..? 
 (go to PART3)   
 
PART2 Is this partner pregnant in the past three months?  
 
Yes   No   Unknown   
 
If yes, then explain that there is a danger to her health and that of the baby. Refer to OB-
GYN clinic or hospital.  
 
PART3 Where is this partner originally from? 
 
1. Mainland China 
Specify province:___________________________________________________ 
2. Hong Kong, Taiwan 
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3. Other country, specify:___________________________________________________ 
 
PART4 To the best of your knowledge, what is the highest level of education this partner 
(#) has completed? 
1. No school       
2. Below primary school     
3. Primary school       
4. Middle school       
5. High school      
6 Above High School     
7.  Unknown      
8. Refused        
 
PART5 To your knowledge, what was your partner’s work? Mark only one.  
1. Public servant           
2. Company managers or owner         
3. Commercial representatives (sales representatives)      
4.         Workers (manual labourers, including migrants)  
5. Student           
6.          Taxi; truck, company driver  
7.          Waiters, waitress  
8. Teachers, professors and health professionals      
9.          Farmers  
10.        Army personnel  
11.        No job  
12. Small business/store manager, owner.       
13 . Retired           
14. Company staff         9 
15. housewife                
16. Other, specify           
____________________________________________________________________________ 
 
PART6 Where did you first meet partner (#)?  mark only one 
 
1. Through family or mutual friends        
2. At school, college or university         
3. At work           
4. Park,             
5. Bar, beauty parlour, sauna, barber shops, karaoke bars, massage parlours,    
 foot massage parlour          
6. Internet          
7. Unsure          
8. Refused           
9. Other (specify) 
_____________________________________________________________________________ 
 
  
208 
PART7  In which place did you meet this sex partner? 
  
1. This city        
 Specify district ______________________________________________ 
  
2.  Mainland China     
 Specify province, city:____________________________________________ 
   
3. Taiwan, Hong Kong       
4. Other country, specify:        
 
 
PART8 What is your relationship to this partner?  
1. Spouse          
2. Lover          
3. Casual/temporary sex partner unpaid      
4. Casual/temporary sex partner paid        
5. Unsure          
6. Refused to answer         
 
 
PART9 How long did you know this partner before you first had sex? Mark ONE ONLY 
1. Number of ___________  days, OR 
2. Number of ___________  months, OR 
3. Number of___________ years  
 
PART10 When did you first have sex with this partner?  
 
__ __ /__ __/__ __ __ __ 
Day/month/year    
 
 
PART11 When was the most recent time you had sex with this partner?  Enter as a specific 
date    __ __ /__ __/__ __ __ __ 
     Day/month/year    
 
PART12 How often did you have sex with this person? 
1. Once a day or more        
2. 2-3 times per week        
3. About once per week        
4. 1-3 times per month        
5. Less than once per month       
6.  Only once ever        
7. Refused to answer         
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PART13 In last session or last date; how often did you have intercourse?   
Give number of times: 
_________________     Refused 
 
PART14 In the past 3 months, Did you have vaginal, anal or oral sex with this person?  
Mark all applicable with 1 for the most frequent and 3 for the least.  Mark 2 
if the first two are equal. Mark all with the same number if equal. Mark 0 if 
none 
1. Vaginal       
2. Anal         
3  Oral        
4. Refused       
 
PART15 How often was a condom (either male or female condom) used with this partner 
in the past three months? 
1. Never        
2 Less than 1/2 the time      
3 About 1/2 the time      
4 More than 1/2 the time     
5 Always       
6 Unsure 
7         Refused to answer       
 
PART16 At the most recent episode of sexual intercourse with this partner, was a condom  
used? 
Yes   No    Refused 
PART17 To your knowledge, who else does this partner have sex with?  Mark all that  
apply. 
 
1. Spouse          
2. Lover          
3. Boyfriend           
4. Casual /temporary sex partner unpaid     
5. Temporary sex partner paid          
6. Unsure          
7. Refused to answer          
 
PART18 To the best of your knowledge, has this partner ever injected drugs in the last 12 
months?   
1 Yes           
2 No           
3 Don't know          
4 Refused to answer          
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PART19 Have you ever given this partner anything in exchange for sex? 
1. Money           
2. Food, shelter, clothing or something of value     
3 Drugs           
4 Never given anything         
5 Refused to answer         
  
PART20 Have you ever received anything from this partner in exchange for sex? (Sold sex) 
1. Money           
2. Food, shelter, clothing or something of value     
3 Drugs           
4 Never given anything         
5 Refused to answer         
 
PART21 Have you ever discussed with this partner whether or not she or he has HIV? 
 
Yes   No    Refused  
 
PART22 Have you ever discussed with this partner whether or not they have ever had an 
STD? 

Yes   No    Refused 
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A2.2 Approval from Annals of Internal Medicine 
 
 
 
WAA1016675 
 
June 20, 2011 
 
College of Arts and Science 
Vaccine and Infectious Disease Organization 
University of Saskatchewan 
A233-VIDO, 120 Veterinary Rd 
Saskatoon, Saskatchewan, Canada S7N 5E3 
 
Dear Dr Liao: 
 
Thank you for your request to print the following from Annals of Internal Medicine: 
 
Appendix figure: Kimberly A. Workowski, et al, Emerging Antimicrobial Resistance in 
Neisseria gonorrhoeae: Urgent Need to Strengthen Prevention Strategies. Ann Intern Med April 
15, 2008 148 
 
Permission is granted to print the preceding material with the understanding that you will give 
appropriate credit to Annals of Internal Medicine as the original source of the material. Any 
translated version must carry a disclaimer stating that the American College of Physicians is not 
responsible for the accuracy of the translation. This permission grants non-exclusive, worldwide 
rights for this edition in print for not for profit only. ACP does not grant permission to reproduce 
entire articles or chapters on the Internet unless explicit permission is given.  This letter 
represents the agreement between ACP and Mingmin Liao, MD, MMed, PhD candidate for 
request WAA1016675 and supersedes all prior terms from the requestor. 
 
Thank you for your interest in Annals of Internal Medicine. If you have any further questions or 
would like to discuss the matter further, please contact me at 856-489-4446 or fax 856-489-4449. 
 
Sincerely, 
 
Gina Brown 
Permissions Coordinator 
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A2.3 Oxford University Press (Yang et al 2006, J Antimicrob Chemother) 
 
OXFORD UNIVERSITY PRESS LICENSE 
TERMS AND CONDITIONS 
 
Sep 04, 2010 
 
This is a License Agreement between Mingmin Liao ("You") and Oxford University Press 
("Oxford University Press") provided by Copyright Clearance Center ("CCC"). The license 
consists of your order details, the terms and conditions provided by Oxford University Press, and 
the payment terms and conditions. 
 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
 
License Number: 2501991197249 
 
License date: Sep 04, 2010 
 
Licensed content publisher: Oxford University Press 
 
Licensed content publication: Journal of Antimicrobial Chemotherapy 
 
Licensed content title: Antimicrobial susceptibility and molecular determinants of quinolone 
resistance in Neisseria gonorrhoeae isolates from Shanghai 
 
Licensed content author : Yang Yang, et al. 2006. 
 
Type of Use: Thesis/Dissertation 
 
Permissions cost: 0.00 USD 
 
Value added tax: 0.00 USD 
 
Total: 0.00 USD 
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A2.4 Oxford University Press (Liao et al 2008, J Antimicrob Chemother) 
 
OXFORD UNIVERSITY PRESS LICENSE 
TERMS AND CONDITIONS 
 
Sep 04, 2010 
 
This is a License Agreement between Mingmin Liao ("You") and Oxford University Press 
("Oxford University Press") provided by Copyright Clearance Center ("CCC"). The license 
consists of your order details, the terms and conditions provided by Oxford University Press, and 
the payment terms and conditions. 
 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
 
License Number: 2502000221164 
 
License date: Sep 04, 2010 
 
Licensed content publisher: Oxford University Press 
 
Licensed content publication: Journal of Antimicrobial Chemotherapy 
 
Licensed content title: Clusters of circulating Neisseria gonorrhoeae strains and association with 
antimicrobial resistance in Shanghai 
 
Licensed content author: Mingmin Liao, et al. 2008 
 
Type of Use: Thesis/Dissertation 
 
Permissions cost: 0.00 USD 
 
Value added tax: 0.00 USD 
 
Total: 0.00 USD 
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A2.5 Oxford University Press (Liao et al 2011, J Antimicrob Chemother) 
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A2.6 American Society of Microbiology (Liao et al 2009) 
 
 
AMERICAN SOCIETY FOR MICROBIOLOGY LICENSE 
TERMS AND CONDITIONS 
 
Sep 04, 2010 
 
This is a License Agreement between Mingmin Liao ("You") and American Society for 
Microbiology ("American Society for Microbiology") provided by Copyright Clearance Center 
("CCC"). The license consists of your order details, the terms and conditions provided by 
American Society for Microbiology, and the payment terms and conditions. 
 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
 
License Number; 2502000749142 
 
License date: Sep 04, 2010 
 
Licensed content publisher: American Society for Microbiology 
 
Licensed content publication: Journal of Clinical Microbiology 
 
Licensed content title: Comparison of Neisseria gonorrhoeae Multiantigen Sequence Typing and 
porB Sequence Analysis for Identification of Clusters of N. gonorrhoeae Isolates 
 
Licensed content author: Mingmin Liao, Jo-Anne R. Dillon 
 
Licensed content date: Feb 1, 2009 
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A3 Mingmin Liao Curriculum Vitae 
 
LIAO, Mingmin, M.D., M.Med, Ph.D. Candidate (Defended June 2011) 
Research Scientist, Vaccine and Infectious Disease Organization (VIDO) 
Laboratory Manager, College of Arts and Science 
 University of Saskatchewan 
 
Room A233, 120 Veterinary Road 
VIDO, Saskatoon, SK S7N 5E3; CANADA 
Tel: (306) 966-1539; Fax: (306)966-7478 
Email: mil395@mail.usask.ca 
 
Language Competency: 
 English: Reading, writing and speaking  
 Chinese: Reading, writing and speaking  
Education: 
 Ph.D. candidate: Department of Microbiology & Immunology, University of 
Saskatchewan, Saskatoon, Canada (January 2007 – June 2011). Research topic: 
Molecular epidemiology and molecular mechanisms of antimicrobial resistance in 
Neisseria gonorrhoeae in China: Implications for disease control (Supervisor- Dr. Jo-
Anne R. Dillon) 
 Master of Medicine (MMed): Graduate study in Microbiology/Parasitology, Fudan 
University (Formerly Shanghai Medical University), Shanghai, China (09/1985-07/1988) 
Research topic: Ultrastructure of metacercarial membrane of and immune response of 
rats infected with Paragonimus westermani (Supervisor- Dr. TingHuang Wen and Dr. 
PeiFang Fan). 
 Bachelor of Medicine (MD): Fudan University School of Public Health (Formerly 
Shanghai Medical University, School of Public Health), Shanghai, China (09/1980-
06/1985)  
 Postdoctoral Fellow: Hormone and Development Division, Ottawa Health Research 
Institute, Ottawa, Canada (05/1999-03/2003). Research topic: steroid hormone receptor 
(Supervisor- Dr. Robert Hache) 
 Postdoctoral training: The Laboratories for Reproductive Biology, Department of 
Biophysics and Biochemistry, University of North Carolina at Chapel Hill, North 
Carolina, USA (11/1995-03/1999). Research topic: Androgen receptor and reproductive 
biology (Supervisor- Dr. Elizabeth M. Wilson and Dr. Frank S. France)  
 Other professional training: Clinical laboratory diagnosis of STD, UNC Hospital, 
University of North Carolina at Chapel Hill (UNC-CH). (Supervisor- Dr. Myron Cohen) 
 Other professional development: 
o Pass standing MCCEE (Medical Council of Canada Evaluating Examination) 
o Associate member, Canadian College of Microbiologists 
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Employment & Experience: 
 
 Sept.2004-present (I):  Laboratory manager, University of Saskatchewan, Saskatoon, 
Canada. (Supervisor- Dr. Jo-Anne R. Dillon) 
 I have managed a research unit with ~8 staff and several research grants simultaneously 
for more than 6 years.  
1. Responsibilities: I am responsible for the managerial and academic dimensions of a 
research laboratory with multiple ongoing research projects, overseeing these projects 
from formulation to dissemination of results.  
1) ensure safety regulations are followed, including transportation/receiving dangerous 
goods and importation of pathogens; 
2) develop standard operation procedures; 
3) oversee the efficient operation of the laboratory and multiple research grant 
management; 
4) recruit and supervise students, technicians, postdoctoral fellows and other personnel 
on a day-to-day basis; 
5) oversee the design of data management systems;  
6) maintain a comprehensive overview of all research projects and their progress;  
7) appraise and consult research literature;  
8) develop and perform appropriate research activities;  
9) co-ordinate/manage result and data, and utilize biomedical and bioinformatics to 
analyze data;  
10) write/design/present manuscripts, grants, reports and abstracts;  
11) overview budget;   
2. Preparation of grant application and report: In addition to the grants I applied for as 
a co-investigator, I have drafted/vented several research grant proposals for the 
laboratory PI to CIHR, NSERC, IDRC, SHRF and other funding agencies.  
3. Fund management through UNIFI of the University of Saskatchewan. 
4. Collaboration: Establishment and maintenance of broad regional, national and 
international collaborations of this research unit by organizing and communicating 
with broad stakeholders of research teams, including research grant applications, 
managing collaborating projects and exploring funding opportunities for such 
collaborations. 
 
 Sept.2004-present (II): Research scientist, Vaccine and Infectious Disease Organization, 
University of Saskatchewan, Saskatoon, Canada. (Supervisor- Dr. Jo-Anne R. Dillon) 
1. Molecular epidemiology of infectious diseases:  In collaboration with researchers 
from U of Ottawa, U of Saskatchewan and the Shanghai Skin Disease and STD 
Hospital, I have investigated antibiotic resistance and strain specific transmission of 
Neisseria gonorrhoeae and Chlamydia trachomatis infections in China using 
comprehensive approaches of epidemiology, molecular epidemiology, social sciences, 
genetics and bioinformatics.  
2. Molecular microbiology: I have used various methods to explore cell division 
mechanisms using N. gonorrhoeae and Enterococcus faecalis as model 
microorganisms. Those techniques include molecular biology, biochemistry, phase 
contrast and fluorescence microscopy, microbiology and genetics. DNA sequencing; 
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molecular cloning; quantitative PCR; assembly and/or use of protein-expression 
constructs. 
 
 Feb. 2003-Aug.2004: Research Associate, Dept. of Biochemistry, Microbiology and 
Immunology, University of Ottawa, Ottawa, Canada. (Supervisor- Dr. Jo-Anne R. Dillon) 
1. Molecular microbiology: Research focus on molecular mechanisms of bacterial cell 
division of E. faecalis. Systems and techniques used include mutagenesis, yeast two 
hybrid, bioinformatics, co-immunoprecipitation, GST pulldown, RT-PCR, 
fluorescence microscopy. DNA sequencing; molecular cloning; quantitative PCR; 
assembly and/or use of protein-expression constructs. His-tagged protein expression 
and purification. 
2. Antimicrobial resistance in bacterial pathogens 
3. Mentoring undergraduate and graduate students 
4. Writing grant applications, scientific papers and presentations. 
5. Management of research, human resources and funds for the unit. 
 
 May 1999- Feb. 2003 Postdoctoral Fellow, Hormone and Development Division, Ottawa 
Health Research Institute, Ottawa, Canada. (Supervisor- Dr. Robert Hache) 
1. Molecular biology: Research focus on MMTV transcription regulation by 
glucocorticoid receptor and octamer protein. Systems and techniques used include 
mammalian two hybrid, yeast two hybrid, xenopus oocyte microinjection, cloning, 
PCR, RT-PCR, footprinting, IP, chromatin-IP, Northern blot and Southern blot 
2. Academic instruction of undergraduate students 
 
 1996-1999 Postdoctoral Fellow, Laboratories for Reproductive Biology, Department of 
Biochemistry and Biophysics, University of North Carolina at Chapel Hill, North 
Carolina, USA. Co-sponsored by the International Training and Research Program in 
Population and Health of the John E. Fogarty International Center for Advanced Study in 
the Health Sciences. (Supervisor- Dr. Elizabeth M. Wilson and Dr. Frank S. France)  
1. Endocrinology and reproductive biology 
2. Research project on androgen receptor overexpression, purification and 
characterization. Techniques used included cloning, mammalian cell culture and 
protein expression, chromatography, DNA mobility shift assay, monoclonal antibody 
production, etc.   
 
 1995-1996  Clinical laboratory diagnosis of STD. UNC Hospital, University of North 
Carolina at Chapel Hill (Supervisor- Dr. Myron Cohen) 
 
 1994-1995 Physician and public health researcher, Shanghai Institute for Planned 
Parenthood Biology, WHO Collaborating Center, Shanghai, China  
1. Clinical physician in STIs 
2. Studies focus on clinical epidemiology and health social science of STIs 
3. Management of Foreign Affair Office of the institute 
 
 1991-1994 Physician and epidemiological researcher, Shanghai Skin Disease and STD 
Hospital, Shanghai, China 
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1. Clinical physician in skin diseases and STIs  
2. Research on social science and epidemiology of STIs/AIDS 
3. Office management and editor of the hospital journal 
 
 1989-1991 Residency, HuaShan Hospital, Shanghai Medical University, Shanghai, China 
 
Research Funding: 
 ―Strain specific transmission of sexually transmitted diseases in sexual networks in China: 
implications for prevention‖. The Canadian Institutes of Health Research (CIHR), 
Operating grant.  A.M. Jolly, Y. Chen, J.R. Dillon, M. Liao, W. Gu, L.E. Leonard, P.A. 
Sandstrom and J.L. Wylie. 2005 – 2008, extended to Mar 2011; $326,883.  
 ―Strain specific transmission of gonorrhoeae in sexual networks in Shanghai: 
implications for prevention‖.  CIHR, International Opportunity Program; one time 
collaborative research project grant (OPC67917). Ann M. Jolly, Yue Chen, Jo-Anne R. 
Dillon, Mingmin Liao, and Weiming Gu. May 2004 – May 2005, 99,500$. 
Awards and Honours: 
 Best post award, Epidemiology, the 15th International Pathogenic Neisseria Conference 
(IPNC), September 10-16, 2006, Cairns, Australia. 
 Travel grant: Sino-US AIDS research collaborating program, sponsored by NIH and 
China Health Ministry. October 28
th
-November 3
rd
, 2002. Beijing, China. 
 Travel grant: The 85th Annual Meeting of American Society of Endocrinology, June 12-
15
th
, 2000. Toronto, Canada 
 Forgarty International Postdoctoral Scholarship: For postdoctoral training in reproductive 
biology at the University of North Carolina at Chapel Hill USA, 01/1997-03/1999. 
 WHO Scholarship: For research training in microbiology of sexually transmission 
diseases at the University of North Carolina at Chapel Hill USA, 11/1995-11/1996. 
 Fogarty travel grant: The annual meeting of the international research training sponsored 
by Fogarty International Center and NIH. May 11-12
th
, 1997. Bethesda, USA 
 WHO scholarship: Seminar on laboratory diagnosis of STDs/HIV in Nanjing, China 
Sponsored by World Health Organization, May-June, 1989 
 Distinct student awards: 1983, 1984, 1985. Shanghai Medical University 
 Distinct undergraduate award: 1985, Shanghai Medical University 
 
Supervisory Experience (from 2001):  
 
Undergraduate classes: 
 Micro 390, Fall 2010, Lab, U of Sask 
Micro 391, Fall 2009, Lab, U of Sask 
Micro 216, Spring 2009, lecture to lab, lab instruction and marking, U of Sask 
Micro 390, Lab, Fall 2008, U of Sask 
Micro 391, Lab, Fall 2007. U of Sask 
 
Individual or group supervision from 2004 to present:  
I have provided mentoring/direct instruction/supervision on a day-to-day basis to the 
following students and research personnel (ongoing and completed, as of May 24, 2011).  
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 Research Associate (2) 
 Postdoctoral fellow (5) 
 Graduate students (MSc and PhD) (10) 
 Research technician and Research Office Administrator (16) 
 Visiting scientist (3) 
 Honours and summer student (12) 
 High school student (6) 
 
Committee: 
 Abstract reviewer. Committee of Antimicrobial Resistance. The 17th International 
Pathogenic Neisseria Conference (IPNC), Banff, Alberta, Canada. September 11-16, 
2010. 
 
Memberships: 
 Associate member- Canadian College of Microbiologists (CCM), 2009- 
 Member – Canadian Association for Clinical Microbiology and Infectious Diseases 
(CACMID), 2010- 
 Member- American Society of Microbiology (ASM), 2005- 
 Member- American Sexually Transmitted Disease Association (ASTDA), 2005- 
 Member- International Collaboration on Gonococci (ICG) and ICG website curator 
(www.icgngo.org). 2005- 
 
Publications: 
 
Papers in referred journals: [Papers derived from the PhD study are indicated with stars (n=3)] 
 
1. *M. Liao, W-M Gu, Y. Yang and J.R. Dillon. 2011. Analysis of mutations in multiple loci of 
Neisseria gonorrhoeae isolates reveals effects of PIB, PBP2 and MtrR on reduced 
susceptibility to ceftriaxone. J. Antimicrob. Chemother. 66:1016-1023. 
2. P.S. Ruddock, M. Charlan, S. Ramirez-Arcos, A. Lopez, G.H.N. Towers, J.T. Arnason, M 
Liao, J.R. Dillon. 2011. Antimicrobial activity of Piper lanceaefolium and other Colombian 
medicinal plants against antibiotic susceptible and resistant strains of Neisseria gonorrhoeae. 
Sex. Transm. Dis.  38:82-88.  
3. *M. Liao, S. Helgeson, W-M Gu, Y. Yang, A.M. Jolly and J.R. Dillon. 2009. Comparison of 
Neisseria gonorrhoeae Multiantigen Sequence Typing and porB sequence analysis for 
identification of clusters of N. gonorrhoeae isolates. J. Clin. Microbiol. 47:489-491. 
4. M.D. Rigden, C. Baier, S. Ramirez-Arcos, M. Liao, M. Wang and J.R. Dillon. 2008. 
Identification of the coiled-coil domains of Enterococcus faecalis DivIVA that mediate 
oligomerization and their importance for biological function. J. Biochem. 144:63-76. 
5.  *M. Liao, K. Bell, W-M Gu, Y. Yang, N.F. Eng, W. Fu, L. Wu, C-G Zhang, Y. Chen, A.M. 
Jolly, and J.R. Dillon. 2008. Clusters of circulating Neisseria gonorrhoeae strains and 
association with antimicrobial resistance in Shanghai. J. Antimicrob. Chemother. 61:478-487. 
6. V. Greco-Stewart S., Ramirez-Arcos, M. Liao and J.R. Dillon. 2007. N-terminus 
determinants of MinC from Neisseria gonorrhoeae mediate interaction with FtsZ but do not 
affect interaction with MinD or homodimerization. Arch. Microbiol. 187:451-458. 
7. Yang Yang, M. Liao, Wei-Ming Gu, Kelli Bell, Lei Wu, Nelson F. Eng, Chu-Guang Zhang, 
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Yue Chen, Ann M. Jolly, and Jo-Anne R. Dillon. 2006. Antimicrobial susceptibility and 
molecular determinants of quinolone resistance in Neisseria gonorrhoeae isolates from 
Shanghai.  J. Antimicrob. Chemother. 58:868-872. 
8. M. Liao, P. S. Ruddock, A. S. Rizvi, S. H. Hall, F. S. French and J. R. Dillon 2005. Cationic 
peptide of the male reproductive tract, HE2α, displays antimicrobial activity against 
Neisseria gonorrhoeae, Staphylococcus aureus and Enterococcus faecalis. J. Antimicrob. 
Chemother. 56: 957-961. 
9. Sandra Ramirez-Arcos, M. Liao, Susan Marthaler, Marc Rigden, and Jo-Anne R. Dillon. 
2005. Enterococcus faecalis divIVA: an essential gene involved in cell division, cell growth, 
and chromosome segregation. Microbiol. 151:1381–1393. 
10. Ruddock PS, M. Liao, B. Foster, L. Lawson, J.T. Arnason and J.R. Dillon. 2005. Garlic 
natural health products exhibit variable constituent levels and antimicrobial activity against 
Neisseria gonorrhoeae, Staphylococcus aureus and Enterococcus faecalis. Phytother. Res. 
19:327–334. 
11. W-M Gu, M. Liao, Y. Yang, Lei WU, WZ Hu. 2004. [Detection of HSV-2-IgG, HBsAg and 
HCV in patients with STD and HIV infection.] Chin J Dermatol 37(5):288-289. [English 
abstract]. 
12. Savory JG, Prefontaine GG, Lamprecht C, Liao M, Walter RF, Lefebvre YA, Hache RJ. 
2001. Glucocorticoid receptor homodimers and glucocorticoid-mineralocorticoid receptor 
heterodimers form in the cytoplasm through alternative dimerization interfaces. Molec. Cell. 
Biol. 21(3):781-93. 
13. M. Liao and Elizabeth W. Wilson. 2001. Production and Purification of Histidine-Tagged 
Dihydrotestosterone Bound Full-Length Human Androgen Receptor.  Methods in Molecular 
Biology Volume 176, Steroid Receptor Methods—Protocols and Assays Edited by Benjamin 
A. Lieberman, Humana Press, p67-80. 
14. Liao M, Zhou ZX, Wilson EM. 1999. Redox-dependent DNA binding of the purified 
androgen receptor: evidence for disulfide-linked androgen receptor dimers. Biochem. 
38(30):9718-27. 
15. H.Z. Qian, M. Liao and P.F. Zhao. 1998. [Analysis of Infection Sources and Care-seeking 
Behaviour among STD Clinic Clients] (English abstract). Chinese Journal of 
Dermatology [Zhonghua Pi Fu Ke Zha Zhi] 31(3):171-173 
16. P.F. Zhao, H. Lu, M. Liao, Shah I, Mundigo A. 1997. [Sexual behaviour and condom use 
among STDs patients in Shanghai. In: Gao Ersheng, Shah I, eds. Progress of social science 
research on reproductive health: anthology of treatises of the international symposium on 
social science research in reproductive health]. Beijing. China Population Publishing House, 
1997, 29–39. 
17. M. Liao, P.F. Zhao, L.B. Xiao. 1996. [Social-demographic characteristics and treatment-
seeking behaviour of STD patients in China.] Chin J Dermatol Sex Transm Dis 10:286–287. 
18. P.F. Zhao, M. Liao, HZ Qian et al 1996. [Analysis of Ages of first sexual intercourse and 
influence factors in STD patients in Shanghai]. Chin STD and AIDS Prevention [Zhongguo 
Xing Bing Ai Zhi Bing Fang Zhi] 2:10-13. 
19. Zhao PF, Qian HZ, M. Liao, Lu H. 1996. [Psycho-social & behavioral characteristics of STD 
patients].  Chin J STD/AIDS Prev Control. 2:270-273. 
20. Zhao PF and M. Liao. 1994. [In-depth interview plus behavioral survey of STD patients in 
Shanghai: a pilot report] [Article in Chinese] Chin Sexol [Zhongguo Xin Xue] 1:35-37. 
21. M. Liao and Xiao LB. 1991. [Vaginal spermicide against STDs in women (review)] [Article 
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in Chinese] Foreign Med Dermatol. [Guo Wai Yi Xue Pi Fu Bing Feng Che] 17(3): 150-153. 
22. Xiao LB and M. Liao. 1991. [Sexually transmitted diseases: their prevalence and research 
status in China (review)]. Medicine Progress [Yi Xue Jing Zhang]  p143-146. 
23. M. Liao, Gu WM, Xiao LB, Le JY. 1991. [Prevalence of chlamydia trachomatis infection in 
STD high risk groups in Shanghai]. Chin J Dermatol [Zhonghua Pi Fu Ke Zha Zhi] 24(2): 
253-255. 
24. M. Liao, Huan PF and Wen TH. 1991. [Histological study of matercercariae of Paragonimus 
westermani]. Chin J Parasitic Dis Control [Zhongguo Ji Sheng Chong Bin Yi Fan Zha Zhi] 
3(2):143-145. 
25. M. Liao, Huan PF, Wen TH. 1990. [Ultrastructure of metacercarial membrane and 
immunohistochemical localization of metacercarial membrane reaction of Paragonimus 
westermani]. [English Abstract]. Chin J Parasitol Parasitic Dis [Zhongguo Ji Sheng Chong 
Xue Yu Ji Sheng Chong Bing Za Zhi] 8(2):108-109. 
26. M. Liao, Huan PF and Wen TH. 1990. [Antibody response of rabbit infected with 
Paragonimus westermani] [Article in Chinese] Shanghai Immunol J [Shanghai Mian Yi Xue 
Zha Zhi] 10(1):19-21. 
27. ....M. Liao …. 1986. [China Environmental microbiology], the second author, derived from 
my undergraduate thesis. 
 
Manuscripts in preparation: [Papers derived from the PhD study are indicated with stars (n=1)] 
 
1. *M. Liao, W-M Gu, Y. Yang and J.R. Dillon. 2011. Trends of antimicrobial resistance in 
Neisseria gonorrhoeae in China. To be submitted to Sex Transm Dis. 
2. M. Liao, M. Wang, C. Baier, K. Perdrizet, Y. Li, D. Sikora, S. Ramirez-Arcos and J.R. 
Dillon. 2011. Novel Protein Interactions Characterize Cell Division in Enterococcus faecalis. 
To be submitted to Mol Microbiol.  
3. S.D. Thakur, M. Liao, E. Nagle, C. Heldin, P. Levett, G. Horsman, J.R. Dillon. 2011. Trends 
in antimicrobial resistance of Neisseria gonorrhoeae isolates from Saskatchewan: Need to 
make more effective use of antimicrobial agents. In preparation. 
4. S. Starnino, P. Galarza; I. Pagano; M. E. Trigoso; A. Schwartz Benzaken; V. M. Pinto; A. 
Maldonado Ballesteros; O. M. Sanabria Cruz; A. Llop; E. Aguilar Jarrin; N. Aguayo; J. L.  
Portilla Carbajal; G. Borthagaray; A. Acevedo; D. Payares, M. Liao, M. Ruben, A. Storey
 
and J. R. Dillon. 2011. Neisseria gonorrhoeae antimicrobial susceptibility in Latin America 
and Caribbean (2000 -2009): A contribution to the treatment guidelines revision. To be 
submitted to STD. 
5. D. Biswas, R. Parti, M. Wang, M. Liao and J.R. Dillon. A MinD mutant of 
enterohemorrhagic E. coli O157:H7 has reduced adherence to human epithelial cells.  
Submitted to Microbial Pathogenesis July 22, 2010.  MS#: YMPAT-D-10-00134. Under 
revision, 2011. 
6. S. Starnino, K. Brandt, R.R. McDonald, P.N. Levett, M. Liao and J.R. Dillon. 2011. Typing 
Neisseria gonorrhoeae and Chlamydia trachomatis from co-infected patients by analyzing 
gonorrhoea positive urine speciments. Sex. Tansm. Dis. MS# STD11-43. Submitted in 
February 2011. Under revision.  
7. S. Vidovic, M. Liao, G.B. Horsman and J.R. Dillon. 2011. A gonococcal MLST scheme 
suitable for short and long-term molecular epidemiological analyses that provides a high 
index of discrimination. In preparation. 
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Meeting presentations, published abstracts/posters: [Papers derived from the PhD study are 
indicated with stars (n=9)] 
 
1. S.D. Thakur, E. Nagle, P.N. Levett, G. Horsman, M. Liao, and J.R. Dillon. 2011. Emerging 
molecular mutations of reduced susceptibility to third-generation cephalosporins in Neisseria 
gonorrhoeae isolates from Saskatchewan, Canada. Abstract accepted. The 19
th
 Biennial 
Meeting of the International Society for Sexually Transmitted Disease Research (ISSTDR), 
10-13 July, 2011. Quebec City, Canada. 
2.  S. Starnino, P.G. Galarza, I. Panago, M.E. Trigoso, A.S. Benzaken,  V.M. Pinto, A.M. 
Ballesteros, O.M.S. Cruz, A. Llop, E. Aguilar, N. Aguayo, J.L.P. Carbajal, G. Borthagaray, 
A. Acevedo, D. Payares, M. Liao, M. Ruben, A. Storey, and J.R. Dillon. 2011. Survey of 
methodology used for the identification and antimicrobial susceptibility testing of Neisseria 
gonorrhoeae in Latin America and the Caribbean. Abstract accepted. The 19
th
 Biennial 
Meeting of ISSTDR, 10-13 July, 2011. Quebec City, Canada.  
3. S. Starnino, P.G. Galarza, I. Panago, M.E. Trigoso, A.S. Benzaken,  V.M. Pinto, A.M. 
Ballesteros, O.M.S. Cruz, A. Llop, E. Aguilar, N. Aguayo, J.L.P. Carbajal, G. Borthagaray, 
A. Acevedo, D. Payares, M. Liao, M. Ruben, A. Storey, and J.R. Dillon. 2011. Neisseria 
gonorrhoeae Antimicrobial Susceptibility in Latin America and the Caribbean (2000-2009): 
A Contribution to the Treatment Guidelines Revision. Abstract accepted. The 19
th
 Biennial 
Meeting of ISSTDR, 10-13 July, 2011. Quebec City, Canada.  
4. S. Vujanovic, S. Vidovic, M. Liao, J.R. Dillon. 2010. Multilocus sequence typing reveals 
outbreaks and circulating strains of Neisseria gonorrhoeae. 2010 NSERC USRA Poster 
Event. August 27, 2010. Student Lounge, College of Education, University of Saskatchewan. 
5. J.R. Dillon, C. Hedlin, E. Nagle, G. Horsman and M. Liao. 2009. Spatial and Temporal 
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